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ABSTRACT
DEPRESSIVE SYMPTOMS AND SURVIVAL AMONG LUNG CANCER
PATIENTS; BIOMARKERS AND POTENTIAL BENEFITS OF AN IPOD- AND
MINDFULNESS-BASED INTERVENTION
Chelsea J. Siwik, M.S.
June 10, 2019
Lung cancer patients experience high levels of distress, which commonly
manifests as depressive symptoms. Importantly, depressive symptoms have demonstrated
prognostic significance in cancer contexts, although the biological pathways by which
depressive symptoms lead to poorer survival remain unclear and warrant greater
attention. In addition to understanding the biological pathways by which depressive
symptoms accelerate disease, identification of efficacious and effective psychological
treatments for depressive symptoms are needed to improve both quality and quantity of
life for cancer patients. Interventions that reduce depressive symptoms and improve
downstream clinical outcomes are certainty needed; however, because many cancer
patients face considerable burden, interventions that offer feasibility and accessibility are
also desirable. Thus, this study has two primary aims: 1) to test the prognostic
significance of depressive symptoms and explore the role of two biomarkers – cortisol
and leukocyte telomere length (LTL) – as they relate to the depression-survival pathway
and 2) to explore the ameliorative role of an iPod and mindfulness-based intervention on
depressive symptoms and related outcomes among lung cancer patients.
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Non-small cell lung cancer patients (N = 67) who had received a diagnosis within
five years were recruited to participate in the current study. Participants reported on
depressive symptoms, provided a blood sample for LTL assessment, and collected homebased saliva samples for cortisol assessment at both baseline and at a three-month followup. Participants were invited to partake in an optional iPod and mindfulness-based pilot
intervention that occurred between baseline and follow-up. The intervention involved
listening to pre-recorded audio tracks adapted from the Mindfulness-based Stress
Reduction program. A number of statistical tests, including ANCOVAs, hierarchical
linear regressions, Cox Proportional Hazards regressions, and Kaplan-Meier analyses
using the log rank test, were conducted to assess hypothesized relationships. Spearman’s
rank-order correlations were used to assess theoretically derived control variables.
Variables that were moderately related to outcomes (r > .3, < .5) were adjusted for.
Regarding Aim 1, results revealed only clinical, not sub-clinical levels of
depression at baseline predicted shorter survival; ethnic minorities evidenced greater
shortening of LTL; and contrary to expectation, an increase in LTL was associated with
shorter survival. Regarding Aim 2, results revealed that the intervention was associated
with an increase in depressive symptoms and LTL and shorter survival. Although an
increase in depressive symptoms was initially observed to be associated with a decrease
in LTL, upon closer examination, there was an interaction effect. Post-hoc analyses
revealed that as depressive symptoms increased, LTL only shortened among patients who
did not participate in the intervention, whereas LTL lengthened among those who
participated.
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Although results from the current investigation should be interpreted cautiously
due to a number of limitations, these findings point to longer LTL as one potential
biological explanation for the depression-survival relationship among lung cancer
patients. Surprisingly, the less supported biomarker, LTL, as compared to cortisol,
emerged as a potential link between depressive symptoms and shorter survival, a
relationship that warrants continued attention and greater clarification. These results also
cohesively suggest that the intervention was associated with poorer psychological and
physical health and poorer clinical outcomes among this small sample of lung patients.
Contrary to the intended and expected benefits of the pilot iPod- and mindfulness-based
intervention, it yielded concerning negative associations that cannot be ignored. While a
number of potential explanations for the current findings are discussed, elucidation of the
components of the current intervention that may have worsened outcomes demand further
investigation.
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INTRODUCTION
A cancer diagnosis and treatment are exceptionally stressful experiences that pose
significant psychological and physical challenges. In addition to the acute stress of
receiving a life-threatening diagnosis, patients must cope with treatment side effects and
disruption of social and vocational roles (Andersen, Kiecolt-Glaser, & Glaser, 1994).
Cancer-related stressors, such as fear of recurrence (Costanzo et al., 2007) and
psychosocial symptoms (Harrington, Hansen, Moskowitz, Todd, & Feuerstein, 2010) can
persist beyond treatment into survivorship, demonstrating the potentially profound and
pervasive impact of on-going cancer-related stress over the course of a cancer journey.
Lung Cancer
In addition to stressors common to all cancers, lung cancer patients experience
disease-specific challenges. Compared to other cancers, lung cancer grows rapidly,
spreads quickly, and often remains undiagnosed until the disease has progressed to a later
stage – an indicator of the extent of tumor growth and metastasis – that is a strong
predictor of survival (Yang et al., 2005). Indeed, 65.1% of lung cancers are diagnosed at
a late (III or IV) opposed to early (I or II) stage (Siegel, Ma, Zou, & Jemal, 2014). While
the 5-year survival rate of lung cancer is estimated at 18%, those diagnosed at a later
stage have a survival rate of less than 5%, and more than half of those with lung cancer
die within the first year of their diagnosis (Henningfield & Adjei, 2017; Siegel, Miller, &
Jemal, 2016). Despite efforts to improve diagnostic and treatment methods, the survival
rate has remained relatively unchanged for the past three decades
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(Siegel, Miller, & Jemal, 2018), suggesting there may be other prognostic factors that are
currently unrecognized. Although immunotherapy, a newer, molecular targeted treatment,
has demonstrate improvement to the median survival in a limited group of non-small cell
lung cancer (NSCLC) patients, these therapies are, unfortunately, not available to many
patients (Massarelli, Papadimitrakopoulou, Welsh, Tang, & Tsao, 2014). In addition to
the aggressive nature of lung malignancy, lung cancer patients report experiencing high
levels of disease-related stigma (LoConte, Else-Quest, Eickhoff, Hyde, & Schiller, 2008),
as lung cancer is often perceived as a self-inflicted disease due to its strong association
with smoking (Henningfield & Adjei, 2017). Thus, lung cancer patients are among the
most distressed of all cancer patients (Carlson et al., 2004).
Depression and Cancer
Depression is a common psychological manifestation of stress in cancer contexts.
Estimated at approximately 12.5% (Linden, Vodermaier, Mackenzie, & Greig, 2012),
depression rates across cancer types exceed those among non-medically ill populations
by four times (Lutgendorf & Andersen, 2015; Raison & Miller, 2003). Among lung
cancer specifically, the prevalence of depression has been estimated between 11- 44%
(Hopwood, Stephens, & Party, 2000; Massie, 2004), which is among the highest when
compared to other cancers (Linden et al., 2012). Nonetheless, not all cancer patients
become depressed and depressive symptoms are not explained by disease severity
(Brown, Levy, Rosberger, & Edgar, 2003), indicating cancer-related stress confers risk
for depression, but does not predict it (Raison & Miller, 2003). While sadness and other
vegetative symptoms are common in cancer contexts, and although it can be difficult to
tease apart (Fisch, 2004), patients with comorbid symptoms of depression suffer from
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distinct and intensified symptoms that extend beyond typical adjustment and lead to
marked impairment of functioning (Chochinov, 2001) that can affect treatment
compliance and clinical outcomes.
Depression and cancer survival. Mounting evidence points to depression as a
predictor of shorter survival in cancer (Spiegel & Giese-Davis, 2003). Not only do metaanalyses indicate depression is predictive of earlier mortality across a number of cancers
(Satin, Linden, & Phillips, 2009), including lung (Pinquart & Duberstein, 2010), but in a
different study, depressive symptoms were the most consistent psychological predictor of
shortened survival compared to cancer-related distress, anxiety, mood, sense of control,
and perception of physical health, even after controlling for demographic (e.g., age,
gender) and medical (e.g., cancer site and stage, treatment status) factors (Brown et al.,
2003). Thus, depressive symptomology specifically appears to be a strong prognostic
indicator of survival in cancer compared to other psychopathologies and distress more
broadly (Brown et al., 2003), and some have identified depressive symptoms to be as
important as traditional prognostic indictors of survival including stage at diagnosis and
disease recurrence (Zimmaro et al., 2018). Furthermore, decreases in depressive
symptoms obtained via psychosocial interventions have been linked to longer survival
among breast cancer patients (Giese-Davis et al., 2011; Spiegel, Kraemer, Bloom, &
Gottheil, 1989). In one randomized control trial (RCT) in metastatic breast cancer, after
adjusting for medical factors, women with improved depressive symptoms lived almost
twice as long over a 14 year span as women whose depressive symptoms worsened over
the course of the year following study entry (Giese-Davis et al., 2011), demonstrating the
magnitude of untreated depression in cancer contexts. Taken together, although a handful
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of studies have reported a null association between depression and earlier cancer
mortality (Spiegel & Giese-Davis, 2003), considerable evidence points to depressive
symptoms as a predictor of shorter survival in cancer.
Current gaps. First, despite abundant evidence demonstrating the prognostic
nature of depressive symptoms across a number of cancers, the mechanisms by which
depressive symptoms lead to shorter survival in cancer contexts remains unknown.
Behavioral pathways, such as treatment noncompliance, have been examined as potential
explanations for this relationship given that depression-related motivation deficits can
inhibit patients from attending appointments. Indeed, depressed patients are more likely
to experience breaks in treatment (DiMatteo, Lepper, & Croghan, 2000), which can lead
to increased risk for earlier mortality (Fesinmeyer, Mehta, Blough, Tock, & Ramsey,
2010). However, a recent study among head and neck cancer patients identified
biological, opposed to behavioral, pathways as a significant mediator of the depressionsurvival relationship (Zimmaro et al., 2018). In this study, depressive symptoms,
measured prior to treatment onset, predicted shorter 2-year overall survival. Additionally,
although depressive symptoms were associated with increased treatment disruption,
treatment disruption did not mediate the depression-survival relationship, whereas
treatment response – a dichotomous clinical biological indicator of treatment success –
did. When entered simultaneously into survival models, depression remained a significant
predictor, indicating treatment response partially mediated the depression-survival
relationship. This recent investigation points to biological, opposed to behavioral
mechanisms as an explanation for the depression-survival relationship.
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Indeed, many biobehavioral reviews foundational for the field of psychooncology have already proposed a number of biological pathways by which
psychological distress, including depressive symptoms, may promote poorer cancer
outcomes (Andersen et al., 1994; Antoni et al., 2006; Armaiz-Pena, Lutgendorf, Cole, &
Sood, 2009; Eismann, Lush, & Sephton, 2010; Lutgendorf & Sood, 2011; Reiche, Nunes,
& Morimoto, 2004; Sephton & Spiegel, 2003). Yet, no clear explanation for how
depressive symptoms lead to shorter survival in cancer has been reported to date,
necessitating continued effort. The majority of these seminal overviews emphasize the
role of immune and neuroendocrine biomarkers given that substantial literature has
demonstrated dysregulation of these systems in depressive and cancer contexts, both
individually and jointly. However, few comprehensive biobehavioral reviews have
integrated telomeres, a marker of cellular aging, and the majority of these reviews are
largely all encompassing, such that they provide detailed explanations of the biological
underpinnings associated with psychological stress and cancer broadly, but do not focus
on depressive symptoms specifically. Given that Brown and colleagues (2003)
demonstrated distinct forms of distress (e.g., depression) have unique effects on survival
outcomes, broad stress models may not be adequately capturing meaningful, nuanced
explanations for the depression-survival pathway. Thus, a more specific approach may be
required to elucidate how depressive symptoms cause shorter survival in cancer.
Second, despite growing evidence for the prognostic significance of depressive
symptoms, the treatment of depressive symptoms remain under prioritized in cancer
contexts. Although efforts to acknowledge and treat comorbid mental illnesses among
cancer populations have certainly improved (Pirl, 2004), interventions that are both
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efficacious and effective warrant continued attention to potentially improve both quality
and quantity of life for cancer patients. Psychosocial interventions have demonstrated
efficacy in decreasing depressive symptoms in cancer contexts, although less attention
has been given to mindfulness-based interventions, especially compared to cognitivebehavioral and supportive group approaches (Li, Fitzgerald, & Rodin, 2012).
Mindfulness-based approaches, which foster attitudes of acceptance, detachment from an
anticipated outcome, and emotion regulation by enhancing present moment awareness,
warrant greater exploration given the lack of control, considerable uncertainty, and
continual adjustment that accompanies cancer (Carlson et al., 2013). Additionally, given
the considerable burden many cancer patients face, interventions that promote feasibility,
through mobile and flexible formats, for example, are desirable. Thus, interventions that
reduce depressive symptoms and prevent/ameliorate related downstream clinical
consequences and promote feasibility in cancer populations remain a need.
Therefore, the current study attempts to begin elucidating how depressive
symptoms lead to shorter survival and how to efficaciously and effectively treat
depressive symptoms and related outcomes among NSCLC patients via two primary
aims: 1) test the prognostic significance of depressive symptoms and the role of two
biomarkers – cortisol and leukocyte telomere length (LTL) – as they relate to the
depression-survival pathway and 2) explore the ameliorative role of an iPod-based
MBSR intervention on depressive symptoms and related outcomes.
Aim 1: The Potential Role of Two Biomarkers in the Depression-Survival Pathway
1) Cortisol. Cortisol, a glucocorticoid hormone, has many widespread biological
functions, implicated in mood, emotional memory, and cognition (Keller et al., 2006). It
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is both the end product of the hypothalamic-pituitary-adrenal (HPA) neuroendocrine
stress response and a central communicator between the central nervous system (CNS)
and the periphery that synchronizes biological function and initiate behavioral action.
Cortisol secretion, therefore, occurs both in response to stressors and operates diurnally
on a circadian schedule.
The neuroendocrine stress response. When threat is detected, a downward
cascade of biological reactions is initiated via the sympathetic nervous system and the
HPA axis, resulting in the production of catecholamines and glucocorticoids (cortisol in
humans), respectively (Sapolsky, Romero, & Munck, 2000). Activation of the HPA axis
is initiated via secretion of corticotropin release hormone (CRH) from the paraventricular
nucleus (PVN) of the hypothalamus. The pituitary gland is then stimulated and releases
adrenocorticotropic hormone (ACTH), which travels via systemic circulation to the
adrenal gland and stimulates the release of cortisol into the blood (Sapolsky et al., 2000).
Because cortisol is the product of the neuroendocrine stress response, it is both a
biomarker of acute and chronic stress, with particular sensitivity to uncontrollable and
social-evaluative stressors (Dickerson & Kemeny, 2004).
Although cortisol secretion is adaptive in response to a stressor, as it prepares an
organism to endure threat (Armaiz-Pena et al., 2009), chronic production of cortisol can
become maladaptive. Excessive cortisol production can cause desychronization of the
HPA-axis and other cortisol-related biological systems, disrupting a number of biological
functions (Pariante & Miller, 2001). Upon chronic exposure to cortisol, glucocorticoid
receptors (GRs) become desensitized and negative feedback loops fail to regulate cortisol
levels, eventually causing the system to become blunted. Because GRs are widely
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distributed across the human body with dense concentrations in certain areas of the brain
(Rosenfeld, Van Eekelen, Levine, & de Kloet, 1993), it is apparent cortisol has influence
on a number of diverse biological processes (Weiner, 1992), including neural,
cardiovascular, immune, and metabolic functions (McEwen, 2008). Consequently, in
addition to the considerable “wear and tear” chronic stress can ensue on the HPA axis, it
can also cause widespread biological dysregulation with far reaching consequences,
including greater risk for disease. For a comprehensive overviews of the extensive inner
workings of a neuroendocrine response via the HPA axis, see McEwen (2000, 2008) and
Miller et al. (2007).
Circadian rhythms. In addition to production of cortisol in response to a stressor,
cortisol secretion occurs rhythmically on a diurnal schedule (Halberg, 1960). In fact, it is
becoming more evident that many biological functions in addition to cortisol production,
such as sleep/wake cycles, cell proliferation, immune activity (Fu & Lee, 2003), DNA
damage repair mechanisms (Innominato et al., 2014), and cell senescence (Fu & Kettner,
2013), are regulated via an internal “clock.” This clock appears to function normally
independent of external cues, but aligns closely with the Earth’s 24-hour rotation
(Shostak, 2017). These biological circadian rhythms are believed to be evolutionarily
advantageous as they allow the host’s physiology to naturally adapt to environmental
surroundings. Although cortisol production is responsive to the environment, circadian
rhythms allow the CNS to control biological function without taxing limited higher-level
resources (i.e., conscious thought). Glucocorticoids are one of the primary mechanisms
by which the suprachiasmatic nuclei (SCN; i.e., the central pacemaker or mammalian
clock) of the CNS can communicate peripherally to coordinate important biological
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functions (Innominato et al., 2014). Thus, cortisol secretion follows an endogenous
diurnal rhythm to facilitate synchronization of these functions (Fu & Lee, 2003). For an
extensive review on the mammalian central clock and how it coordinates peripheral
systems, see Dibner et al. (2010).
Cortisol profiles. Research has identified typical, healthy diurnal cortisol profiles
as the following: highest levels in the morning upon waking, known as the cortisol
awakening response (CAR), followed by tapering levels throughout the day, and lowest
levels prior to sleep between 2100 – 2400 hours (Clow, Hucklebridge, Stalder, Evans, &
Thorn, 2010). Therefore, steeper diurnal cortisol slopes are considered normal/healthy,
whereas flattened slopes are aberrant, indicative of circadian and/or HPA dysregulation,
and have been linked with poorer health outcomes. See Figure 1 for a depiction of a
normal cortisol profile and a steep slope. Although cortisol rhythms tend to follow this
daily pattern, cortisol secretion is influenced by a number of factors including exercise,
sleep, and consumption of food, medication, and other substances (e.g., alcohol, tobacco,
etc.). Daily mean diurnal cortisol is also influenced by these factors, and can be more
challenging to interpret, as it is more inter-individually variable. While chronic
production of cortisol and elevated mean cortisol levels at bedtime are considered
aberrant, higher overall diurnal mean cortisol is more challenging to classify given that
cortisol production is influenced by genetics (Ouellet-Morin et al., 2008). In other words,
diurnal cortisol slope is a more stable marker of circadian rhythmicity as it reflects daily
pattern, whereas overall diurnal mean cortisol is more susceptible to inter-individual
variation. Thus, although elevated mean cortisol can be indicative HPA hyperactivity, it
should be interpreted cautiously, as higher overall mean cortisol does not always reflect
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aberration. Lastly, CAR, despite substantial discussion in depression literature, has
significant methodological limitations (Clow, Thorn, Evans, & Hucklebridge, 2004) and
its significance regarding health outcomes remains complex (Clow et al., 2004).
Therefore, empirically supported markers of cortisol profiles – mean diurnal cortisol and
diurnal cortisol slopes - will remain the focus of the current study.
Taken together, cortisol has become a widely used, reliable biomarker of acute
and chronic psychological stress (Hellhammer, Wust, & Kudielka, 2009), the
neuroendocrine stress response (Riad-Fahmy, Read, & Walker, 1980), and systemic
circadian coordination (Windle, Wood, Lightman, & Ingram, 1998) when assessed and
interpreted correctly. Because the PVN receives neural input from the SCN, which
controls the HPA axis and circadian coordination, respectively, the two systems are
tightly linked (Clow et al., 2010). Thus, given the diagnostic hallmarks of depression,
which include significant changes to metabolic function (e.g., appetite and sleep), it is not
surprising abnormal cortisol profiles have been observed among depressed individuals.
Additionally, because circadian rhythms are central to many biological processes
including cortisol secretion and cell proliferation (Hrushesky, Lannin, & Haus, 1998), it
is logical that desychronization of circadian cortisol rhythms has been observed in
patients with cancer, a disease described by rapid and uncontrolled cell division.
Depression and cortisol. Substantial literature has linked aberrant cortisol
profiles and depression. Elevated cortisol was originally observed among depressed
patients upwards of 50 years ago (Board, Wadeson, & Persky, 1957) and a significant
number of experiments and subsequent reviews on the depression-cortisol association
have confirmed HPA axis hyperactivity and diminished sensitivity of GR feedback loops
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among depressed individuals (Burke, Davis, Otte, & Mohr, 2005; Herbert, 2013; Pariante
& Miller, 2001). Approximately half of depressed individuals demonstrate an impaired
recovery response to a dexamethasone suppression test (Gold et al., 1986), which is used
to assess functioning of GR mediated feedback loops (see Carroll (1984) for a
comprehensive description and overview). Despite inconsistent prevalence rates, Miller
et al. (2007) reported a striking effect: depressed individuals have demonstrated cortisol
levels one standard deviation greater than levels among non-depressed counterparts
following a dexamethasone test, suggesting meaningful differences in GR-mediated HPA
axis function.
With respect to diurnal cortisol rhythms, a couple of small studies have reported
abnormal circadian profiles – one among men suffering from an acute depressive episode
(n = 11) compared to age-matched controls (n = 7; Linkowski et al. (1987), and another
among individuals with MDD (n = 14) compared to individuals with PTSD (n = 15) and
healthy men (n = 15; Yehuda, Teicher, Trestman, Levengood, and Siever (1996). Both of
these studies, however, collected multiple samples of cortisol over one day, which has
been shown to be an unreliable estimate (Segerstrom, Boggero, Smith, & Sephton, 2014).
In a different study, approximately half of individuals with depression demonstrated
elevated evening cortisol levels (Claustrat, Chazot, Brun, Jordan, & Sassolas, 1984), a
marker of abnormal diurnal rhythmicity. Taken together, decades of research have
identified hyperactivation and subsequent dysregulation of the HPA axis, measured
through cortisol, as a hallmark of depression (Herbert, 2013; Jehn et al., 2006), although
the evidence of disrupted diurnal rhythmicity is more limited. Consequently, depression
has been hypothesized to be a result of chronic activation of the neuroendocrine stress
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response (Pariante & Lightman, 2008). Despite consistent observation of aberrant cortisol
in depression, the inconsistencies associated with the type of aberration (e.g., only 50%
demonstrate elevated evening cortisol levels) are puzzling, but may be explained by
methodological discrepancies in cortisol assessment. Alternatively, these inconsistencies
may be indicative of subtypes of depression, as Bonanno’s longitudinal work has
consistently identified distinct depressive trajectories (e.g., emergent post-event, chronic,
depressed prior followed by improvement) following a host of stressful events including
a spinal cord injury (Bonanno, Kennedy, Galatzer-Levy, Lude, & Elfström, 2012),
bereavement (Galatzer-Levy & Bonanno, 2012), and a medical diagnosis (Morin,
Galatzer-Levy, Maccallum, & Bonanno), all of which activate the HPA axis. Thus,
greater exploration into the role of dysregulated cortisol profiles in different depressive
contexts (e.g., cancer) warrants greater attention.
The prognostic significance of cortisol in cancer. Miller et al. (2007) stated,
“stressors that threaten physical integrity, involve trauma, and are uncontrollable,” much
like cancer, “elicit a high, flat diurnal profile of cortisol secretion” (p. 25). Indeed,
aberrant diurnal cortisol profiles marking circadian disruption have been linked to poorer
clinical outcomes in cancer, including tumor development, disease progression (Eismann
et al., 2010; Fu & Lee, 2003; Hrushesky et al., 1998; Mormont & Levi, 1997), and
shorter survival in breast (Sephton, Sapolsky, Kraemer, & Spiegel, 2000), renal cell
(Cohen et al., 2012), lung (Sephton et al., 2013), and ovarian (Schrepf et al., 2015)
cancer. Although the number of studies examining cortisol and survival in cancer are
limited, mounting evidence points to the prognostic significance of circadian-regulated
neuroendocrine disruption in cancer. Because the circadian clock regulates diurnal
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cortisol and important aspects of the cell cycle, disruption to its function appears to have
profound influence on tumor development and the host’s survival. Indeed, experimental
manipulation of circadian disruption of endocrine function has been shown to cause
spontaneous tumor onset (Filipski et al., 2002; Fu & Lee, 2003) and accelerate growth
(Sapolsky & Donnelly, 1985) in animal models. Despite the long held belief that the
circadian clock suppresses tumors (Eismann et al., 2010; Fu & Kettner, 2013), more
recent evidence suggests, in some circumstances, it may also promote tumorigenesis
(Shostak, 2017), highlighting the vital, yet debated, role of circadian function on tumor
behavior. Nonetheless, glucocorticoids have been shown to stimulate growth (Moran,
Gray, Mikosz, & Conzen, 2000), increase the invasive potential (Sood et al., 2006), and
inhibit tumor cell death (Volden & Conzen, 2013) in tumor microenvironments. Taken
together, circadian clock regulated coordination of diurnal cortisol appears to play a
central role to maintenance of healthy biological functioning on a systemic, cellular, and
molecular level, and disruptions to this system have been linked to cancer onset, growth,
and poorer survival.
Depression and cortisol in cancer. Cortisol appears to be a biological correlate
of depression and cancer (Pasquini & Biondi, 2007). Elevated bedtime cortisol has been
associated with depressive symptoms (Lutgendorf et al., 2008) and shorter survival
(Schrepf et al., 2015) in ovarian cancer patients. Dysregulated diurnal cortisol profiles
have also been linked with greater vegetative depression, but not stress or distress, among
ovarian cancer patients (Weinrib et al., 2010). Additionally, a decline in vegetative
depressive symptoms reported by ovarian cancer patients six months post-surgery was
associated with reductions in mean bedtime cortisol levels (Schrepf et al., 2013),
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suggesting patients with improved psychological symptoms also experienced
improvements in physiological health.
Jehn et al. (2006) extended these findings beyond ovarian cancer by
demonstrating greater dysregulation of diurnal cortisol among depressed compared to
non-depressed cancer patients; although depression and disease status were not
independent, suggesting the depression-cortisol association could be confounded by
disease severity. In a different sample, however, depressed compared to non-depressed
breast cancer patients had significantly lower mean waking cortisol levels at study entry,
which could not be fully explained by disease status, suggesting a unique association
between depression and circadian coordinated cortisol function independent of disease
(Giese-Davis et al., 2006). In a unique study involving a dexamethasone suppression test,
patients with both depression and cancer demonstrated high plasma cortisol levels
following the test, indicating disrupted glucocorticoid-mediated feedback loops in the
HPA axis (Musselman et al., 2001). Depressive symptoms were also correlated with
plasma cortisol levels in this sample, suggesting HPA dysregulation increased with
depression severity.
In contrast, Sephton and colleagues (2000) reported a null association between
depressive symptoms and cortisol slopes, which are prognostic of survival, among a
sample of metastatic breast cancer patients. In a later analysis using a subset of the same
metastatic breast cancer sample, however, Sephton and colleagues (2009) reported an
association between greater depressive symptoms and higher waking cortisol and
“accentuated” cortisol slopes. While these findings are somewhat contrary to expectation
as higher waking cortisol is typically interpreted as physiologically beneficial, this
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relationship may be reflective of increases in HPA activity. Taken together, although
these findings are somewhat inconsistent, majority of the positive associations between
depression and cortisol were observed among ovarian cancer, whereas most null and
contradictory findings were among breast cancer patients. Further, the number of studies
examining depression and cortisol in cancer, let alone cancer survival, is surprisingly
scarce. Even fewer studies report null or contradictory findings, making it difficult to
deduce conclusions. Nonetheless, a comprehensive meta-analytic review of 80 studies
that examined associations between diurnal cortisol slopes and 12 different indices of
mental and physical health indicated flatter diurnal cortisol slopes were associated with
10 of the 12 health outcomes, which included depression and cancer, suggesting
dysregulation of circadian markers correspond to poor downstream health outcomes
(Adam et al., 2017).
It is not surprising depressed cancer patients experience earlier mortality (Pinquart
& Duberstein, 2010; Satin et al., 2009) Theoretically, cancer patients with comorbid
depression experience compounded cortisol dysregulation, both depression-driven HPA
axis disruptions as well as aberrations in diurnal cortisol rhythmicity that have been
linked with tumors. A comprehensive review on the interaction of circadian clock
regulated cortisol profiles and HPA axis systems by Nadar and collegues (2010) provided
evidence that the two systems are highly interrelated biologically and that the central
circadian clock system dictates activity of the HPA axis. It remains intriguing, however,
that the cortisol aberrations observed in depressed individuals appears to be HPA-related,
whereas the aberrations associated with cancer seem to reflect dysregulation in diurnal
cortisol rhythmicity. Thus, although cortisol is a clear correlate of depression and cancer,
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the nuanced biological underpinnings of the aberrations in cortisol profiles observed
across conditions are complex and should be interpreted thoughtfully.
Cortisol and the depression-survival relationship. All together, the literature
indicates a complex interaction between depressive symptoms, aberrant cortisol profiles,
and survival in cancer contexts, although the directionality of the relationship between
depression and cortisol remains unknown. Because the temporal onset of HPA
dysregulation in depression remains unclear, elucidation of these relationships in the
context of illness, especially an illness strongly linked to aberrations in cortisol profiles,
is a challenge. While the role of genetics will be central in clarifying these relationships,
further examination of these stress factors offer opportunity to begin understanding such
relationships.
Dysregulated cortisol profiles have been proposed as a mediator of the
depression-survival relationship (Cohen et al., 2012; Eismann et al., 2010; Sephton et al.,
2003). Cohen and colleagues (2012) replicated the association between both depressive
symptoms and aberrant cortisol profiles with shorter survival among renal cell carcinoma
patients. When controlling for diurnal cortisol rhythms, the strength of the association
between depressive symptoms and survival time was substantially reduced, suggesting
aberrant cortisol profiles may have partially mediated the depression-survival
relationship. However, because the authors reported a null association between
depressive symptoms and cortisol and did not report if the main effect of cortisol or the
interaction between depression and cortisol were statistically significant, the analytic
approach was not clear and did not seem to meet updated criteria for mediation (Chmura
Kraemer, Kiernan, Essex, & Kupfer, 2008). Further, it is unlikely the authors included
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the interaction term in the Cox regression models, which is another criterion of mediation
outlined in the MacArthur approach (Chmura Kraemer et al., 2008). This is problematic
because it is unclear if depressive symptoms and aberrant cortisol profiles were “working
together” to cause earlier mortality or if cortisol is truly serves as an explanation for how
depressive symptoms lead to shorter survival (Kraemer, Stice, Kazdin, Offord, & Kupfer,
2001), warranting prospective analysis following more rigorous statistical criteria.
Nonetheless, Cohen and colleagues (2012) only reported partial, opposed to full
mediation, suggesting other biological processes may also be contributing to this
pathway. Indeed, substantial literature has already demonstrated a central role of the
immune system in the intersection of depression, neuroendocrine function, and cancer
(Costanzo, Sood, & Lutgendorf, 2011; Lutgendorf & Andersen, 2015; Reiche et al.,
2004), yet no evidence exists to date suggests immune markers explain the depressionsurvival relationship. A more recent, yet growing body of evidence (discussed below)
suggests telomeres, typically extracted from leukocytes, may be an important biomarker
of psychological stress, including depressive symptoms, and clinical outcomes in cancer
as well. Although empirical exploration continues to unravel the underlying complexities
of telomere biology, emerging evidence suggests telomeres are intertwined with tumor
onset and growth, and therefore, survival. Thus, the current study aims to expand on
current biobehavioral literature by integrating a newer, less amalgamated biomarker –
telomere length – that holds promise as a contributor to the depression-survival
relationship.
2) Telomere length (TL). Telomeres are DNA-based protein structures capping
the ends of chromosomes that serve to maintain cellular integrity and stability
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(Blackburn, Epel, & Lin, 2015). Upon each cell division, telomeric DNA is lost, resulting
in cumulative shortening of telomeres over time; a process that determines how fast cells
age and when they die (Rivera-Tavarez, 2017). Thus, the slow, cumulative shortening of
telomeres over the course of the lifespan is consistent with typical, healthy aging;
however, the loss of TL can be accelerated by environmental factors such as chronic
stress (Epel et al., 2004), an effect that is observable as early as intrauterine life
(Entringer et al., 2011), and is inconsistent with typical, healthy aging as it is considered
premature. Indeed, stress has been experimentally shown to accelerate telomere attrition
in animal models (Haussmann & Heidinger, 2015; Kotrschal, Ilmonen, & Penn, 2007).
Therefore, the lifetime decline in TL is influenced by a host of elements including
genetics, developmental and environment factors, and physiology (e.g., oxidative stress
exposure; Blackburn (2001). Telomeres are also under control of a biological (mitotic)
clock, although timing of this clock is related to previous number of cell replications,
rather than diurnal circadian rhythmicity (von Zglinicki, 2002). Nonetheless, telomeric
processes including cell proliferation (Fu & Lee, 2003), DNA damage repair mechanisms
(Innominato et al., 2014), and programmed cell death, or senescence (Fu & Kettner,
2013), are all regulated via an internal biological “clock,” demonstrating biological
parallels between cortisol and telomeric function.
When telomeres become “too short,” the cell initiates a DNA damage response –
it stops dividing or dies – causing cellular changes that can permanently inhibit tissue
replacement and subsequent wide-spread genomic instability (Augustine, Maitra, & Goel,
2017). Cells are only able to divide a finite number of times, known as the Hayflick limit
(Hayflick, 1965), and when cells approach the limit, they become senescent (Blackburn,
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2000). The underlying biological role of senescence is to prevent growth arrest (McHugh
& Gil, 2017), and cells become senescent via two pathways: programmed (naturally
occurring) and premature stress-induced (Bielak-Zmijewska, Mosieniak, & Sikora,
2017). Cell senescence is biologically beneficial as it limits excessive cell proliferation
(e.g., tumor progression) since cells are unable to replicate under such conditions. In
contrast, cell senescence has been identified as a cause of age related disease, such as
cancer (McHugh & Gil, 2017), and experimental ablation of senescent cells in mice has
been shown to extend health (Baker et al., 2011) and life (Baker et al., 2016) by delaying
onset of age-related pathologies.
Consistent with other biological systems, when functioning properly in a state of
homeostasis, cell division is seamless, balanced between cell proliferation and
senescence. However, stressors commonly disturb homeostasis. The body elicits
biological responses in response to stress in an attempt to restore equilibrium, a process
known as allostasis – fluctuations in biological processes to meet the demands of external
pressures (McEwen & Stellar, 1993). Just as the release of cortisol is adaptive in response
to perceived stress, but can become maladaptive when chronically activated, cell
senescence adaptively counterbalances cell proliferation, but can also become
problematic when the system is strained, telomeres shorten rapidly, and cells become
senescent prematurely. Telomere shortening and cell senescence are therefore natural
biological processes that seem to become maladaptive when they occur prematurely at an
accelerated rate as a result of an unbalanced system, potentially caused by stress. Thus,
telomeres appear to be yet another biomarker of how “stress gets under the skin” and can
lead to poorer health. Indeed, aged, senescent cells have been linked with tumor
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progression and appear to support cancer cell proliferation (Krtolica, Parrinello, Lockett,
Desprez, & Campisi, 2001), factors that influence the host’s survival.
Fortunately, telomeres are maintained and can be lengthened by the enzyme
telomerase, which serves to balance terminal DNA loss during cell proliferation
(Blackburn, 2000). Without telomerase, cells would continuously divide and shorten at an
accelerated rate, leading to widespread, premature cell senescence and greater risk of agerelated diseases including cancer and earlier mortality (Blackburn et al., 2015). Although
telomeres are maintained and lengthened via telomerase, which is required for eukaryotic
survival, there appears to be a delicate balance between the two and their related
processes (Blackburn, 2001). Recent work by Margalef and colleagues (2017)
demonstrated telomerase can compromise cell replication and contribute to telomere
shortening under certain conditions, highlighting the complex molecular relationship
between TL and telomerase that is not yet fully understood. The complexity of this
relationship is further complicated by the fact that telomerase is not the only determinant
of TL, as growing evidence suggests other biological processes including oxidative stress
and inflammation can also accelerate TL shortening (von Zglinicki, 2002; Wolkowitz et
al., 2011).
Despite the need for elucidation of the interactions between TL attrition during
cell division, TL maintenance via telomerase, and cell senescence both in and out of
allostatic contexts, the past two decades of research have identified TL as a robust
biomarker of cellular aging. When controlling for chronological age, which accounts for
only 10% of TL variation (Blackburn et al., 2015), and other risk factors, shorter TL has
been shown to predict all-cause mortality (Needham et al., 2015; Rode, Nordestgaard, &
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Bojesen, 2015). Demonstrated by within-pair twin analyses, Bakaysa and colleagues
(2007) evidenced twins with shorter telomeres had a three times greater risk of dying
compared to co-twins with longer telomeres (Bakaysa et al., 2007), suggesting TL may
account for all-cause mortality in older age even when controlling for developmental and
genetic influence. Given that TL has been crowned the biomarker of cellular aging, and
that both depression and cancer have been conceptualized as age-related diseases
(Herrmann, Pusceddu, März, & Herrmann, 2018; Lindqvist et al., 2015), it makes sense
TL has been linked to both depression and cancer independently; however, these
relationships have rarely been explored simultaneously. In fact, Elizabeth Blackburn, a
Nobel Prize recipient, and colleagues (2015), have explicitly encouraged further
exploration into the interaction between psychological distress, telomeres, and disease, as
they are likely “powerful” and remain relatively “unexplored” (p. 1197). Thus, to adhere
to the scope of the current investigation, the relationships between depression, TL, and
cancer will be reviewed briefly. For more comprehensive, detailed reviews, see Lindqvist
et al. (2015) and Manoliu, Bosch, Brakowski, Brühl, and Seifritz (2018) for a review on
depression and TL, and Gunes, Avilla, and Rudolph (2017) and Herrmann et al. (2018)
for a review on TL and cancer.
Depression and TL. According to Schutte and Malouff’s (2015) relatively recent
meta-analysis, only 25 studies have examined depression and TL, which is considerably
less than the existent literature examining the association between depression and
cortisol. Nonetheless, a growing body of evidence demonstrates a link between
psychological stress, depressive symptoms, and TL. Simon et al. (2006) demonstrated
individuals with mood disorders (MDD and bipolar with and without comorbid anxiety)
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had significantly shorter leukocyte telomere length (LTL) compared to aged-matched
controls. The three mood disorders were grouped together as significant differences in TL
were not observed between them, likely due to power restrictions (n = 15). Nonetheless,
the authors reported a striking effect among the depression-only group: telomere attrition
represented approximately 10 years of accelerated aging compared to healthy controls,
demonstrating clinical opposed to statistical significance. Further, Vakonaki and
colleagues (2018) recently reviewed the current empirical evidence on the relationship
between psychological illness (schizophrenia, depression, and anxiety) and TL and
concluded that majority of studies report shorter TL among patients with a psychological
disorder. Taken together, it seems mental health disparities broadly are linked with
shorter telomeres.
Furthermore, Hartmann and colleagues (2010), among others, have provided
evidence of an association between depression and shorter TL, independent of other
mood disorders. A prospective study showed depression predicted shorter LTL at a twoyear follow-up compared to age-matched controls when controlling for potential
confounds including sex, smoking status, activity, physical health, and body mass index
(Vance et al., 2018). Further, a relatively recent meta-analysis involving over 21,040
individuals and 32 studies reported those with depression had 71% greater odds of having
shorter TL (Schutte & Malouff, 2015). Although the reported effect size of this metaanalysis was small (r = - .12), the results reflect a difference of approximately 97
chromosomal base pairs. This finding is meaningful because the minimum TL required to
maintain stability in human leukocytes is 3.81kb (Lin et al., 2014), demonstrating that a
small change in TL can have a significant impact despite small statistical magnitude
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(Blackburn et al., 2015). Further, a more recent meta-analysis reported a moderate to
large effect size between depression and shorter LTL among 5,369 individuals (Hedge’s
g = -.55; Darrow et al. (2016). Nonetheless, not all studies reported a significant
association between depression and TL. In a recent review, Lindqvist et al. (2015)
evidenced just under half of the included studies (4 out of 11) reported no significant
differences in LTL between depressed and non-depressed individuals. Additionally, of
the studies that did reported a significant difference, the effect size ranged from .04 to .98
with a mean of .41, suggesting that as TL continues to become integrated into interdisciplinary research, standardization of assessment procedures need to be established
and communicated.
A number of additional inconsistencies regarding the depression-TL relationship
have been reported. For instance, Schutte and Malouff’s meta-analysis (2015) suggested
cross sectional associations between depression and TL were stronger than longitudinal
relationships, which is puzzling, but could explain why a recent prospective study did not
see a relationship between depression and shorter LTL at an 11-year follow-up among
1,250 middle aged female nurses (Chang et al., 2018). In contrast, a dose-response
relationship between depression duration and severity and shorter TL over a four year
span was observed by Verhoeven et al. (2014), and Wolkowitz et al. (2011) have reported
proportionally shorter LTL among individuals with a lifetime history of MDD, especially
when untreated. However, Hartman et al. (2010) and Vance et al. (2018) reported their
results indicated duration, symptom severity, and treatment did not differentially
influence TL. Taken together, although a majority of studies report an association
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between depression and shorter TL (Lindqvist et al., 2015), the strength as well as a
number of factors related to the relationship remain unclear.
The prognostic significance of TL in cancer. Given the fundamental role of
telomere biology during cell proliferation and that cancer is defined as the uncontrolled
division of cells, it is not surprising telomeres have exploded in cancer research over the
past two decades (Blackburn, Greider, & Szostak, 2006). Telomeres appear to be shorter
in cancer cells than cells from normal tissue (Hastie et al., 1990; Heaphy et al., 2010;
Nakamura et al., 2000; Odagiri et al., 1994), and shorter cancer tissue telomeres have
been linked with advanced disease, accelerated disease progression, metastasis, and
poorer survival (Heaphy et al., 2013; Herrmann et al., 2018). Current hypotheses posit
that as telomeres from cancer cells shorten rapidly and near senescence, telomerase
facilitates indefinite cell division in an attempt to re-stabilize telomeres, which ultimately
leads to a state of “immortalization” (Augustine et al., 2017). As such, overexpression of
telomerase has been observed in 90% of cancer cells and experimentally induced
inhibition of telomerase limited the number of cancer cell divisions (Kim et al., 1994). It
has therefore been hypothesized that depletion of telomerase in tumor microenvironments
would eliminate the cell’s ability to excessively proliferate, although experiments have
revealed the opposite – eventual loss of telomere function among cells depleted of
telomerase led to greater tumor progression (De Lange & Jacks, 1999). This research
indicates that the disruption of the delicate balance between cell division (telomere
shortening) and telomerase in the tumor microenvironment appears to activate
tumorigenesis, although the specific timing and mechanisms of this process remain
unclear (Hackett & Greider, 2002). See Gunes et al. (2017) for an extensive review on
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telomeric biology and tumors. Taken together, although elucidation of telomeric biology
in tumor environments continues to unfold, it is becoming clear that telomeres play a
central role in tumor onset and progression, and therefore, survival in cancer.
Peripheral TL has also been identified as a prognostic marker in cancer. Typically
measured as a mean from leukocytes, shorter LTL has been linked to increased risk (Ma
et al., 2011; Shao et al., 2007; Wentzensen, Mirabello, Pfeiffer, & Savage, 2011; Willeit
et al., 2010; Wu et al., 2003), earlier mortality (Wentzensen et al., 2011; Willeit et al.,
2010), and shorter survival (Callahan et al., 2017; Renner, Krenn-Pilko, Gruber,
Herrmann, & Langsenlehner, 2018; Valls, Piñol, Reñé, Buenestado, & Viñas, 2011;
Weischer et al., 2013; Zhang, Chen, et al., 2015) across a number of cancer types, and a
few reviews have demonstrated a robust relationship between shorter TL and shorter
cancer survival. For instance, in one longitudinal study (N = 47,102), shorter LTL was
associated with reduced survival across multiple cancer types at a 20-year follow-up
(Weischer et al., 2013). A meta-analytic review by Wentzensen and colleagues (2011)
involving 25 studies demonstrated patients with shorter TL had higher risk of incidence
and mortality across a number of cancer types, although the strength and consistency of
these relationships may have been driven by stronger effects among specific cancers.
This analysis only included two studies in lung cancer, evidencing a clear
underrepresentation of this disease type. Lastly, a more recent meta-analysis involving 33
studies by Zhang and colleagues (2015) supported the association between shorter TL
and poorer cancer survival (n = 11,429). However, their analysis included studies that
collected TL from both tumor tissue and blood, which is problematic given the distinct
biological underpinnings of peripheral telomeres and telomeres collected from tumor
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microenvironments. Nonetheless, similar to the findings reported by Wentzensen and
colleagues (2011), upon examination of disease-specific associations between TL and
survival, Zhang et al (2015) reported variation in the strength of the relationship across
cancer types, pointing to the importance of examining these relationships in diseasespecific contexts. Of the 27 studies examining overall survival included in the analysis,
only one study was among lung cancer patients, further demonstrating the need for
greater inclusion of lung cancer samples in future investigations.
Consistent with these meta-analytic findings, Callahan and et al. (2017) reported
shorter LTL predicted shorter disease-specific survival in renal cell carcinoma, but noted
strong effects among stage-I patients, indicating prognostic significance of LTL early in
the disease. Puzzling and contradictory findings by Svenson and et al. (2008)
demonstrated longer TL was prognostic of disease-specific survival among breast cancer
patients with advanced disease. Others have also reported null and contradictory
associations between TL and cancer risk (Hou, Zhang, Gawron, & Liu, 2012; Yuan et al.,
2018), although fewer have reported these associations with survival outcomes. Despite
these discrepancies, promising evidence points to a relatively robust relationship between
shorter systemic TL and shorter survival in cancer, although this relationship has yet to
be examined in lung cancer.
Depression and TL in cancer. TL appears to be an important biomarker in both
depressed and cancer populations, although only two studies have examined them
simultaneously, neither of which were among lung cancer. One of the studies, conducted
among a large sample of bladder cancer patients (n = 464), reported current depressive
symptoms, both independently and combined with shorter TL, were associated with
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shorter survival (Lin et al., 2015). The authors reported shorter TL was a stronger
predictor of survival than depressive symptoms, but the differences were negligible. In
this sample, patients with depressive symptoms and shorter TL had a 4-times greater risk
for mortality and shorter disease-free survival compared to patients without depressive
symptoms and longer TL, suggesting TL accounted for some of the variance explaining
the depression-survival relationship. However, the authors reported no association
between depressive symptoms and TL, thus mediation analysis criteria was not met. The
only other study examining depression and TL in cancer was conducted by Sharpley et al.
(2018), but survival was not included in the analysis. In this sample of prostate cancer
patients, irritability, but not depression (both measured via the PHQ-9 depression
questionnaire), was associated with shorter TL. The authors suggested that because
depression is typically characterized by irritability opposed to sadness in males these
results are not unexpected. Although only two studies have examined depression and TL
in cancer, the results are promising for the possibility that TL may partially explain the
depression-survival relationship.
Integration of TL into psychobiological cancer models. There is paucity of
telomere biology in current biobehavioral cancer models despite mounting evidence
demonstrating a robust effect of stress on TL (Shalev et al., 2013; Starkweather et al.,
2014), a biomarker that appears to play a central role in tumor onset and progression and
has been linked to shorter cancer survival. Nonetheless, there have been some attempts to
integrate telomeres into stress-aging models (Epel, 2009; Epel & Prather, 2018;
Wolkowitz, Epel, Reus, & Mellon, 2010). Although the causal association between
psychological stress/depressive symptoms and telomere attrition remains unknown, Epel
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(2009) provided compelling evidence for the downstream effects of chronic stress on
cortisol disruption and subsequent telomere attrition. In contrast, Wolkowitz and
colleagues’ (2010) model postulates stress-related biomarkers (e.g., cortisol and TL)
precede psychiatric and medical symptoms. Although longitudinal and experimental
studies among humans and animals have demonstrated psychological and experimentally
induced stress, respectively, can lead to telomere attrition (Epel et al., 2004; Hau et al.,
2015; Herborn et al., 2014; Kotrschal et al., 2007), this does not translate directly to
psychological illness, such as depression. While Chen et al. (2007) provided evidence for
depression’s shortening effect on TL, and the majority of the literature suggests
depressive symptoms precede telomere attrition, Gotlib and colleagues (2015) provided
evidence suggesting the opposite. The authors demonstrated that at-risk females aged 10
– 14 whose mothers have depression had significantly shorter telomeres compared to
peers who did not have a familial risk for depression. These associations were not
assessed longitudinally, but demonstrated the possibility that telomere attrition could
have a role in the onset of depression rather than just a consequence. Taken together,
although it is known psychiatric disorders including depression predict shorter TL, it
remains unclear if the telomeric shortening process precedes onset of certain disorders
(Epel & Prather, 2018). Therefore, greater exploration of this association is needed.
Biological Interplay Between Cortisol and TL. Manipulation of glucocorticoids
in animal models has helped establish the causal effect of cortisol on TL. In one study,
experimental exposure to corticosterone, the main glucocorticoid in many species,
resulted in significantly shorter telomeres during the “late life” phase in seabirds
compared to controls (Herborn et al., 2014). In a different study, following one year of
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experimental exposure to stressors during adulthood (intended to mimic experience of
chronic stressors typical in humans), stress-exposed birds had shorter TL than nonstressed controls (Hau et al., 2015), although no differences in glucocorticoids were
observed. These findings further demonstrate the impact of stress on TL, but also the
possibility that chronic stress may burden cellular aging systems prior to and potentially
independent of endocrine systems. However, because there are considerable differences
in stress appraisal and biological processes between non-mammals and humans, the
generalizability of these findings is limited. Reductions in leukocyte telomerase, implying
reductions in telomere maintenance, however, have been observed in humans following
experimental exposure to cortisol (Choi, Fauce, & Effros, 2008). Taken together,
although the results of these studies demonstrate glucocorticoid cause telomere attrition
in animal models, the opposite effect is still possible, as the effect of telomere attrition on
glucocorticoids has not been reported to date.
Cortisol and TL and the depression-survival relationship. Decades of research
have evidenced strong associations between depressive symptoms, cortisol profile
aberrations, and shorter survival in cancer patients. Although TL is a relatively new
biomarker, supported by far less research and associated with greater uncertainties,
evidence for associations between these constructs and shorter TL also exists. Certainty,
fewer investigations have examined depressive symptoms, telomeres, and survival in
cancer simultaneously, but of the studies that have, lung cancer is markedly
underrepresented. The causality of the relationships between depressive symptoms and
each of the two biomarkers remains unconfirmed, yet the integration of depression and
cancer literature adequately supports the plausibility that aberrant cortisol profiles and
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shorter TL could play a role in the pathway linking depressive symptoms and shorter
survival in cancer. Thus, it is proposed cortisol profiles, a biomarker of circadian
coordinated neuroendocrine function, and TL, a biomarker of cellular aging, help explain
how depressive symptoms lead to shorter survival in lung and other cancers.
While the elucidation of biological explanations for the depression-survival
relationship in lung and other cancers is needed, cancer patients with untreated
depression continue to suffer from poorer quality and quantity of life, pointing to the
need for efficacious and effective psychosocial interventions. Despite more recent
improvements in efforts to acknowledge and treat comorbid mental illnesses among
cancer populations, continued efforts are warranted as they have the potential to mitigate
the unpleasant experience of depressive symptoms and related downstream clinical
consequences. Mindfulness-based interventions (MBIs) broadly and Mindfulness-based
Stress Reduction (MBSR) in particular, have demonstrated promise for reducing
psychological and biological aspects of stress in cancer populations, although fewer
studies have examined their role in reducing depressive symptoms and related outcomes.
Aim 2: Mindfulness-based Interventions in Cancer Contexts
Since Jon Kabat-Zinn (1982) introduced the first MBI, known as the MBSR
program, to chronic pain patients at the University of Massachusetts Medical Center in
1979, the use of MBIs in western health settings has advanced at an accelerated rate (R.
A. Baer, 2003). Rooted in Buddhist philosophy, mindfulness has been described as
“paying attention in a particular way: on purpose, in the present moment, and
nonjudgmentally” (Kabat-Zinn (1994), p. 4). A skill that is typically obtained through
meditative practice – “the intentional self-regulation of attention from moment to
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moment” (Kabat-Zinn, 1982), p.34) – these philosophies and skills, stemming largely
from Kabat-Zinn’s seminal work, have been adapted into a host of health-related
interventions. Referred to as the “third wave” of therapy (Hayes, 2004), MBI’s have been
adapted to reduce symptoms of distress in traditional psychotherapeutic settings as well
as in medical contexts.
Despite differences between them, MBI’s, including MBSR, are largely centered
on acceptance without judgment, practice without attachment to an outcome, and an
intention to enhance the mind-body connection in order to regain a degree of control over
one’s well being. Unlike other stress-reducing strategies, such as problem-focused
coping, which involves direct attempts to change a stressor (Lazarus & Folkman, 1984),
mindfulness-based strategies are detached from the expectation for things to be different
via an attitude of acceptance. These theoretical pillars resonate with many aspects of
chronic illness, including cancer, given that illness typically sources a lack of control and
considerable uncertainty and requires continual adjustment (Carlson et al., 2013). As
such, MBSR has been adapted specifically for cancer patients by Carlson and colleagues
(2010), a program referred to as mindfulness-based cancer recovery (MBCR),
demonstrating the applicability of mindfulness in cancer contexts.
The traditional, manualized MBSR program developed by Kabat-Zinn is an 8week group intervention that meets weekly for approximately two and a half hours to
provide participants with instruction, practice, and discussion of mindfulness and
mindfulness-based skills (e.g., walking, standing, eating, body scan). In addition to
meditation practices, to obtain “detached self-observation” (Kabat-Zinn (1982), p. 34)
hatha yoga is included to enhance bodily sensations and strengthen the mind-body
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connection. Participants are also asked to practice at least 45 minutes per day, six days
per week between in-person weekly group meetings, and are encouraged to participate in
a day log (~6 hour) retreat toward the end of the program. For an extensive description of
the structure and content of the MBSR program, see Kabat-Zinn (1982). Taken together,
the format of MBSR and MBCR, which mirrors the format of MBSR closely, requires
considerable commitment and in-person attendance.
Effectiveness of MBSR in Cancer. Certainly, the in-person group format of
these interventions likely fosters benefit, potentially in the form of a sense of
connectedness (Carlson, 2013), social support, and accountability; however, the
commitment in-person interventions require limits feasibility for some patients,
particularly those with greater burden and fewer resources. A focus group conducted
among a small group of lung cancer patients (N = 11) designed to discuss perceptions of
MBIs identified the following barriers to participation: transportation and financial
issues, limits to physical functioning, lack of interest, feeling overwhelmed with new
appointments/obligations, cognitive changes including forgetfulness, and time
commitment (Lehto & Wyatt, 2013). Further, as MBSR has recently been described as “a
phenomenon of wealthy white western women” (Carlson, 2018), it is plausible groupbased MBIs may not be appealing to individuals who do not fall into those
sociodemographic categories.
To start addressing these barriers, Zernicke and colleagues (2013) conducted an
online MBCR program to promote feasibility. Although this program reported a small
(20%) drop out rate, confirming feasibility for this program in mobile format, this
intervention preserved the group component by requiring a set virtual meeting time each
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week. Participants essentially formed an online classroom environment equipped with an
instructor. Thus, this study largely maintained the structure of traditional MBSR despite
being accessible remotely via a website. Although the intervention demonstrated
significant improvements in mood disturbance and stress symptoms, it did not shed light
on whether group participation is an active component or if these changes can be
achieved through mobile platforms that forego a group commitment. Of the 1,800
patients invited to participate, only 180 expressed interest with a final enrollment of 62,
warranting further exploration into the potential benefits of a mobile MBSR program that
delivers core components (e.g., meditation practice), but does not require group
involvement.
Lengacher and colleagues (2018) recently piloted the efficacy and feasibility of an
iPad-based MBSR(CR) intervention that eliminated the group component among a small
sample (N = 15) of breast cancer survivors. Results from the study revealed statistically
significant improvements in psychological and somatic symptoms of depression with a
large effect size (d = 0.85), in addition to a host of other symptom improvements.
Additionally, patients described the iPad intervention as “convenient and easy to use,”
and approximately 87% of the enrolled participants completed the program (p. 527).
Although a small pilot, this study provides preliminary evidence for the efficacy and
feasibility of mobile MBSR intervention that forgo the group, face-to-face components.
Efficacy of MBSR in Cancer. Depressive symptoms. Although the active
components and mechanisms by which MSBR enhances one’s ability to cope with
disease, the optimal “prescribed” amount and the optimal intervention time point remains
unknown (Dobkin & Zhao, 2011; Hunt, Al-Braiki, Dailey, Russell, & Simon, 2018),
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MBSR has demonstrated efficacy in reducing psychological distress and depressive
symptoms in cancer contexts (Dobkin & Zhao, 2011; Lengacher et al., 2018; Shennan,
Payne, & Fenlon, 2011). Two separate meta-analyses that examined the efficacy of
MBSR interventions among breast cancer patients demonstrated significant
improvements in depressive symptoms (Huang, He, Wang, & Zhou, 2016; Zainal, Booth,
& Huppert, 2013); d = 0.575). In contrast, a more recent meta-analysis indicated MBSR
efficaciously reduced depressive symptoms for all cancers patients except for breast
cancer (Zhang, Wen, et al., 2015). These contradictory results are somewhat puzzling,
especially given that the majority of MBI studies have been conducted among breast
cancer samples.
Further, although the majority of studies report improvements to stress symptoms
broadly, some report no improvements to depressive symptoms specifically. For instance,
in one RCT among cancer patients with varied types of cancers, MBSR did not
demonstrate a significant reduction in depressive symptoms at a 6-month follow-up
(Bränström, Kvillemo, & Moskowitz, 2012). In this study, however, the majority of
patients (86%) had received their diagnosis over a year from study participation,
suggesting MBSR interventions may be most efficacious when conducted closer to
diagnosis. Taken together, some of the inconsistent findings regarding MBSR’s effects
on depressive symptoms may stem from variation in cancer types, assessment time
frames, and intervention time points in the cancer trajectory (e.g., at diagnosis versus in
survivorship), necessitating further investigation into the effects of MBSR’s on
depressive symptom among patients who suffer from cancers other than breast, including
lung, and at time points more proximal to the intervention.
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Cortisol. In addition to reducing psychological aspect of stress, MBIs and MBSR
have demonstrated some, although more mixed, evidence for the efficacy of improving
aspects of physical health (Ledesma & Kumano, 2009). Although, few interventions to
date have examined the efficacy of MBSR on markers of cortisol in cancer contexts,
some evidence exists. For example, Lengacher and colleagues (2012) reported a
significant reduction in cortisol levels from pre-MBSR following week one and three of
the 6-week intervention among a sample of advanced (stage III or IV) cancer patients,
which included lung malignancies (20% of the sample). Although there were no
significant differences in cortisol levels pre- and post-intervention, only at week one and
three during the intervention, the authors reported cortisol levels were much lower
(roughly half) from pre to post, differences that may have been undetected due to a small
sample size (N = 26). Similarly, Branstrom and colleagues (2013) did not observe effects
of the MBSR intervention on cortisol at a 3- and 6-month follow-up among women with
different cancers, but the authors observed a moderating intervention effect – patients that
participated in the intervention with initially low levels of waking cortisol demonstrated
an increase whereas those with initially high levels of waking cortisol demonstrated a
decrease at the 3-month follow-up. Although the implications of these findings are
somewhat ambiguous, these results suggest MBSR may have the potential to regulate
aberrant HPA-axis activity, whether initially hyper- or hypo-active.
Similarly, Carlson and colleagues (2004) reported no changes in diurnal mean
cortisol or cortisol slope among early staged (I or II) breast and prostate cancer patients
(N = 59) following an MBSR intervention. However, they did observed fewer elevations
in evening cortisol post-intervention as well as shifts in abnormal cortisol secretion
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patterns from an inverted V shape (highest levels in the afternoon) to a V shape (lowest
levels in the afternoon), reflecting a shift toward more regulated diurnal cortisol profiles.
Interestingly, upon re-assessment at 6- and 12-months post-intervention (N = 33), a linear
decrease in overall diurnal mean cortisol, mostly driven by decreases in evening levels,
was observed across time points (Carlson, Speca, Faris, & Patel, 2007), indicative of a
healthier diurnal cortisol profile. In a different RCT comparing the effects of an MBCR
intervention to a group, emotion-focused intervention (SET) and a one-day stress
management control condition among breast cancer survivors, cortisol slopes were
maintained in both treatments compared to the control condition, whose slopes became
flatter (Carlson et al., 2013). Although these results did not demonstrate unique effects of
MBSR on cortisol profiles, it highlights the potential for decline in neuroendocrine
function when cancer patients forego psychosocial interventions. Taken together, the
evidence for the efficacy of MBSR interventions on regulation of cortisol profiles
remains both mixed and convoluted, but seem to suggest MBSR interventions may delay,
rather than improve dysregulation of neuroendocrine function that tends to accompany
tumor progression. However, the majority of studies examining these effects have been
conducted primarily among certain cancers (i.e., breast) among earlier stages of disease,
warranting greater attention to other malignancies, especially those typically diagnosed at
later stages, such as lung.
TL. Despite the relatively recent surge of both TL and MBIs in stress and cancer
research, nearly no studies to date have examined them simultaneously. While somewhat
greater attention has been directed toward the effects of MBIs on TL in non-clinical
samples (Epel, Daubenmier, Moskowitz, Folkman, & Blackburn, 2009) and has
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demonstrated some efficacy for lengthening telomeres (Conklin et al., 2018; Hoge et al.,
2013), limited studies have been conducted in and out of cancer populations. One nonmindfulness-based intervention (phone counseling) among cervical cancer survivors
reported a moderating effect of decreased distress with increased TL, indicating TL is
potentially modifiable via psychosocial interventions following reduction in
psychological distress (Biegler, Anderson, Wenzel, Osann, & Nelson, 2012). The only
study that has examined the effects of an MBI on TL in cancer contexts to date was
conducted by Carlson and colleagues (2015). Building on the parent RCT described
above (Carlson et al., 2013), a sample of distressed breast cancer survivors were
randomized to the MBCR, SET, or a one-day stress management control condition.
Results revealed no significant differences in TL between groups post intervention.
Similar to the cortisol findings, however, there was a trend observed between the
intervention groups and the control condition – TL in either intervention group (MBCR
or SET) was maintained, whereas TL decreased among control condition patients. While
the differences were not statistically significant and the long-term effects were not
reported, these results point to the possibility that MBSR could contribute to TL
maintenance (lack of a decrease) over the course of a 3-month intervention period,
although further investigation is needed.
The only other intervention study in cancer that examined TL was conducted by
Ornish and colleagues (2013). The intervention consisted of a host of comprehensive
lifestyle changes in diet, activity, social support, and stress management, which included
elements of MBSR (i.e., yoga-based stretching, breathing, meditation, progressive
relaxation) among low-risk prostate cancer patients that had opted to undergo
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surveillance opposed to typical treatment. Results from a 5-year follow-up demonstrated
a significant increase in TL among the intervention group and a decrease in TL among
the control group, although it is unclear if the improvements stemmed from the stress
management component or were driven by other aspects of the intervention. Taken
together, the potential benefits of an MBI on TL among cancer patients remains relatively
unexplored despite considerable evidence demonstrating psychological distress has
shortening effects on TL, a biological mechanism that has important implications in
tumor development and progression. Although the evidence is scarce, MBSR may be one
avenue to target depressive symptoms and downstream consequences, including TL.
Survival. Although debated extensively for some time, psychological
interventions have demonstrated efficacy for improving survival time among cancer
patients (Andersen et al., 2008; Spiegel et al., 1989). Reviewed comprehensively by
Spiegel (2011) and Antoni (2013), a number of studies have established compelling
evidence to conclude psychosocial interventions can foster benefit by enhancing quality
and quality of life for cancer patients. Despite being one of the most distressed cancer
type populations (Carlson et al., 2004), the effects of a psychosocial intervention,
including an MBI, on survival have yet to be tested among lung cancer patients. The
majority of psychosocial interventions have been rooted in cognitive behavioral therapy
(CBT) or functioned as an emotional support group and have largely been conducted
among breast cancer patients/survivors (Antoni, 2013), necessitating greater attention to
the potential benefits of MBIs on both quality and quantity of life among lung cancer
patients.
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Taken all together, evidence suggests that cancer patients experience high levels
of distress and depressive symptoms, which have demonstrated prognostic significance in
cancer contexts. Although the biological pathways by which depressive symptoms lead to
poorer survival currently remain unclear, evidence points to the dysregulation of
circadian coordinated neuroendocrine function and cellular aging processes, which can be
assessed by markers of cortisol and TL, respectively. Current literature points to the need
for greater exploration into the role of these biological systems in the context of the
depression-survival relationship. Nonetheless, knowing that depressive symptoms worsen
both quality and quantity of life in cancer contexts, interventions that efficaciously and
effectively reduce depressive symptoms that offer feasibility and accessibility are a
clinical priority.
Study Aims
The current study attempts to begin elucidating how depressive symptoms lead to
shorter survival and how to efficaciously and effectively treat depressive symptoms and
related outcomes among NSCLC patients. Thus, the primary aims of the current study are
to 1) replicate the prognostic significance of depressive symptoms and explore the role of
two biomarkers – cortisol and leukocyte telomere length (LTL) – as they relate to the
depression-survival pathway and 2) explore the ameliorative role of an iPod-based
MBSR intervention on depressive symptoms and related outcomes among NSCLC
patients. Specifically, regarding Aim 1, if depressive symptoms emerge as a significant
predictor of shorter survival and are significantly associated with a biomarker (cortisol
and LTL), then the association between the significant biomarker(s) and the depressionsurvival pathway will be explored. Additionally, regarding Aim 2, if the iPod-based
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MBSR intervention attenuates depressive symptoms, then the benefits of the intervention
will be explored among biological and clinical outcomes. In accordance with the primary
aims of this study, the following hypotheses are outlined below and visually presented in
Figure 1.
Hypotheses
Aim 1. Hypothesis 1a. More depressive symptoms will predict shorter survival.
Hypothesis 1b. More depressive symptoms will be associated with greater cortisol
dysregulation (higher overall mean and bedtime cortisol and flatter diurnal cortisol
slopes).
Hypothesis 1c. More depressive symptoms will be associated with shorter LTL.
Hypothesis 1d. If hypothesis 1a and 1b emerge as significant, then greater cortisol
dysregulation will be associated with both depressive symptoms and shorter survival.
Hypothesis 1e. If hypothesis 1a and 1c emerge as significant, then shorter LTL
will be associated with both depressive symptoms and shorter survival.
Aim 2. Hypothesis 2a. Participation in and use of the intervention will be
associated with fewer depressive symptoms from baseline to follow-up.
Hypothesis 2b. Participation in and greater use of the intervention will be
associated with improved diurnal cortisol rhythmicity from baseline to follow-up.
Hypothesis 2c. Participation in and greater use of the intervention will be
associated with maintenance of LTL (lack of a decrease) from baseline to follow-up.
Hypothesis 2d. Participation in and use of the intervention will be associated with
longer survival.
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METHODS
Data were collected as part of a larger study investigating the prognostic
significance of circadian disruption in lung cancer patients (University of Louisville IRB
13.0508).
Participants
NSCLC patients were recruited from the James Graham Brown Cancer Center
with the assistance and support of collaborating medical staff, such as oncologists and
nurses. Eligible patients were diagnosed with non-small cell lung cancer within five years
of study entry, were ages 18–85, resided within a 120-mile radius of the recruitment
center, had no medical diagnosis likely to influence six-month survival, no immunecompromising condition, and no recent history of psychiatric hospitalization or substance
abuse. A total of 65 patients met inclusion criteria and consented.
Procedure
Recruitment. Recruitment personnel checked eligibility criteria using a
standardized chart review. Following identification of eligible participants, collaborating
physicians introduced patients to study personnel during their scheduled appointment.
Recruitment personnel provided patients with an overview of the study, answered
questions, and obtained informed consent from those willing to participate. All study
procedures were conducted in accordance with University of Louisville Human Subjects
Protection Program guidelines.
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Baseline data collection. Participants received detailed instructions and materials
for 10-day at home baseline data collection. Materials included a packet containing a
battery of questionnaires to be completed in one sitting, a packet of daily questionnaires
to be completed each morning and night over the course of the 10 days, and a salivary
cortisol kit containing 20 salivettes. Prior to leaving the clinic, participants completed a
blood draw for telomere length assessment conducted by a trained phlebotomist. Study
personnel called participants mid-way through data collection (approximately day five) to
check-in, provide reminders, and answer questions regarding data collection. Following
the baseline data collection, study personnel collected materials from participants,
compensated their efforts with a $100 Visa gift card, and re-introduced the iPod-based
MBSR intervention in detail.
iPod- and mindfulness-based pilot intervention. Study personnel introduced
mindfulness to participants as a distress-reducing technique, invited participants to attend
a bi-weekly drop-in mindfulness-based cancer support group, and provided participants
with an iPod containing mindfulness audio tracks. The audio tracks were recorded by
clinical psychologist and co-investigator, who is both knowledgeable and skilled in
mindfulness practice. The tracks were based on the Mindfulness-based Stress Reduction
(MBSR) program (Kabat-Zinn, 1982). Some of the tracks provide instructional narratives
about the foundations of mindfulness, whereas others function as guided meditation on
eating, breathing, listening, thinking, feeling and the body as a whole. A list of tracks is
provided in Table 1. Participants that agreed to participate in the optional pilot
intervention were taught how to use the device, and to enhance feasibility and adherence,
patients were asked to listen to tracks of their choice for 30 minutes per day, five days per
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week. Although the iPods documented which tracks were selected and completed,
participants were also provided with a log to document listening behavior. Participants
returned their iPods and listening logs at their three month follow-up appointment. Over
the course of the three month intervention, study personnel called to check-in, provide
reminders, and answer questions about the intervention at approximately one and two
months. Study personnel downloaded track data using iTunes software and returned the
iPod to participants to compensate their intervention participation efforts.
Follow-up data collection. Regardless of whether patients opted to participate in
the intervention, they were asked to attend a three month follow-up appointment at the
Cancer Center. Similar to baseline data collection, participants were provided with
instructions and materials for at home data collection, but for six instead of 10 days.
Materials included a packet containing a battery of questionnaires to be completed in one
sitting, a packet of daily questionnaires to be completed each morning and night over the
course of the six days, and a salivary cortisol kit containing 12 salivettes. Participants
provided another blood sample prior to leaving the clinic. Following follow-up data
collection, study personnel met with participants to collect materials, provide them with a
second $100 Visa gift card to compensate them for follow-up data collection efforts, and
obtain feedback about the study.
Salivary cortisol. Collection. Participants were asked to collect two saliva
samples per day – one immediately upon waking and the other as close to bedtime as
possible for 10 and six consecutive days of baseline and follow-up data collection,
respectively, to enable calculation of diurnal cortisol profiles. The salivary cortisol kit
that participants received for baseline and follow-up contained 20 and 12 “salivettes,”
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respectively. The salivettes were pre-labeled and arranged consecutively by day and time
with space for participants to record their assigned study ID, the date, and the exact time
that the sample was collected in sharpie. Salivettes were also color coordinated by
collection time; salivettes to be collected at waking had yellow labels whereas bedtime
salivettes had blue labels to maximize likelihood of participants’ accuracy.
To collect a sample, participants were instructed to remove the salivette cap, place
the cotton swab in their mouth for approximately two minutes, or until the swab was fully
saturated. While the cotton swab was in the participants’ mouths, they were advised to
record their study ID, the date, and time of collection on the tube. Participants were then
asked to spit the saturated cottons swab back into the salivette tube, replace the salivette
cap, and store the sample in the refrigerator in the provided Ziploc bag. Participants were
instructed to keep collected saliva samples in the refrigerator until materials were
returned to study personnel. Participants were instructed not to put anything in their
mouth – eat, drink, smoke, chew gum, brush their teeth, etc. – 30 minutes prior to
collection a sample to minimize contamination of cortisol. The importance of collecting
morning samples immediately upon waking, recording the exact time that the sample was
collected, and reporting any deviations from the protocol was explained to participants by
study personnel. To enhance adherence and accuracy, participants were advised to keep
the salivary cortisol kit next to their bedside. The daily questionnaire packet participants
were asked to complete each morning and night contained detailed instructions for saliva
collection and space to record deviations from the protocol as needed.
Assay. Once study materials were returned, saliva samples remained in the
refrigerator until they were prepared to be assayed. The majority of the samples were
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prepped within a few days of collection of the last sample, although no samples were
prepped beyond one month of the at home collection of the last sample. Saliva samples
were centrifuged for 15 minutes at 453 g at 25°C. Samples were then aliquoted into
microcentrifuge tubes and stored at -80°C until they were assayed. Cortisol levels were
then assed using an enzyme-linked immunoabsorbent assay (ELISA; Salimetrics, Inc.,
State College, PA). Assay sensitivity was 0.007 µg/dL. The average inter-assay and intraassay coefficients of variation (CV) were under 10% for both the low and high control.
Leukocyte telomere length (LTL). Collection. Blood samples were collected in
K2 EDTA purple top tubes during baseline and follow-up appointments at the Cancer
Center and were kept on ice until they were transferred to the laboratory by study
personnel. At the laboratory samples were centrifuged at 1300 RCF for 10 minutes at
4°C. The layer of plasma on top of each tube was transferred via pipet into 3-5 (volume
dependent) 1.5 mL microcentrifuge tubes that were kept on ice. The remaining cell pellet
(red blood cell + white blood cell) at the bottom of each tube was also transferred via
pipet into 3-5 (volume dependent) 1.5 mL microcentrifuge tubes that were kept on ice.
All tubes were then frozen immediately at -80°C. This procedure did not exceed two
hours from the blood draw.
Following completion of data collection, a total of 107 (67 baseline and 40
follow-up) frozen blood cell pellet samples were packed and shipped from the University
of Louisville to Dr. Elizabeth Blackburn’s laboratory at the University of California San
Francisco. Shipping procedures adhered to the University of Louisville’s Department of
Environmental Health and Safety protocol. Grant funds were used to compensate Dr. Jue
Lin of Dr. Blackburn’s Laboratory, who conducted telomere length assays using an
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adapted protocol (Lin et al., 2010) from methodology originally outlined by Cawthon
(2002).
Assay. The following methodological description of the assay process was
provided by Dr. Lin, “A telomere (T) primer and single copy gene (S) primer pair were
prepared. The primers used for the telomere polymerase chain reaction (PCR) were
tel1b [5'-CGGTTT(GTTTGG)5GTT-3'], used at a final concentration of 100 nM,
and tel2b [5'-GGCTTG(CCTTAC)5CCT-3'], used at a final concentration of 900 nM. The
primers used for the single-copy gene (human beta-globin) PCR were
hbg1 [5'GCTTCTGACACAACTGTGTTCACTAGC-3'], at a final concentration of 300
nM, and hbg2 [5'-CACCAACTTCATCCACGTTCACC-3'], at a final concentration of
700 nM. The final reaction mix contained 20 mM Tris-HCl, pH 8.4; 50 mM KCl; 200
mM each dNTP; 1% DMSO; 0.4x Syber Green I; 22 ng E. coli DNA per reaction; 0.4
Units of Platinum Taq DNA polymerase (Invitrogen Inc.) per 11 µl reaction; ~6ng of
genomic DNA. Tubes containing 26, 8.75, 2.9, 0.97, 0.324 and 0.108ng of a reference
DNA (a commercial genomic DNA from pooled leukocytes from Roche Diagnostics
Corporation, Indianapolis, IN) are included in each PCR run so that the quantity of
targeted templates in each research sample can be determined relative to the reference
DNA sample by the standard curve method. The same reference DNA was used for all
PCR runs.
The telomere thermal cycling profile consisted of cycling for telomeric (T) PRC:
96°C for 1 minute; denature at 96°C for 1 second, anneal/extend at 54°C for 60 seconds,
with fluorescence data collection for 30 cycles and cycling for single copy gene (S) PCR:
96°C for 1 minute; denature at 95°C for 15 seconds, anneal at 58°C for 1 second, extend
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at 72°C for 20 seconds, 8 cycles; followed by denature at 96°C for 1 second, anneal at
58°C for 1 second, extend at 72°C for 20 seconds, hold at 83°C for 5 seconds with data
collection for 35 cycles.
To control for inter-assay variability, 8 control DNA samples are included in each
run. In each batch, the T (telomeric) /S (single copy gene) ratio of each control DNA is
divided by the average T/S ratio for the same DNA from 10 runs to get a normalizing
factor. This is done for all 8 samples and the average normalizing factor for all 8 samples
is used to correct the participant DNA samples to get the final T/S ratio. The T/S ratio for
each sample will be measured twice. When the duplicate T/S value and the initial value
vary by more than 7%, the sample will be run the third time and the two closest values
were reported. The average CV for this study was 2.4%.”
Survival data. An electronic chart review was conducted on February 15th, 2019
at the Cancer Center, which revealed a survival rate sufficient for analysis (46.3%; Bland
and Altman (2004). The date of death was recorded and entered into SPSS for any
participant who had passed away. It is expected, that as of the cut off date (2/15/19),
survival data may lag behind actual data by approximately six months.
See Figure 3 for a visual depiction of the phases of the study when variables of
interest were collected.
Measures
Demographic and medical variables. Medical and demographic variables were
gathered via self-report and confirmed through medical chart review and are summarized
in Table 2. Smoking history was quantified as ‘pack years,’ which reflects the product of
number of packs of cigarettes per day by years of smoking.
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Depressive symptoms. The packet of questionnaires completed by participants
during baseline and follow-up data collection included the Center for Epidemiological
Studies – Depression (CES-D; Radloff (1977), which was used to measure depressive
symptoms. The CES-D is composed of 20 items that assess depressive symptoms over
the past week on a four-point scale ranging from “rarely or none of the time (less than
one day)” and “most of all of the time (5-7 days).” The total score is comprised of the
sum of the 16 depressive symptoms items and the reverse score of the four positive affect
items. Scores greater than 16 indicate risk for clinical depression. The CES-D is a
commonly used measure of depressive symptoms among medically ill populations,
including cancer. Among breast cancer patients, the CES-D has demonstrated high
internal consistency (Cronbach α = 0.85), adequate test-retest reliability, and construct
validity (Hann, Winter, & Jacobsen, 1999). In the present study, internal consistency was
acceptable and good at baseline and follow-up (Cronbach α = .77; .83), respectively.
Cortisol. Salivary cortisol was collected at two time points over the course of 10
days based on empirically driven recommendations for reliable between-person cortisol
estimates for calculation of diurnal cortisol slope (Segerstrom et al., 2014). However, to
lessen the burden and increase likelihood of participation, follow-up cortisol data
procedures were reduced to six days of at home collection. After samples were assayed,
the CV was checked.
LTL. The relative T/S ratios obtained from the quantitative PCR is a reflection of
overall LTL.
Statistical Analyses
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Data preprocessing. Data preparation and analyses were conducted using SPSS
v25.0 (SPSS IBM, Armonk, NY, 2017). Data was entered by two research assistants
separately in independent datasets and subsequently compared to ensure accuracy.
Data reduction and scoring. Sample characteristics. Characteristics of the
sample were determined by calculating frequency, percentage, and mean data on
demographic and medical factors and are provided in Table 2.
Depressive symptoms. Summary scores were calculated for the CES-D assessed
at baseline and follow-up. For less than 50% of data missing from the CES-D, missing
data points were replaced using the mean of other responses. If a participant missed more
than half of the questionnaire, missing data was not replaced.
Cortisol. Raw cortisol data consisted of an exact collection time from the saliva
collection tubes and a laboratory-generated cortisol value (µg/dl) from the assay. Sample
collection times reported by subjects were checked and corrected using wrist-worn
actigraphy data, which was collected for aims of the parent study. Cortisol samples
collected more than 15 minutes after waking (as determined by the actigraphy data) were
excluded. Raw cortisol values were log-transformed to adjust for positive skew. Diurnal
mean cortisol values were calculated for waking, bedtime, and overall mean using logtransformed values for each individual. Cortisol values were also regressed on collection
time to calculate a diurnal cortisol slope for each individual (Sephton, 2000; Sephton et
al., 2013). The regression of 20 values (waking and bedtime collected over 10 days) and
12 values (waking and bedtime collected over six days) were calculated for baseline and
follow-up, respectively. The unstandardized beta (slope of the regression) represents the
diurnal salivary cortisol slope (Kraemer et al., 2006). Diurnal slopes are typically
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negative with higher values indicative of flattened slopes. Thus, three indicators of
diurnal cortisol included in analyses included: 1) log-transformed overall mean, 2) logtransformed bedtime mean, and 3) diurnal slope using log-transformed values. Waking
mean will be excluded as a variable in the analysis as it has not previously demonstrated
distinct associations with depression or survival in cancer, whereas overall mean (Board
et al., 1957), bedtime mean (Schrepf et al., 2015), and slope (Sephton et al., 2013) have.
Intervention. Because the intervention was a pilot, presented as optional, and
lacked a randomized control group, participants’ participation status was coded as
participated (n = 25) or not (n = 42). Using the data logged by the iPod and downloaded
by study personnel following the intervention, variables indicating total listening time
and total number of tracks listened to were created. Prior to calculation of variables, the
listening log that participants completed by hand was used to crosscheck the data
recorded by the device.
Survival. A categorical variable (yes/no) indicating whether the patient had died
(all cause mortality) as of February 15, 2019 was created. The amount of time (in days)
from date of study entry to date of death was calculated for patients who had died. For
living patients, this tracking variable reflects the number of days from study entry to the
cessation of tracking on February 15th, 2019. Survival or tracking time (in days) was also
calculated from each participant’s date of diagnosis to either date of death or the date of
tracking cessation (e.g., February 15, 2019).
Analytic approach. The overall analytic approach followed the MacArthur
approach (Chmura Kraemer et al., 2008) and recommendations outlined by Kraemer and
colleagues (2001). Prior to regression analysis, all continuous independent and control
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variables (e.g., age at diagnosis) were median centered and binary control variables (e.g.,
sex) were effects coded (i.e., -1/2, +1/2) to improve interpretation and minimize error
(Kraemer & Blasey, 2004).
Theoretically derived control variables were identified for each dependent
variable. A data driven approach was then taken to test the contribution of each proposed
variable using Spearman’s rank-order correlations. According to Kraemer and colleagues
(2001) indicators that are only associated with the dependent variable should be entered
into the first step of the model as a covariate, whereas indicators that are associated with
both the independent and the dependent variable should be entered into the first step of
the model as a ‘proxy’ with the independent variable and the interaction between the two.
‘Proxy risk factors’ are risk factors, but are correlates of the independent variable, an
association that should be accounted for according to Kraemer et al. (2001). This
approach was taken for the current analysis. Thus, the association between each
theoretically derived covariate and the independent and dependent variable was examined
prior to the proposed analysis. Indicators were included in the model if they demonstrated
a strong enough relationship with the dependent and/or independent variable (effect size
> 0.3) to ensure contribution without increasing risk of multicollinearity (effect size <
0.5). Additionally, because the intervention was not randomized, intervention
participation status (yes/no) was also tested as a covariate in all models that included a
longitudinal variable.
Preliminary analysis. Data were explored and tested for assumptions of
parametric data, including tests for normality, significant outliers, linearity, and
homoscedasticity (Field, 2013). All variables were examined for outliers; scores greater
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than four standard deviations from the mean were assessed for removal prior to analysis.
Scatterplots, boxplots, histograms, and Predicted probability (P-P) plots were examined
for each continuous variable. Skewness and kurtosis statistics were calculated for
continuous variables by dividing the statistic by the standard error. Those that failed to
meet assumptions by visual inspection or by z-skewness values outside of the 95%
confidence interval (values > 1.96) were assessed for transformation. Variables were
transformed according to the parameters provided by Field (2013). All transformed
variables were re-assessed for assumptions prior to analysis.
Additional assumptions were checked prior to conducting ANCOVA tests. To
confirm the independence of the covariate and treatment effect, independent-samples ttests were conducted between the independent variable and the covariant to ensure that
the covariate was independent of the treatment effect. As a part of the analysis, the
Levine’s test was used as a preliminary assessment of the homogeneity of regression
slopes analysis.
All other assumptions for survival statistical tests (i.e., Kaplan-Meier using log
rank and Cox Proportional Hazards regressions) were confirmed prior to running
analyses.
Primary analysis. In addition to examining each hypothesized association
including constructs assessed at baseline, to examine change in constructs over time
(from baseline to follow-up), a within-subjects regression coefficient analysis was
conducted on depressive symptoms, markers of cortisol, and LTL for each participant. In
other words, for each participant, the slope of change (from baseline to follow-up) and
intercepts were calculated for depressive symptoms, markers of cortisol, and LTL. Each
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variable (e.g., depressive symptoms) was regressed on collection time points – baseline
and follow-up – to calculate a slope of change (the unstandardized beta) using a linear
regression. Thus, the calculated slope represents a change (e.g., in depressive symptoms)
over the intervention period for each participant, regardless of participation status. The
intercept value was entered as a covariate to control for baseline individual differences.
Regarding loss to follow-up, analyses were first conducted with the available
data. Analyses were subsequently conducted handling missing data using the intent-totreat principles outlined by Lachin (2000). Following these principles, baseline values
were used to replace missing values at follow-up, resulting in a slope of zero (i.e., no
observed change).
Covariates. Spearman’s rank-order correlations were used to assess the
contribution of theoretically derived indicators in cancer samples for each independent
and dependent variable. Theoretically derived and tested indicators of survival,
depression, and markers of cortisol included: disease stage, age, age at diagnosis, sex,
prior/current treatment (chemotherapy/radiotherapy), and tobacco history in pack-years.
Theoretically derived and tested indicators of LTL included: disease stage, age, age at
diagnosis, sex, prior/current treatment (chemotherapy/radiotherapy), tobacco history in
pack-years and ethnic minority status. Results from these analyses were used to
determine inclusion of covariates in the subsequent analyses (see Tables 3 – 5).
Aim 1. Hypothesis 1a. Baseline. To test the prognostic value of baseline
depressive symptoms on survival calculated from the date of study entry and the date of
diagnosis two separate two-tailed Cox Proportional Hazards regressions were conducted.
Sex was entered into the first step of the model as a covariate on survival calculated from
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study entry (Table 3). Each model was run with and without intervention participation
status included as a covariate.
Slope of change and intent-to-treat principles. To test the prognostic value of
change in depressive symptoms on survival calculated from the date of study entry and
the date of diagnosis, two separate two-tailed Cox Proportional Hazards regressions were
conducted. Sex was entered into the first step of the model as a covariate on survival
calculated from study entry (Table 3). Each model was run with and without use of the
intervention included as a covariate. The same analyses were subsequently conducted
using intent-to-treat principles outlined by Lachin (2000); i.e., baseline values were used
to replace missing values at follow-up, resulting in a slope of zero (i.e., no observed
change), resulting in a total of eight regressions.
Hypothesis 1b. Baseline. To test the baseline association between depressive
symptoms and markers of diurnal cortisol profiles (overall mean, bedtime mean, and
diurnal slope), separate hierarchical linear regressions were conducted. Each marker of
cortisol was tested as the outcomes in separate models. Age at study entry and age at
diagnosis were entered into the first step of two separate models as a covariate on
bedtime mean cortisol (Table 4).
Slope of change and intent-to-treat principles. To test the association between
change in depressive symptoms and change in cortisol profiles (overall mean, bedtime
mean, and diurnal slope), separate hierarchical linear regressions were conducted. Each
marker of cortisol was tested as the outcome in separate models. Each model was run
with and without use of the intervention included as a covariate. The same analyses were
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subsequently re-conducted using intent-to-treat principles outlined by Lachin (2000),
resulting in a total of 12 regressions.
Hypothesis 1c. Baseline. To test the association between depressive symptoms
and LTL assessed at baseline, a hierarchical linear regression was conducted. Age at
diagnosis was entered into the first step of the model as covariate (Table 5).
Slope of change and intent-to-treat principles. To test the association between
change in depressive symptoms and change in LTL, a hierarchical linear regression was
conducted. Minority status was entered into the first step of the model as covariate (Table
5). The model was run with and without use of the intervention included as a covariate.
The same analyses were subsequently re-conducted using intent-to-treat principles
outlined by Lachin (2000), resulting in a total of four regressions.
Hypothesis 1d. Because the proposed conditions were not met (see results of
hypothesis 1a and 1b), hypothesis 1d (i.e., if hypothesis 1a and 1b emerge as significant,
then greater cortisol dysregulation will be associated with both depressive symptoms and
shorter survival) was not examined.
Hypothesis 1e. Because the proposed conditions were only partially supported
independent of the intervention (see results of hypothesis 1a), hypothesis 1e (i.e., if
hypothesis 1a and 1c emerge as significant, then shorter LTL will be associated with both
depressive symptoms and shorter survival) was not examined as proposed. However, as a
part of the post-hoc analysis to elucidate results that emerged following the analysis of
hypothesis 2c, the prognostic significance of LTL was ultimately examined.
Aim 2. Because the intervention was a pilot, not randomized, an exploratory
analysis was conducted to elucidate baseline group differences between patients who
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participated in the intervention and those who did not. Demographic and medical factors
were compared between the two groups using independent samples t-tests, Chi-square
tests, and Mann-Whitney U tests to elucidate potential confounding continuous,
dichotomous, and categorical variables, respectively. Results from these analyses were
used to determine inclusion of covariates in the subsequent analyses (see Table 6).
Hypothesis 2a. Participation. To test if participation in the intervention (yes/no)
was associated with a change in depressive symptoms, an ANCOVA was conducted.
Both chemotherapy treatment status at baseline (yes/no; Table 6), and the intercept from
the within-subjects regression coefficient analysis (to control for individual differences at
baseline) were entered as covariates. The same analyses were subsequently re-conducted
using intent-to-treat principles outlined by Lachin (2000), resulting in a total of two
ANCOVAs. Levene’s tests were used to test the assumption of homogeneity of variances.
Use of the intervention. Among those who completed the intervention, to test if
greater participation (total listening time and total number of tracks listened to) was
associated with a change in depressive symptoms, separate hierarchical linear regressions
were conducted. The same analyses were subsequently conducted using intent-to-treat
principles outlined by Lachin (2000), resulting in a total of four regressions.
Hypothesis 2b. Participation. To test if participation in the intervention (yes/no)
was associated with a change in markers of cortisol (overall mean, mean bedtime, and
diurnal cortisol slope), separate ANCOVAs were conducted. Chemotherapy treatment
status at baseline (yes/no; Table 6) and the intercept from the within-subjects regression
coefficient analysis (to control for individual differences at baseline) were entered as
covariates in each model. The same analyses were subsequently conducted using intent-

56

to-treat principles outlined by Lachin (2000), resulting in a total of six ANCOVAs.
Levene’s tests were used to test the assumption of homogeneity of variances.
Use of the intervention. Among those who completed the intervention (n = 25), to
test if greater participation (total listening time and total number of tracks listened to) was
associated with a change in markers of cortisol (overall mean, mean bedtime, and diurnal
cortisol slope), separate hierarchical linear regressions were conducted. The same
analyses were subsequently conducted using intent-to-treat principles outlined by Lachin
(2000), resulting in a total of 12 regressions.
Hypothesis 2c. Participation. To test if participation in the intervention (yes/no)
maintained LTL, an ANCOVA was conducted. Chemotherapy treatment status at
baseline (yes/no; Table 6) and the intercept from the within-subjects regression
coefficient analysis (to control for baseline differences) were entered as covariates. The
same analyses were subsequently conducted using intent-to-treat principles outlined by
Lachin (2000), resulting in a total of two ANCOVAs. Levene’s tests were used to test the
assumption of homogeneity of variances.
Use of the intervention. Among those who completed the intervention, to test if
greater participation (total listening time and total number of tracks listened to) was
associated with change in LTL, two hierarchical linear regression was conducted. The
same analyses were subsequently conducted using intent-to-treat principles outlined by
Lachin (2000), resulting in a total of four regressions.
Hypothesis 2d. Participation. To test if participation in the intervention (yes/no)
was associated with survival time calculated from date of study entry and date of
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diagnosis, two separate Kaplan-Meier analyses (Kaplan & Meier, 1958) using the log
rank test were conducted.
Use of the intervention. Among those who completed the intervention, to test if
greater participation (total listening time and total number of tracks listened to) was
associated with survival time calculated from study entry and date of diagnosis, four
separate two-tailed Cox Proportional Hazards regressions were conducted. In models
with survival calculated from study entry as the outcome, sex was entered into the model
as a covariate (Table 3).
Post-hoc analysis. Aim 1. Hypothesis 1a. Baseline. To determine if clinically
significant depressive symptoms at baseline predicted overall survival, the sample was
split between participants who endorsed clinically significant levels of depression (score
> 16 on the CES-D, n = 29) and those who did not (score < 16 on the CES-D, n = 30).
Two separate Kaplan-Meier analyses using log rank tests were conducted to test if
survival distributions calculated from study entry and date of diagnosis differed between
those who endorsed experiencing clinically significant depressive symptoms and those
who did not.
Hypothesis 1b. Baseline. To determine if clinically significant depressive
symptoms were associated with markers of cortisol dysregulation (higher overall mean
and bedtime cortisol and flatter diurnal cortisol slopes), the sample was split between
participants who endorsed clinically significant levels of depression (score > 16 on the
CES-D) and those who did not (score < 16 on the CES-D), and separate hierarchical
linear regressions were conducted. Each marker of cortisol was tested in a separate
model. The covariates that emerged as significantly associated with bedtime mean
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cortisol (age at baseline and age at diagnosis; Table 4) were included in the models with
bedtime mean cortisol as the outcome.
Hypothesis 1c. Baseline. To determine if clinically significant depressive
symptoms were associated with LTL, the sample was split between participants who
endorsed clinically significant levels of depression (score > 16 on the CES-D) and those
who did not (score < 16 on the CES-D), a hierarchical linear regression was conducted.
The covariate that emerged as significantly associated with LTL (age at diagnosis; Table
5) was included in the model.
Hypothesis 1c. Slope of change and intent-to-treat principles. To elucidate
findings that emerged as significant following primary analysis of hypothesis 1c, an
interaction term between change in depressive symptoms and minority status (yes/no)
was calculated. A hierarchical linear regression was conducted to re-assess the
association between change in depressive symptoms and change in LTL including the
same covariates that were included in the model initially (primary analysis) of hypothesis
1c (minority status (Table 5) and participation in the intervention (yes/no) in addition to
the interaction term.
Aim 2. Hypothesis 2a. Participation. To elucidate the findings that emerged as
significant following the primary analysis of hypothesis 2a, an interaction term between
participation in the intervention (yes/no) and chemotherapy treatment status at baseline
(yes/no) was calculated. An ANCOVA was conducted to re-assess the association
between the intervention and change in depressive symptoms using intent-to-treat
principles. The same covariates were included as the primary analysis (the intercept from
the within-subjects regression coefficient analyses and chemotherapy treatment status at
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baseline) in addition to the interaction term. The Levene’s test was assessed to test the
assumption of homogeneity of variances.
Use of the intervention. In an attempt elucidate results that emerged contrary to
hypotheses following primary analysis of hypothesis 2a, subsequent post-hoc analysis
were conducted using variables reflective of intervention use (i.e., total listening time and
total number of tracks listened to).
Among those who participated in the intervention (n = 25), total listening time
and total number of tracks listened to were median split to create two groups: low and
high use of the intervention. Two separate independent-samples t-tests were conducted to
determine if change in depressive symptoms following intent-to-treat principles differed
between low versus high use of the intervention.
Among those who participated in the intervention, variables were created to
capture use of didactic (i.e., instructional) and practice tracks. For each participant, the
average total amount of time that didactic and practice tracks were listened to was
calculated. Similarly, for each participant, the total number of tracks that were
categorized as didactic and practice were calculated. Unexpectedly, separate linear
regressions could not be conducted using didactic track variables (total time and total
number of tracks listened to) due to a low sub-sample size (n = 2). Thus, separate linear
regressions were conducted to test the association between total amount of listening time
and number of tracks listened to for practice tracks and change in depressive symptoms
following intent-to-treat principles.
Finally, the total listening time and total number of times that the practice track
titled, “Awareness of the breath” (11minutes and 5 seconds in length) was listened to was
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examined using separate linear regressions to test the association with change in
depressive symptoms following intent-to-treat principles.
Hypothesis 2c. Participation. An independent-samples t-test was conducted to
elucidate the findings that emerged following primary analysis of hypothesis 2b, which
demonstrated that there was a significant difference in baseline diurnal cortisol slope
between the two groups (those who participated in the intervention versus those who
declined).
Hypothesis 2c. Participation. To elucidate findings that emerged following
primary analysis of hypothesis 2c, an ANCOVA was conducted to examine the
association between the intervention (yes/no) and change in LTL with an interaction term
between participation intervention status and chemotherapy treatment status at baseline.
The model adjusted for baseline differences in LTL (the intercept from the withinsubjects analysis) and chemotherapy treatment status at baseline (yes/no; Table 6).
Cox Proportional Hazard regressions were conducted to examine the prognostic
value of LTL with and without adjusting for intervention participation status (yes/no).
Separate models including survival calculated from date of study entry and date of
diagnosis were conducted.
Despite being considerably underpowered, a hierarchical linear regression was
subsequently conducted to examine the association between change in depressive
symptoms and change in LTL with an interaction between change in depressive
symptoms and the intervention after controlling for minority status (yes/no; Table 5).
Hypothesis 2d. Use of the intervention. In an attempt elucidate results that
emerged contrary to hypothesis 2d, subsequent post-hoc analysis were conducted using
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variables capturing intervention use (i.e., total listening time and total number of tracks
listened to).
Similar to hypothesis 2a, among those who participated in the intervention, total
listening time and total number of tracks listened to were median split to create two
groups: low and high use of the intervention. Kaplan-Meier analysis using log rank tests
were conducted to test if survival distributions calculated from study entry and date of
diagnosis differed between low versus high use of the intervention.
Among those who participated in the intervention, variables were created to
capture use of didactic (i.e., instructional) and practice tracks. For each participant, the
average total amount of time that didactic and practice tracks were listened to was
calculated. Similarly, for each participant, the total number of tracks that were
categorized as didactic and practice were calculated. Similar to hypothesis 2a, Cox
Proportional Hazard regressions could not be conducted using didactic track variables
(total time and total number of tracks listened to) due to a low sub-sample size (n = 2).
Thus, total of four Cox Proportional Hazard regressions were conducted to test the
association between total amount of listening time and number of tracks listened to for
practice tracks and survival calculated from study entry and date of diagnosis.
Finally, the total listening time and total number of times that the practice track
titled, “Awareness of the breath” (11minutes and 5 seconds in length) listened to was
examined using four Cox Proportional Hazard regressions to test potential associations
with survival calculated from study entry and date of diagnosis.
Power analysis
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G*Power version 3.1, previous studies, and an online power calculator (HyLown
Consulting LLC) were all used to estimate the anticipated power of the proposed study
aims based on final samples sizes: N = 67; n = 59, 58, 58, 57, and 64 for depressive
symptoms, overall mean cortisol, mean bedtime cortisol, diurnal cortisol slope, and LTL,
respectively. All power estimates were calculated with a 5% Type I error (α = .05).
Aim 1. Hypothesis 1a. The estimated power for hypothesis 1a is based on a
similar study that reported depression was a significant predictor of 6-month survival
among 43 NSCLC patients, 13 of which experienced death, with a medium to large odds
ratio of 5.30 (Pirl et al., 2008). These results suggest the current sample of 59 with
approximately a 50% rate of death should attain adequate power. Further, based on the
expectation of a hazards ratio of 2 in our sample of 57, the online power calculator
(HyLown Consulting LLC) provided an estimated of .66.
Hypothesis 1b – 1c. Small to large effect sizes have been reported between
depressive symptoms and markers of cortisol. Large effect sizes between depression and
higher afternoon cortisol (Cohen’s d = .83; (Burke et al., 2005) and overall mean cortisol
(Cohen’s d = .60; (Stetler & Miller, 2011) have been reported among non-medically ill
samples. Small to moderate effects (Cohen’s f = .17) have been reported between
depressive symptoms and higher evening cortisol in an ovarian cancer sample
(Lutgendorf et al., 2008). Among non-medically ill participants, moderate effect sizes
have been reported between depressive symptoms and shorter LTL (Hedge’s g = -.55;
Darrow et al. (2016). No effect size estimates are available for depressive symptoms and
TL in cancer contexts given that only two studies have examined these constructs among
cancer populations, neither of which reported an effect size. Based on the expectation of a
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small to large effect size on biological markers in our sample of 57, our power will range
between .18 and .99.
Aim 2. Hypothesis 2a. Medium to large effect sizes of an MBSR intervention on
depressive symptoms have been reported among cancer patients in mobile (Cohen’s d =
0.85; N = 15) and non-mobile (Cohen’s d = 0.56) formats, respectively (Lengacher et al.,
2018; Zhang, Wen, et al., 2015). Based on the expectation of a medium to large effect
size on depressive symptoms in our sample of 59, our power will range between .17 and
.99.
Hypothesis 2b – 2c. Small effects of an MBSR intervention on cortisol slope (η2 =
0.02) and medium effects on bedtime cortisol (η2 = 0.05) have been reported among
breast cancer patients (Carlson et al., 2013); overall diurnal mean cortisol was not
reported. A small to medium effect (η2 = 0.043) of an intervention involving components
of MBSR on maintenance of TL has been reported among a breast cancer sample
(Carlson et al., 2015). However, there are a limited number of studies that have examined
the effects of an MBSR intervention on biological markers. Thus, it should be noted that
the current investigation is exploratory opposed to confirmatory in nature. Nonetheless,
based on the expectation of a small to medium effect of the intervention on biological
outcomes in our sample of 57, our power will range between .06 and .99.
Hypothesis 2d. The effects of MBSR or an MBI on survival have not been tested
among cancer populations. A small effect of a psychological intervention involving a
combination of stress reduction, problem solving, social support enhancing, and health
behavior techniques on 11 year survival (HR = 0.44) has been reported, which indicated
breast cancer patients who were randomized to the intervention were half as likely to die
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from breast cancer (Andersen et al., 2008). Based on the expectation of a hazards ratio of
2 in our sample of 67, the online power calculator (HyLown Consulting LLC) provided a
power estimate of .66. Nonetheless, the proposed analyses are exploratory, not
confirmatory, in nature.
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RESULTS
Preliminary analysis
All of the independent-samples t-tests conducted to assess the independence of
the treatment variable and the covariate assumption for the ANCOVA were not
statistically significant; thus, the assumption was met for each analysis.
Primary analysis
Covariates. Results of the Spearman’s rank-order correlations are summarized in
Tables 3 – 5.
Aim 1. Hypothesis 1a. Baseline. Sex (female) emerged as significantly associated
with longer survival calculated from study entry. No theoretically derived covariates were
significantly associated with survival calculated from date of diagnosis. No theoretically
derived covariates were significantly associated with the independent variable, depressive
symptoms; therefore, no variables were entered as a ‘proxy’ (Table 3).
Contrary to hypotheses, after adjusting for participation in the intervention, although
both Cox Proportional Hazards regression models emerged as significant (study entry: p
= .018; date of diagnosis: p = .022), depressive symptoms assessed at baseline did not
predict survival calculated from study entry or date of diagnosis. Participation in the
intervention emerged as a significant predictor of shorter survival in both models
calculated from study entry (P(Wald) = .017; hazard ratio, 0.396; 95% confidence
interval [CI], .185 - .850) and date of diagnosis (P(Wald) = 0.021; hazard ratio, 0.405;
95% confidence interval [CI], .188 - .870). Results are presented in Table 7.
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Slope of change and intent-to-treat principles. No indicators emerged as
significantly associated with the independent variable, change in depressive symptoms
(including intent-to-treat variables). Therefore, because sex emerged as significantly
associated with longer survival calculated from study entry, it was again entered as a
covariate in models with survival calculated from study entry at the outcome. No
additional covariates were entered into models with survival calculated from date of
diagnosis as the outcome. No models included a ‘proxy’ (Table 3).
Contrary to hypotheses, change in depressive symptoms did not emerge as a
statistically significant predictor of survival calculated from study entry or date of
diagnosis following Cox Proportional Hazards regression analysis with or without use of
the intervention included in the model. Results are summarized in Table 7.
Loss to follow-up Cox Proportional Hazards regression analyses using intent-totreat principles yielded similar statistically non-significant associations between change
in depressive symptoms and both measures of survival with and without the intervention
included in the model. Although the overall model was again significant for survival
calculated from study entry (p = .040), only participation in the intervention emerged as a
significant predictor (P(Wald) = .021; hazard ratio, 0.400; 95% confidence interval [CI],
.184 - .871. The model including survival calculated from date of diagnosis neared
significance (p = .052), but only use of the intervention emerged as a significant predictor
(P(Wald) = 0.020; hazard ratio, 0.391; 95% confidence interval [CI], .178 - .860).
Results are summarized in Table 7.
Hypothesis 1b. Baseline. In the anticipated direction, both older age at study entry
and older age at diagnosis emerged significantly associated with increased bedtime mean
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cortisol. No theoretically derived covariates were significantly associated with any other
marker of cortisol. No theoretically derived covariates were significantly associated with
the independent variable, depressive symptoms; therefore, no variables were entered as a
‘proxy’ (Table 4).
The regression conducted to assess the association between depressive symptoms
and mean bedtime cortisol assessed at baseline while controlling for age emerged as
significant, F(2,52) = 3.720, p = .031 and accounted for 12.5% variance. Only age was
significantly associated with mean bedtime cortisol (p = .010) and accounted for 11.5%
of the variance. Similarly, the regression used to assess the association between
depressive symptoms and mean bedtime cortisol assessed at baseline while controlling
for age at diagnosis emerged as nearly significant, F(2,52) = 3.133, p = .052 and
accounted for 10.8% variance. Again, only age at diagnosis was significantly associated
with mean bedtime cortisol (p = .017) and accounted for 8.3% of the variance. The
association between depressive symptoms and both diurnal cortisol slope and overall
mean cortisol assessed at baseline did not emerge as significant in the model. Results are
summarized in Table 8.
Slope of change and intent-to-treat principles. No theoretically derived covariates
were significantly associated with any change in any of the markers of cortisol (including
intent-to-treat variables; Table 4). Therefore, no additional theoretically derived variables
were entered as a covariate or a ‘proxy’ in any of the models.
Contrary to hypotheses, the hierarchical linear regressions conducted to assess the
associations between change in depressive symptoms and change in markers of cortisol
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(overall mean, bedtime mean, and diurnal slope) both with and without adjusting for the
intervention did not emerge as significant. Results are summarized in Table 8.
Loss to follow-up analyses using intent-to-treat principles similarly yielded no
statistically significant associations between change in depressive symptoms and change
in markers of cortisol. Results are summarized in Table 8.
Hypothesis 1c. Baseline. Older age at diagnosis emerged as significantly
associated with shorter LTL at baseline. No theoretically derived covariates were
significantly associated with the independent variable, depressive symptoms; therefore,
no variables were entered as a ‘proxy.’ Spearman’s rank-order correlations are
summarized in Table 5.
The regression conducted to assess the association between depressive symptoms
and LTL at baseline while controlling for age at diagnosis emerged as significant, F(2,54)
= 3.915, p = .026 ,and accounted for 12.7% variance. However, only age at diagnosis was
significantly associated with TL (p = .015) and accounted for 9.1% of the variance.
Slope of change and intent-to-treat principles. As expected, minority status (nonWhite participants) emerged as significantly associated with a more negative change
(steeper slope) in LTL and was entered into the first step of the model as a covariate.
Because minority status was not significantly associated with the independent variable,
change in depressive symptoms, no variables were entered as a ‘proxy.’ Spearman’s
rank-order correlations are summarized in Table 5.
The regression conducted to assess the association between change in depressive
symptoms and change in LTL while controlling for minority status emerged as
significant, F(2,24) = 4.914, p = .016 and accounted for 29% of variance. Both minority
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status (p = .012) and change in depressive symptoms (p = .029) were significantly
associated with LTL. The regression controlling for both minority status and the
intervention also emerged as significant, F(3, 23) = 4.930, p < .01 and accounted for 39%
of variance. Both minority status (p = .015) and change in depressive symptoms (p < .01)
were, again, significantly associated with LTL, but participation in the intervention did
not significantly contribute to the model (Table 9). As demonstrated in Figure 4, the slope
of change in depressive symptoms and change in LTL was negative. Consistent with
hypotheses, as depressive symptoms increased over time (from baseline to follow-up)
LTL decreased over time, and the LTL among minority participants was shorter than
non-Hispanic White participants.
No indicators, including minority status, were significantly associated with a
change in LTL and following intent-to-treat principles; therefore, no covariates or proxies
were included in the models. Loss to follow-up analyses using intent-to-treat principles
yielded no statistically significant associations (Table 9).
Aim 2. The Chi-square test between intervention status and current chemotherapy
status revealed a significant difference between groups, X2(1, N = 59) = 3.845, p = .050.
No other factors emerged as significant. Results of the exploratory analysis are presented
in Table 6.
Hypothesis 2a. Participation. After adjusting for baseline individual differences
in depressive symptoms and chemotherapy treatment status at baseline, the intervention
did not demonstrate statistically significant associations with change in depressive
symptoms (Table 10). There was homogeneity of variances, as assessed by Levene's test
of homogeneity of variance (p = .503).
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Loss to follow-up ANCOVA analysis using intent-to-treat principles yielded a
statistically significant intervention effect on change in depressive symptoms after
adjusting for chemotherapy treatment status at baseline, F(1,54) = 5.360, p = .024, partial
η2 = 0.090. Contrary to hypotheses, the change in depressive symptoms was positive;
scores increased over time (by approximately three points on the CES-D) in the
intervention group (M = .035, SE = .084) whereas scores decreased/were maintained
(approximately half of a point decrease) among participants who did not complete the
intervention (M = -.005, SE = .047), a mean difference of .042, 95% CI [.006, .079], p =
.024. However, the assumption of homogeneity of variances was violated as assessed by
Levene's test for equality of variances (p = .003). Therefore, the dependent variable,
change in depressive symptoms following intent-to-treat principles, was re-examined
more conservatively. Outliers (n = 1) beyond three, opposed to four, standard deviations
(values less than .22) were excluded from a subsequent ANCOVA analysis. The model
remained significant, F(1,53) = 4.275, p = .044, partial η2 = 0.075 and the change in
depressive symptoms remained significantly positive in the intervention group (M =
.024, SE = .064) whereas the change in depressive symptoms remained negative among
those who did not complete the intervention (M = -.005, SE = .047), a mean difference of
.032, 95% CI [.001, .062], p = .044 (see Figure 6). Although the Levine’s test for equality
of variances remained significant after excluding the outlier (p = .022), Field (2013)
suggests the Levene’s test is not the most reliable measure of the equal variances
assumption. Instead Field (2013) recommends checking the assumption using a variance
ratio by squaring each group standard deviation, dividing the largest standard deviation
by the smallest, and referencing Figure 5 to determine if the quotient exceeds the critical
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value. In this case, the largest squared standard deviation (.004; n = 23) divided by the
smallest squared standard deviation (.002; n = 34) yielded a variance ratio of 2, which
did not exceed the critical value of ~3 as determined using Figure 5. Thus, according to
Field (2013) the homogeneity of variances assumption was not violated. Results are
summarized in Table 10.
Use of the intervention. Among those who completed the intervention (n = 25)
and provided depression assessment at baseline and follow-up (n = 20), the regressions
conducted to test the associations between intervention use (total listening time and total
number of tracks listened to) and change in depressive symptoms did not emerge as
significant. Results are summarized in Table 11.
Loss to follow-up regression analysis using intent-to-treat principles yielded
similar insignificant associations. Among those who completed the intervention (n = 25),
the regressions conducted to test the associations between intervention use (total listening
time and total number of tracks listened to) and change in depressive symptoms did not
emerge as significant (Table 11).
Hypothesis 2b. Participation. After adjusting for baseline individual differences
in cortisol profiles and chemotherapy treatment status at baseline, the ANCOVA analysis
demonstrated that the intervention did not demonstrate statistically significant association
with change in any of the markers of cortisol (overall mean, bedtime mean, diurnal
slope). However, the intercept from the within-subjects analysis emerged significant
F(1,24) = 9.844, p = .004, partial η2 = 0.291, suggesting that there were significant
baseline differences in diurnal cortisol slope between the two groups. There was
homogeneity of variances, as assessed by Levene's test of homogeneity of variance for
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each ANCOVA (p = .825, p = .572, p = .445, respectively). The results are presented in
Table 12.
Similarly, loss to follow-up ANCOVA analysis using intent-to-treat principles
and adjusting for chemotherapy treatment status baseline did not yield statistically
significant associations between the intervention and change in each marker of cortisol
(overall mean, bedtime mean, diurnal slope). There was homogeneity of variances, as
assessed by Levene's test of homogeneity of variance for each ANCOVA (p = .080, p =
.239, p = .171, respectively). The results are also presented in Table 12.
Use of the intervention. Among those who completed the intervention, none of the
regression conducted to assess the association between total listening time and number of
tracks listened to and change and markers of cortisol emerged as significant. The results
are presented in Table 13.
Similarly, loss to follow-up regression analyses using intent-to-treat principles
yielded no statistically significant associations. Results are also presented in Table 13.
Hypothesis 2c. Participation. After adjusting for baseline individual differences
in LTL and chemotherapy treatment status at baseline, the ANCOVA revealed a
statistically significant intervention effect on change in LTL, F(1,34) = 5.454, p = .026,
partial η2 = 0.138. As demonstrated in Figure 7, for visual not statistical purposes, the
slope of change in LTL was positive among those in the intervention group (M
=.0000423, SE = .000725) whereas the slope of change was negative among those who
did not complete the intervention (M = -.000327, SE = .000437), a mean difference of
0.000470, 95% CI [0.000061, 0.000879], p = .026. In other words, LTL seemed to
increase among those in the intervention group, whereas LTL appeared to decrease
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among those who did not participate. Chemotherapy treatment at baseline also
significantly contributed to the model F(1,34) = 4.914, p = .033, partial η2 = 0.126.
Contrary to expectations, patients who were receiving chemotherapy treatment at
baseline demonstrated an increase in LTL compared to those who did not (see Figure 8).
There was homogeneity of variances, as assessed by Levene's test of homogeneity of
variance (p = .615). The mean number of days from date of blood collection at baseline
to follow-up was 139 (~4.6 months). Results are summarized in Table 14.
Loss to follow-up ANCOVA analysis using intent-to-treat principles that adjusted
for baseline differences in LTL and chemotherapy treatment status at baseline yielded
statistically insignificant associations between the intervention and change in LTL;
however, the statistical significance of chemotherapy at baseline persisted, F(1,53) =
5.652, p = .021, partial η2 = 0.096. There was homogeneity of variances, as assessed by
Levene's test of homogeneity of variance (p = .210). Results are also summarized in
Table 14.
Use of the intervention. Among those who completed the intervention, the
regressions conducted to assess the association between both total listening time and total
number of tracks listened to and change in TL yielded statistically insignificant results.
Results are presented in Table 15.
Similarly, loss to follow-up regression analyses using intent-to-treat principles
yielded no statistically significant associations. Results are also presented in Table 15.
Hypothesis 2d. Participation. Consistent with results that emerged following
hypothesis 1a analyses, the Kaplan-Meier survival analysis using a log rank test revealed
statistically significant differences in survival distributions calculated both from study
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entry and date of diagnosis between those who participated in the intervention (n = 25)
and those who did not (n = 42), χ2(1) = 5.536, p = .019 and χ2(1) = 6.033, p = .014,
respectively. As demonstrated in Figure 9, contrary to hypotheses, participants that
participated in the intervention on average had a shorter time to death in days calculated
from study entry (M = 824.200, SD = 532.443) than those who did not (M = 944.810,
DE = 400.392). Similarly, on average, patients that participated in the intervention had a
shorter time to death in days calculated from date of diagnosis (M = 1450.920, SD =
638.400) than those who did not (M = 1694.260, SD = 751.716; Figure 10).
Use of the intervention. As stated in hypothesis 1a, sex (female) emerged as
significantly associated with longer survival calculated from study entry and was entered
as a covariate in the model (see Table 3).
Among those who completed the intervention (n = 25), the Cox Proportional
Hazards Regression models conducted to test the association between intervention use
(total listening time and total number of tracks listened to) and survival calculated from
study entry (after controlling for sex) and date of diagnosis did not yield statistically
significant results. Results are presented in Table 16.
Post-hoc analysis
Aim 1. Hypothesis 1a. A score of > 16 is indicative of clinical significant on the
CES-D (Radloff, 1977). On average, patients reported experiencing nearly clinically
significant levels of depressive symptoms at baseline (M = 15.5) and clinically significant
levels at follow-up (M = 17.7). Consistent with previous reports that have suggested lung
cancer patients experience some of the highest levels of depression (Linden et al., 2012),
the average depression scores were higher in the current sample than the mean of 11 that
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was reported by a different sample of breast cancer patients (N = 117; Hann et al. (1999),
suggesting that the reported levels of depressive symptoms were not abnormally low in
the current sample. Change in depressive symptoms ranged from -.16 and 3, however,
and the average change was .025. In other words, from baseline to follow-up, regardless
of intervention participation status, the overall change in depressive symptoms was less
than one point on the CES-D.
Baseline. The Kaplan-Meier survival analysis using a log rank test demonstrated
statistically significant differences in survival distributions calculated from date of
diagnosis between participants who endorsed experiencing clinically significant levels of
depression (CES-D score > 16) and those who did not, χ2(1) = 3.832, p = .050. Consistent
with primary analysis of hypothesis 1a, survival calculated from study entry did not
emerge as significant, χ2(1) = 3.232, p = .072. As demonstrated in Figure 11, patients
who endorsed experienced clinically significant depressive symptoms experienced earlier
mortality (M = 23.9, SD = 6.375), than those who did not (M = 7.4, SD = 4.734).
Hypothesis 1b. Baseline. After adjusting for age at study entry (Table 4), the
overall model containing sub-clinical levels of depression emerged as significantly
associated with bedtime mean cortisol, F(2, 24) = 4.265, p = .026; however, sub-clinical
levels of depressive symptoms did not significantly contribute to the model (p = .519).
Similarly, after adjusting for age at diagnosis (Table 4), the overall model containing subclinical levels of depression emerged as significantly associated with bedtime mean
cortisol, F(2, 24) = 3.698, p = .040, although sub-clinical levels of depressive symptoms
did not significantly contribute to the model (p = .461). Contrary to hypothesis, neither
model including clinical levels of depression emerged as significantly associated with
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bedtime mean cortisol. Regarding diurnal slope, only sub-clinical levels of depression
were significantly associated with a flatter slope, F(1, 26) = 5.073, p = .033. No
regressions with overall mean cortisol emerged as significant. Results are presented in
Table 17.
Hypothesis 1c. Baseline. Contrary to hypothesis, after adjusting for age at
diagnosis (Table 5), neither model containing sub-clinical nor clinical levels of
depression emerged as significantly associated with LTL. Results are presented in Table
18.
Slope of change and intent-to-treat principles. The hierarchical linear regression
conducted to assess the association between change in depressive symptoms and change
in LTL remained significant when the interaction term between change in depressive
symptoms and minority status was added to the model, F(4, 22) = 3.795, p = .017 and
accounted for 41% of variance; however, the interaction term did not significantly
contribute to the model (p = .436). Results are presented in Table 19.
Aim 2. Hypothesis 2a. Participation. The ANCOVA used to assess the
association between the intervention and change in depressive symptoms using intent-totreat principles including the interaction term between the intervention and chemotherapy
treatment status at baseline yielded nearly significant results, F(1,53) = 3.142, p = .051,
partial η2 = 0.106, although the interaction term was not significant. However, similar to
primary analysis of hypothesis 2a, the assumption of homogeneity of variances was
violated, as assessed by Levene's test for equality of variances (p = .003). Using the same
procedures outlined for primary analysis of hypothesis 2a, a subsequent ANCOVA was
conducted after excluding outliers (n = 1) beyond three standard deviations (values less
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than 0.22). The model and the interaction term remained insignificant, and similar to
hypothesis 2a, the assumption remained violated as assed by Levine’s test (p = .022).
However, using the procedures outlined by Field (2013), the largest squared standard
deviation (.004; n = 23) divided by the smallest squared standard deviation (.002; n = 34)
yielded a variance ratio of 2, which did not exceed the critical value of ~3 as determined
using Figure 5. Thus, according to Field (2013) the homogeneity of variances assumption
was not violated. Results are summarized in Table 20.
Use of the intervention. The median total listening time was 806 minutes and the
median total number of tracks listened to was 82 yielding two groups: low (n = 12) and
high (n = 13) use of the intervention. Neither of the independent samples t-tests
conducted to test the association between median split total listening time and total
number of tracks listened to yielded statistically significant differences in change in
depressive symptoms following intent-to-treat principles, suggesting that there was not a
dose-response relationship between use of the intervention and depressive symptoms.
Results are presented in Table 21.
Among the patients that participated in the intervention (n = 25), the average total
amount of time that didactic and practice tracks were listened to were 1633.28 and
1531.357 minutes, respectively, and average number of tracks listened to that were
categorized as didactic and practice were 260 and 129.083, respectively. Of the 44 tracks
recorded and provided to participants via the iPod, 33 of them were didactic (a total of
208.30 minutes) and 11 were practice (a total of 180.85 minutes; Table 1). Neither of the
linear regressions conducted to test the association of use of practice tracks on change in
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depressive symptoms following intent-to-treat principles emerged as significant. Results
are presented in Table 22.
Twenty-three of the 25 patients who participated in the intervention listened to the
“Awareness of the breath” practice track. The total number of minutes the track was
listened to ranged from 11.10 (i.e., once) – 277.50 (M = 77.70, SE = 78.560), and the
number of times the track was played ranged from 1 – 25 (M = 7.00, SE = 7.077).
Neither regression conducted to test the association of use of the practice track
“Awareness of the breath” emerged as a significant predictor of change in depressive
symptoms following intent-to-treat principles. Results are also presented in Table 22.
Hypothesis 2b. Participation. The independent-samples t-test revealed nearly
statistically significant difference in diurnal cortisol slopes at baseline between patients
who agreed to participate in the intervention than those who declined the intervention
t(55) = 1.971, p = .054. As shown in Figure 12, patients who participated in the
intervention demonstrated steeper diurnal cortisol slopes than those who declined the
intervention.
Hypothesis 2c. Participation. The ANCOVA used to assess the association
between the intervention and change in LTL including the interaction term between the
intervention and chemotherapy treatment status at baseline demonstrated a statistically
significant effect of the interaction term, F(1,33) = 5.831, p = .021, partial η2 = 0.150,
after adjusting for baseline differences in LTL and chemotherapy treatment status at
baseline. As demonstrated for visual not statistical purposes, in Figure 13, it seems
patients who received chemotherapy at baseline and participated in the intervention
demonstrated an increase in LTL, whereas patients who were not receiving chemotherapy
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at baseline and did not participate in the intervention evidenced a decrease in LTL. All
other patients did not appear to evidence a change in LTL from baseline to follow-up;
LTL appeared to have been maintained. Results are presented in Table 23.
Change in LTL emerged as a significant predictor of survival calculated from date
of study entry (P(Wald) < .01) and date of diagnosis (P(Wald) = .026) following the Cox
Proportional Hazard regressions. Contrary to expectation, however, an increase in LTL
predicted shorter survival in both models. For visual, not statistical purposes, change in
LTL was median split to demonstrate significant differences in survival patterns from
date of study entry (Figure 14) and date of diagnosis (Figure 15). After adjusting for
intervention participation, both models calculated from study entry (P(Wald) < .01) and
date of diagnosis (P(Wald) = 0.17) remained significant, although the intervention did not
significantly contribute to either model and LTL was not significant in the model
including survival calculated from date of diagnosis. Consistent with findings from
hypothesis 2a, participation in the intervention was associated with shorter survival.
Results are presented in Table 24.
The hierarchical linear regression examining the association between change in
depressive symptoms and change in LTL with an interaction term between change in
depressive symptoms and the intervention participation status, after adjusting for
minority status, emerged as significant, F(4, 22) = 3.623, p = .021 and accounted for
approximately 40% of variance, although the interaction term did not significantly
contribute to the model. Results are presented in Table 25. However, as demonstrated for
visual, not statistical purposes in Figure 16, there appear to be differences in the pattern
of association between change in depressive symptoms and change in LTL between
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intervention groups (participated versus not). The association between change in
depressive symptoms and change in LTL was positive (as depressive symptoms
increased, LTL also increased/lengthened) among those who participated in the group,
whereas the association was negative (as depressive symptoms increased, LTL
decreased/shortened) among those who did not.
Hypothesis 2d. Use of the intervention. The Kaplan-Meier survival analysis using
a log rank tests after median splitting total listening time and total number of tracks
listened to yielded no statistically significant differences in survival distributions
calculated both from either study entry (Time: χ2(1) = .566, p = .019; Tracks: χ2(1) =
.329, p = .566) or date of diagnosis (Time: χ2(1) = .556, p = .456; Tracks: χ2(1) = .556, p
= .456), suggesting that there was not a dose-response relationship between the
intervention and survival.
None of the Cox Proportional Hazard regressions conducted to test the association
between use of practice tracks and survival emerged as significant. Results are presented
in Table 26.
None of the four Cox Proportional Hazard regressions conducted to test potential
associations between use of the practice track “Awareness of the breath” and survival
calculated from study entry or date of diagnosis emerged as a significant. Results are also
presented in Table 26.
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DISCUSSION
In an attempt to integrate a dual emphasis on improving both quality and quantity
of life among cancer patients, this dissertation explored the role of depressive symptoms
and related biological markers of stress and cellular aging on survival as well as the
potential benefits of a pilot MBI among a small sample of NSCLC patients. This
dissertation approached elucidating the hypothesized association between depressive
symptoms and survival from two angles exploring: 1) potential biological pathways and
2) the potential benefits of an intervention as a means to improve psychological and
clinical outcomes among a population facing high mortality. The importance of
elucidating the biological underpinnings of the hypothesized depression-survival pathway
in this population cannot be disregarded, as it provides one avenue to inform
interventions to improve the poor survival rates that lung cancer patients face. As such,
identifying feasible interventions that effectively improve psychological and clinical
outcomes also remains a priority in lung cancer patients, a subset of the cancer population
that remains highly underrepresented in the psycho-oncology literature.
Although all cancer patients face considerable stress from the burden of treatment,
shifts in social and vocational roles, and fear of death as well as a host of other
challenges, lung cancer patients face unique and considerable burden given the low fiveyear overall survival rate that was recently estimated at 18% (Henningfield & Adjei,
2017; Siegel et al., 2016). Not only do more than half of those diagnosed with lung
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cancer die within the first year of diagnosis (Henningfield & Adjei, 2017; Siegel et al.,
2016), a stress-evoking statistic in and of itself, but cancer patients are four times more
likely to experience depression than the non-medically ill populations (Lutgendorf &
Andersen, 2015; Raison & Miller, 2003). Lung cancer patients in particular experience
some of the highest prevalence rates of depression compared to any other type of cancer
(Linden et al., 2012), which cannot be explained by disease severity (Brown et al., 2003).
Thus, when faced with difficult mortality rates, stress may be inevitable, but depression is
not, despite being highly prevalent. Fortunately, there are effective treatments for
depression, providing one avenue for intervention that may subsequently result in
improvements to both quality and quantity of life, given that depression has demonstrated
prognostic value in cancer populations (Pinquart & Duberstein, 2010; Satin et al., 2009).
The current lung cancer sample was recruited within a 120-mile radius of
Louisville, KY, and can be described as mostly female, White, aged 50 – 60 with a high
school education and an annual household income of less than $40,000. Consistent with
the larger lung cancer population, 65% of which are diagnosed at a later stage (Siegel et
al., 2014), the majority of patients from the current sample also received an initial
diagnosis of stage III or IV (65.7%) within two years of study enrollment. Patients
diagnosed at a later stage have a poorer prognosis, and as such, several study participants
in the current study have since passed away – 46.3% of the overall current study sample,
83.9% of which were initially diagnosed with a later stage.
Aim 1 Discussion: The Potential Role of Two Biomarkers in the Depression-Survival
Relationship
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While the intersection of mind and body has gained increasing attention in
medical contexts, the biological underpinning of depression as it relates to shorter
survival among cancer populations remains unknown. The majority of efforts to elucidate
these pathways have primarily focused on the roles of the immune and the
neuroendocrine systems. Although aberrant cortisol profiles have been associated with
both depression and shorter survival among a number of cancer types (Cohen et al., 2012;
Schrepf et al., 2015; Sephton et al., 2000), including lung (Sephton et al., 2013), much
less attention has been given to the role of telomere biology, a system responsible for
maintaining cellular integrity and stability, and is fundamental to cell proliferation
(Blackburn et al., 2015). Despite mounting evidence demonstrating an association
between shorter telomeres and stress (Shalev et al., 2013; Starkweather et al., 2014),
depression (Vance et al., 2018), and shorter survival (Heaphy et al., 2013; Herrmann et
al., 2018), there is a paucity of telomere biology in current biobehavioral cancer models.
Thus, Aim 1 of the current study was to replicate the prognostic significance of
depressive symptoms and to explore the role of two biomarkers – cortisol and leukocyte
telomere length (LTL) – as they relate to the hypothesized depression-survival pathway.
Hypothesis 1a. Hypothesis 1a proposed that more depressive symptoms would
predict shorter survival. Hypothesis 1a was partially supported.
The primary analyses did not yield a significant association between depressive
symptoms (assessed at multiple time points) and survival (calculated from two time
points). However, post-hoc analysis revealed that, when the sample was split between
those who reported experiencing clinically significant levels of depression (CES-D score
> 16) and those who did not (CES-D score < 16), clinically significant levels of
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depression predicted shorter survival calculated from date of diagnosis, but not date of
study entry. Although the observed inconsistency between survival from date of
diagnosis and study entry was unexpected, it may be understood from the medical
heterogeneity of the sample given the inclusion criterion of five years within diagnosis.
The average time between dates of diagnosis and study entry was 704 days (SD = 5423;
~1.9 years), and ranged from 38 – 2455, which reflects considerable variation. Despite
this variability, these results highlight the need to consider severity, and specifically
clinical significance, when examining the association between depression and survival in
cancer samples. This is not to say that sub-clinical levels of depression are of
unimportance. In contrast, patients with sub-clinical depression warrant equal attention as
patients with clinical levels, as there is an opportunity to prevent worsening of symptoms
to clinical levels and the subsequent greater risk of earlier mortality.
These findings extend the growing literature in support of the prognostic
significance of depression in cancer samples, and are clearly, of extreme clinical
importance. These findings further support the need for on-going efforts to routinely
screen all cancer patients for distress and mood symptoms and the need for trained
clinical psychologists in oncology settings to effectively prevent and treat sub- and
clinical levels of depression. Depression is a treatable condition and these findings further
motivate efforts to adapt efficacious interventions for cancer patient populations as well
as elucidate mechanisms driving the association between depression and shorter survival.
Hypothesis 1b. Hypothesis 1b proposed that more depressive symptoms would
be associated with greater cortisol dysregulation (higher overall mean and bedtime
cortisol and flatter diurnal cortisol slopes). Hypothesis 1b was not supported.
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Contrary to hypothesis 1b, depressive symptoms were not significantly associated
with any markers of cortisol assessed at any of the different time points/using different
methodologies (i.e., slope, intent-to-treat) upon primary analysis. Interestingly, only older
age at study entry and at diagnosis was associated with elevated bedtime mean cortisol
levels assessed at baseline. The direction of this association is not surprising given that
the HPA-axis tends to function less efficiently with older age and higher bedtime mean
cortisol is reflective of an unhealthier neuroendocrine system (see Figure 1). However, it
is interesting that older age was only associated with bedtime mean, opposed to overall
mean or diurnal cortisol slope, which are more robust markers of neuroendocrinemediated HPA-axis function. Nonetheless, of the two samples that combine to calculate
the overall mean cortisol and diurnal slope (waking and bedtime), higher bedtime mean
cortisol has previously emerged as a prognostic indicator and has been proposed as a
driver of the HPA-dysregulation observed in cancer samples (Schrepf et al., 2015).
Post-hoc analyses examining sub-and clinical levels of depression only yielded a
significant association between sub-clinical levels of depression and flatter diurnal
cortisol slope. These results are surprising given the dearth of literature linking
depression and hyperactivation/subsequent dysregulation of the HPA axis that worsens
with increases in depression severity (Stetler & Miller, 2011). These results further
support the notion provided under hypothesis 1a that sub-clinical levels of depression are
equally worthy of attention by providers, as flattener diurnal cortisol profiles has been
linked to shorter survival among lung cancer patients (Sephton et al., 2013). It is possible
flattened diurnal cortisol slopes, indicative of a dysregulated HPA-axis, can be detected
earlier, when symptoms are of sub-clinical levels among this population, enhancing the
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overall clinical utility of diurnal cortisol as a biomarker for the convergence of worsening
psychological and disease-related health. It should be noted, however, that power was
limited by the small sub-sample sizes as a result of splitting the sample (sub-clinical: n =
26 - 27; clinical: n = 27 – 28).
Alternatively, these findings may have been further elucidated by the inclusion of
distinct depressive specifiers (e.g., acute versus chronic; first episode versus recurrent)
and subtypes (e.g., atypical and melancholic depression; Association (2013). Although
depressive specifiers and subtypes were not assessed in the current study and extend the
scope of the current dissertation, there is evidence to suggest that distinct depressive
subtypes are differentially associated with aberrant cortisol profiles in non-medically ill
populations (O’Keane, Frodl, & Dinan, 2012; Stetler & Miller, 2011). For example,
melancholic depression, characterized by anhedonia, insomnia, loss of appetite and
feelings of excessive guilt and worthlessness, is associated with greater (54% larger
effect) elevations in cortisol than depressive presentations without melancholic features.
Moreover, a quantitative review conducted by Stetler & Miller (2011) on depression and
HPA-axis activation spanning four decades of research concluded that different
depressive symptom clusters are associated with different patterns of HPA-axis activity.
Taken together, although the CES-D has been shown to be a valid and reliable measure of
depressive symptoms in cancer populations (Hann et al., 1998), it is clear that
considerable variability is introduced by the term “depression,” and that much remains
unknown about the distinct depressive specifiers and subtypes as they relate to nuanced
differences in cortisol profiles both in and out of medical-ill populations. It is plausible to
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hypothesize that variations in symptom clusters within the current sample could be
contributing to insignificant results observed following analysis of hypothesis 1b.
Hypothesis 1c. Hypothesis 1c proposed that more depressive symptoms would be
associated with shorter LTL. Hypothesis 1c was supported.
Regarding depressive symptoms and LTL assessed at baseline, although older age
at diagnosis was significantly associated with shorter LTL, depressive symptoms did not
yield statistical significance. Similar to other biomarkers, including cortisol, it is expected
that older age would be associated with shorter LTL, as it is typically reflective of poorer
biological functioning. Although chronological age is not synonymous with LTL, a
marker of cellular aging (Blackburn et al., 2015), shorter LTL is suggestive of poorer
cellular integrity and stability (Blackburn, 2001). Thus, all other factors held constant, it
is expected that older individuals would have experienced a greater number of cell
divisions and therefore, shorter LTL over the course of their life.
Interestingly, contrary to hypotheses, after adjusting for age at diagnosis, neither
model containing sub- nor clinical levels of depression were significantly associated with
LTL. Similar to the potential explanation provided in hypothesis 1b, null results may be
explained by limited power resulting from small sample sizes after splitting the sample
(sub-clinical: n = 29; clinical: n = 28). Alternatively, given that the time point for
assessment of depressive symptoms was arbitrary (at baseline, whenever patients were
recruited and opted to enroll in the study), it is possible the detrimental effects of
depression reported in the literature would not have affected LTL in the current sample,
as LTL was also assessed at baseline (i.e., within the same week). Unlike changes in
neuroendocrine functioning via the HPA-axis that can be observed relatively proximal to
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a stressor (~within 20 - 30 minutes; Kirschbaum, Pirke, and Hellhammer (1993) through
cortisol assessment, measurable LTL attrition is not conceptualized in the literature as an
equally rapidly occurring process. Although it is believed that the temporal timeline
between depression and subsequent telomere attrition has not yet been reported on in the
literature, telomere attrition is conceptualized as a global marker of cellular aging. Thus,
although the process of cell division, which leads to cumulative telomere attrition, occurs
relatively quickly (within a day), measurable changes in telomere length may require
greater time.
Regarding change in symptoms, the hypothesized association between change in
depressive symptoms and change in LTL was supported. Consistent with hypothesis 1c,
as depressive symptoms increased, LTL decreased. As anticipated, despite a low subsample (n = 11), minority status (non-White participants) emerged as a significant
predictor of shorter LTL, although the interaction between minority status and change in
depressive symptoms did not significantly contribute to the model. In other words,
although minority status and change in depressive symptoms were both significantly
associated with shorter LTL, the effects of a having an ethnic minority background on
LTL was unrelatedly to depressive symptoms in the current sample.
Overall, these findings support the mounting evidence demonstrating an
association between depression and shorter LTL (Lindqvist et al., 2015) and extend the
existing literature linking ethnic differences in LTL observed in non-medically ill
populations (Geronimus et al., 2010; Geronimus et al., 2015; Weber et al., 2018) to lung
cancer patients. Despite mounting evidence demonstrating a robust effect of stress on TL,
there is paucity of telomere biology in current biobehavioral cancer models. TL has been
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linked to both depression and cancer outcomes independently; however, this dissertation
is one of the first investigations into the relationship between depression and TL in a lung
cancer sample.
It is believed that this dissertation is also the first to demonstrate that minority
status significantly predicted shorter LTL in a cancer sample. The fact that minority
status was predictive of a decrease in LTL regardless of depressive symptoms is puzzling.
Given that the majority of the literature discussing shorter LTL among ethnic minorities
has postulated this disparity is a result of discrimination (Chae et al., 2014) and greater
cumulative life stress, referred to as the “weathering hypothesis,” (Forde, Crookes,
Suglia, & Demmer, 2019), it is intriguing that the relationship between ethnic minority
status and LTL was not observed at baseline. These results suggest there may have been
changes in other factor(s), other than depressive symptoms, over the three months
between baseline and follow-up to explain the influence of ethnic minority status on
decrease in LTL. Although it extends the scope of the current investigation, it is plausible
to hypothesize that other stressors that are commonly reported among minority
populations may have been exacerbated by cancer-related stressors to mediate or
moderate the association between minority status and shorter LTL during this 3-month
period. A rich area for exploration, future investigations should investigate the role of
ethnic minority status on stress-related outcomes longitudinally across the cancer
trajectory to elucidate stressors unique to patients with an ethnic minority background.
Summary. Because hypothesis 1a was only partially supported and hypothesis 1b
was not supported, hypothesis 1d and 1e – the role of cortisol markers and telomere
length in the depression-survival relationship – were not tested. Thus, the potential
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contribution of the circadian coordinated neuroendocrine system and telomere biology to
the depression-survival relationship remain unclear and warrant further investigation.
More broadly, although the current investigation was methodologically limited and
exploratory rather than confirmatory in nature, the underlying biological mechanisms
associated with the prognostic significance of depression in cancer remains unanswered
and an important area of future inquiry. Nonetheless, the current investigation provided
some important clues. First, the clinical significance, or severity, of depression appears to
be an important factor in the depression-survival investigation. Despite limited subsample sizes, only clinically significant levels of depression (CES-D score > 16) emerged
as a significant predictor of survival. Second, despite considerably more evidence
supporting the association between depression and markers of cortisol, LTL emerged as
the only significant biomarker in the current investigation. Because cortisol is a hallmark
of depression and has demonstrated robust associations with shorter survival across
different cancers including lung, it should not be ignored in future investigations.
However, the current analyses contribute greater support for future investigations into the
role of telomere biology. Although telomere attrition has been linked to both depression
and clinical outcomes in cancer samples, this dissertation is one of the first to integrate
the two. Taken all together, in depth assessment of depression (i.e., severity, history,
features, and subtypes), ethnic minority status, and the role of LTL may be important
considerations for future investigations.
Aim 2 Discussion: Mindfulness-based Interventions in Cancer Contexts
The need for feasible psychological care in cancer settings continues to become
increasingly more apparent and pressing given the accumulating evidence to suggest
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cancer patients experience high prevalence rates of distress, which is associated with
poorer clinical outcomes. Despite relatively recent advancements in treatments, including
immunotherapy, that have yielded promising results, cancer remains a life-threatening
disease without a cure. In addition to facing this stark reality, cancer patients are faced
with a plethora of other stressors at different points across the cancer trajectory,
warranting stress-reduction strategies. As partially supported by hypothesis 1a,
interventions that reduce stress and depression will not only improve quality, but also a
patient’s quantity of life, and the evidence in support of MBSR as an efficacious
treatment for reduction of depressive symptoms among cancer patient populations
continues to grow (Huang et al., 2016; Zainal et al., 2013; Zhang, Wen, et al., 2015).
Although there are some contradictory findings regarding depressive symptom reduction
specifically (Bränström et al., 2012), MBSR interventions have evidenced strong support
for stress-reduction more broadly among cancer populations (Ledesma & Kumano,
2009), and no study to date has examined the effects of an MBSR intervention on
survival among cancer patients. Nonetheless, the feasibility of interventions, including
MBSR is a major priority given that attending weekly, in-person group sessions is
challenging for many patients, particularly those experiencing greater burden and fewer
resources (i.e., transportation and financial issues, limits to physical functioning, feeling
overwhelmed with new appointments/obligations, cognitive changes, etc. (Lehto &
Wyatt, 2013). As such, there is growing attention to the “e-health” movement in
oncology settings and the healthcare system at large, which provides a host of services,
including MBCR/(CR) (Lengacher et al., 2018; Zernicke et al., 2013), through a host of
mobile, electronic formats. The most recent pilot iPad-based MBSR/(CR) intervention
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conducted by Lengacher and colleagues (2018) demonstrated statistically significant
improvements to somatic symptoms of depression (d = 0.85) among breast cancer
survivors. Thus, Aim 2 of the current study was to explore the ameliorative role of an
iPod-based MBSR intervention on depressive symptoms and related outcomes among
lung cancer patients
Hypothesis 2a. Hypothesis 2a proposed that participation in and use of the
intervention would be associated with fewer depressive symptoms from baseline to
follow-up. Hypothesis 2a was partially supported.
After adjusting for baseline differences in depressive symptoms and
chemotherapy treatment status at baseline since the intervention was optional and not
randomized, participation in the intervention only emerged as a significant predictor of
change in depressive symptoms following intent-to-treat principles outlined by (Lachin,
2000). Following the outlined procedures, baseline values were used to replace missing
values at follow-up, resulting in a slope of zero (i.e., no observed change). Contrary to
hypotheses, change in depressive symptoms was positive (scores increased by
approximately three points) in the intervention group whereas depressive symptoms were
essentially maintained (scores decreased by approximately half of a point) among
participants who did not complete the intervention (Figure 6). Interestingly, despite being
only a three-point increase, the change in mean scores surpassed the clinical threshold
(score of > 16 on the CES-D). In other words, among the intervention group, the average
score at baseline fell in the sub-clinical range and elevated to a clinically meaningful
level following the intervention, which is consistent with findings that emerged following
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the analysis of hypothesis 1a. Thus, the hypothesized association emerged as significant,
but not in the hypothesized direction.
Post-hoc analyses examining the interaction between chemotherapy treatment
status at baseline and the intervention was not significant, suggesting that, although
exploratory analyses revealed patients actively receiving chemotherapy treatment at study
enrollment were significantly less likely to participate in the intervention, it was not a
correlate of the association between the intervention and change in depressive symptoms
in the current investigation. In other words, the stressors that typically accompany
chemotherapy treatment could not statistically explain the outcomes following the
intervention in the current sample. Importantly, however, only six patients actively in
treatment at baseline (chemotherapy: n = 5; radiation: n = 1) participated in the
intervention, providing extremely low power to measure and detect such associations.
Further, post-hoc analysis among those who participated in the intervention,
suggested greater use of the intervention was not associated with an increase in
depressive symptoms, suggesting there was not a dose-response relationship between use
of the intervention and an increase in depressive symptoms, although power was limited.
While the results of the current analysis should be interpreted cautiously for a
number of reasons, namely the limited sample size, the methodological design of the
intervention (optional pilot), and the exploratory, rather than confirmatory nature of the
analysis, the statistically significant associations that emerged following participation in
the intervention only emerged following intent-to-treat principles. Although these
replacement procedures are commonly used among populations with high attrition rates,
such as medically ill populations, the use of such replacement procedures follows the
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rationale that no change was observed, although it remains unknown if a change actually
occurred. In other words, these procedures are not inaccurate based on the data collected
(i.e., no observed change), but they do not ensure accuracy (i.e., change was not
observed, but could have occurred). It is likely that the intent-to-treat principles yielded
significance, whereas the analysis using non-replaced data did not, as a result of
increased power given that the sample size nearly doubled (non-replaced: n = 31; intentto-treat: n = 59).
Nonetheless, the results not only contradict hypothesis 2a, but they are clinically
concerning. Despite evidence to suggest that MBSR/(CR) interventions in both in-person
(Huang et al., 2016; Zainal et al., 2013; Zhang, Wen, et al., 2015) and mobile (Lengacher
et al., 2018) formats reduce stress and depressive symptoms, the majority of this work
was conducted among breast cancer patients, and more specifically, breast cancer
survivors. While there are a number of shared stressors across all cancer patients, there
are disease-specific differences, such as tumor location, treatments, and prognoses, as
well as unique disease-specific stressors that differ across cancer types that could be
contributing to the contradictory and unexpected findings in the current investigation. For
example, breast and lung cancer patients may exist within unique social contexts. Breast
cancer contexts tend to foster a sense of cohesion and societal support as evidenced by
the widely known “pink ribbon” symbol, whereas lung cancer is typically coupled with
smoking-related stigma (Chapple, Ziebland, & McPherson, 2004). This is not to suggest
breast cancer patients do not experience significant distress or stigma or that the pink
ribbon phenomenon is always beneficial, it is simply to acknowledge that cancer patients
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have differing experiences specific to their disease that may have been underappreciated
in the current investigation that are discussed further below.
First, as suggested by the name, lung cancer patient’s tumor is located inside the
lung, the organ responsible for breathing, which is a major focus/component of
mindfulness-based practice (Kabat-Zinn, 1982). In meditative practice, and in many of
the tracks, participants were encouraged to focus their attention to a focal point, which is
not always, but often the breath. Post-hoc analyses revealed that the practice track titled,
“Awareness of the breath,” which was listened to an average of seven times, was not
associated with change in depressive symptoms (following intent-to-treat principles),
suggesting explicit instruction to focus on the breath was no associated with an increase
in depressive symptoms. Nonetheless, it is possible that without the added support of an
in-person instructor, components of the intervention that are inherent to meditative
practice predisposed risk for distress in this sub-sample of the cancer population.
Second, a major difference in the time point in the cancer trajectory during which
the intervention was administered could elucidate contradictory findings. Although
survivorship presents a host of unique stressors (i.e., fear of recurrence), it is distinct
psychologically from in the current sample, 24 of which were actively receiving
treatment at study enrollment (chemotherapy: n = 24; radiation: n = 3), and were far from
survivorship status. Because treatment is acutely stressful and is accompanied with a host
of uncomfortable side effects, it is reasonable to assume that is an optimal time point to
provide patients with stress reduction strategies. Alternatively, learning a new skill under
acute stress can be ineffective (Joëls, Pu, Wiegert, Oitzl, & Krugers, 2006) and
potentially overwhelming. Interestingly, chemotherapy treatment status at baseline
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significantly differentiated the two groups (those who were actively receiving
chemotherapy were more likely to decline the intervention), suggesting that stressors
associated with active treatment were likely not responsible for increasing depressive
symptoms in the current investigation. Nonetheless, because the intervention was not
randomized and only six patients were actively receiving treatment at baseline
(chemotherapy: n = 5; radiation: n = 1), it is difficult to discern if opting out of the
intervention during active treatment was protective or if those were the individuals that
would have benefited most.
Additionally, it is not uncommon for participants to experience discomfort and an
initial increase in distress during participation in an MBI given that the foundation of
meditative practice is to approach (i.e., focus attention), rather than avoid internal
experiences, which can be unpleasant (Dobkin & Zhao, 2011). Thus, while the
underlying goal of meditative practice is not to increase distress, if done correctly,
meditation increases awareness to existing distress, if distress is present. Like many
psychological interventions, MBIs are often challenging in the short-term, but yield longterm benefit. While the overarching goal of mindfulness-based practice is to simply
increase awareness to inner experiences, which can also increase awareness of positive
inner experiences, the results from the current investigation suggest this particular sample
did not attain the intended longer-term stress-reduction benefits of the MBI. There are a
number of potentially explanations for this, including possibilities already discussed;
however, minimal instruction and consultation may have contributed to the poor
outcomes as well. Participants were not instructed to listen to the tracks in any particular
order; they were told to listen to tracks of their choice for 30 minutes per day, five days
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per week (equating to 450 minutes over the 3-month period), introducing considerable
variability in what the intervention experience might have been like for each participant.
Post-hoc analyses revealed that surprisingly, intervention participants almost exclusively
listened to practice, opposed to didactic tracks. Only two of 25 participants listened to a
didactic track. Thus, it is plausible that by listening to almost exclusively practice tracks,
participants missed key instruction and guidance surrounding typical experiences
following increased awareness of inner experiences, such as the anticipation that greater
contact with difficult emotions can be unpleasant. Counterintuitive to the finding (i.e.,
participation in the intervention increased depressive symptoms), in line with this
theoretical position, it is also possible participants did not engage in the intervention
enough to adequately master skills and attain benefit. Participants, on average, did not
listen to the prescribed amount. Following the instruction of 30 minutes per day, five
days per week over the course of three months, the prescribed listening amount was 1,800
minutes, and on average, participants listened significantly less (mean = 1624, median =
806). Thus, it is possible that upon experience of increased attention to existing
discomfort, participants discontinued use of the intervention prematurely, resulting in the
observed increase in depressive symptoms, without the long-term benefits observed after
weeks (i.e., eight) of practice following a typical MBSR intervention.
Further, this risk may have been moderated by minimal consultative support.
Records indicated that only one participant attended the drop-in mindfulness-based
cancer support group once over the 3-month intervention period. Therefore, the format of
the pilot intervention essentially eliminated all interpersonal elements of MBSR. While
the active components of MBSR and MBI’s are unknown, patients not only missed
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opportunity for the benefits of social support that the group format facilitates (Lengacher
et al., 2009), but participants in the current pilot MBI also did not have on-going access
to an instructor, and therefore, lacked the opportunity to engage in on-going dialogue
about their experiences. Although study personnel contacted participants twice over the
course of the three-month intervention to check-in, provide reminders, and answer
questions about the intervention, the degree and consistency of discussion regarding
participants’ experiences was significantly less than what would have been achieved in a
more traditional MBSR intervention.
While the goal of feasibility seemed to be achieved by the current intervention, as
evidenced by one third of the sample opting to participate and lack of attendance at the
in-person support group, a primary difference between the current e-health intervention
and previous studies involving mobile MBIs that yielded psychological benefit, in
addition to differences in cancer sub-types, was lack of access to a trained instructor
(Zernicke et al., 2013). Although a recent study involving an iPad-based MBSR/(CR)
intervention that also lacked access to an in-person instructor led to improvements in
depressive symptoms, study personnel contacted participants weekly, providing a more
frequent avenue for consultation, and the sample was, again, among breast cancer
survivors (Lengacher et al., 2018). Although it cannot be confirmed by the data, as there
was no in-person MBSR comparison condition in the current investigation, it plausible to
hypothesize that having access to a trained instructor, preferable a clinical psychologist,
may have ameliorated the observed increase in depressive symptoms among the
intervention group.
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Taken all together, this finding should be interpreted cautiously given the
possibility of selection effect, but considered, especially given the results that emerged
following analysis of hypothesis 1a indicating clinical levels of depression predicted
shorter survival in this sample. While it remains unknown which, if any, aspects of the
intervention contributed to poor outcomes, there are a number of different factors that
warrant greater consideration in future investigations. Differences between cancer types
and the point in the cancer trajectory during which previous MBIs were administered
may have been underappreciated in the current sample. Researchers and clinicians alike
should consider the broader biopsychosocial perspective of the patient’s cancer
experience to temper the generalizability of conclusions across populations. Lastly, these
results further motivate efforts to dismantle active components of MBIs.
Hypothesis 2b. Hypothesis 2b proposed that participation in and use of the
intervention would be associated with improved diurnal cortisol rhythmicity from
baseline to follow-up. Hypothesis 2b was not supported.
Contrary to hypothesis 2b, the intervention did not change any of the markers of
diurnal cortisol (including analyses following intent-to-treat principles). Additionally,
consistent with hypothesis 1b, no theoretically derived indicators were significantly
associated with changes in any of the markers of cortisol. Given the exploratory nature of
the analysis and the minimal existent evidence to suggest MBSR is efficacious at
improving diurnal cortisol rhythmicity among cancer patients, these null findings are not
particularly surprising. Despite growing evidence to suggest that MBSR and other MBIs
are efficacious at improving the physical health among non-medically ill populations
(Grossman, Niemann, Schmidt, & Walach, 2004), the majority of studies examining the
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effects of an MBI on cortisol among cancer patients have not yielded significance
(Bränström et al., 2013; Lengacher et al., 2012). It is possible cancer patients’
neuroendocrine systems are less malleable to intervention as a result of tumor - and
treatment-related effects. Alternatively, more extensive mindfulness-based training might
be required to observe significant changes. Given Carlson and collogues’ findings that
yielded statistically insignificant changes in cortisol profiles immediately following the
intervention (2004), but significance at the one-year follow-up (2007), the latter is more
likely. Interestingly, although the current investigation did not test mediation, in
conjunction with findings from hypothesis 2a and 1b, it seems cortisol profiles were not a
correlate or an underlying explanation for worsening depression among intervention
participants in the current sample.
Hypothesis 2c. Hypothesis 2c proposed that participation in and use of the
intervention would be associated with maintenance of LTL (lack of a decrease) from
baseline to follow-up. Hypothesis 2c was supported.
After adjusting for chemotherapy treatment status at baseline, the intervention
was significantly associated with a change in LTL. As hypothesized, the slope of change
in LTL was positive among those in the intervention whereas the slope of change was
negative among those who did not complete the intervention. As demonstrated in Figure
7, the LTL increased among those in the intervention group, whereas LTL decrease
among those who did not participate. Chemotherapy treatment status was also
significantly associated with change in LTL. As shown in Figure 8, contrary to
expectations, patients that were receiving chemotherapy treatment at baseline evidenced
longer LTL compared to those who were not. Despite being consistent with the
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hypothesized direction, the effect of the intervention was stronger than hypothesized (i.e.,
LTL was lengthened opposed to just maintained among the intervention group).
Contradictory to what was expected, however, was that relatively proximal chemotherapy
treatment was associated with an increase in LTL. Although these results technically
support hypothesis 2c, they are somewhat puzzling given the results that emerged
following analysis of hypothesis 2a, demonstrating that the intervention led to an increase
in depressive symptoms. This is especially puzzling given that following analysis of 1c, a
significant association emerged between change in depressive symptoms and change in
the predicted direction LTL – as depressive symptoms increased, LTL decreased with
and without adjusting for use of the intervention.
To elucidate the complexity of these findings, post-hoc analyses examining the
prognostic significance of LTL revealed that change in LTL predicted survival from both
date of study entry and date of diagnosis. The results persisted after adjustment for
participation in the intervention. However, contrary to expectations, increasing LTL
predicted shorter survival from both date of study entry and date of diagnosis, suggesting
that longer LTL may have been associated with poorer clinical outcomes in this lung
cancer sample. Moreover, consistent with the results that emerged following analysis of
hypothesis 2a, in the analysis demonstrating that longer LTL predicted shorter survival,
after adjusting for participation in the intervention, results demonstrated that those who
participated in the intervention died sooner. In other words, the intervention was
associated with longer LTL, which predicted shorter survival, contrary to expectations.
While these results suggest that the intervention was associated with an increase
in depression and longer LTL, which unexpectedly predicted shorter survival, these
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findings are inconsistent with results from hypothesis 1c (as depressive symptoms
increased, LTL decreased/shortened after adjusting for minority status). Interestingly, the
association between depression and LTL persisted after controlling for participation in
the intervention. To elucidate these findings and clarify the bigger picture, despite
restricted power, a regression re-assessing the association between depressive symptoms
and change in LTL (hypothesis 1c) with the addition of the interaction term between
change in depressive symptoms and the intervention was conducted. The model emerged
as significant, although the interaction term did not significantly contribute to the model.
Despite lack of statistical significance, as demonstrated for visual not statistical purposes
in Figure 16, there appear to be differences in the pattern of association between change
in depressive symptoms and change in LTL between intervention groups (participated
versus not). The association between change in depressive symptoms and change in LTL
was positive (as depressive symptoms increased, LTL also increased/lengthened) among
those who participated in the group, whereas the association was negative (as depressive
symptoms increased, LTL decreased/shortened) among those who did not. In contrast, as
shown in Figure 17, excluding participation in the intervention, the pattern of findings are
consistent with hypothesis 1c – the association between change in depressive symptoms
and change in LTL is negative (as depressive symptoms increased, LTL
decreased/shortened). Therefore, although the interaction was not statistically significant,
it seems an increase in depressive symptoms was only associated with longer LTL among
patients in the intervention group, providing a more cohesive picture among the current
sample, as each predicted shorter survival and each “worsened” following the
intervention. It is likely differential effects regarding minority status may have also
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emerged after adjusting for intervention status as well with larger power, as only three
individuals from ethnic minority backgrounds participated in the intervention.
Importantly, these findings clarify the results that demonstrated patients who were
receiving chemotherapy at baseline evidenced an increase in LTL. These findings
cohesively support the post-hoc analysis that demonstrated a statistically significant
interaction between intervention participation status and chemotherapy treatment status at
baseline. As demonstrated in Figure 13, patients who received chemotherapy at baseline
and participated in the intervention demonstrated an increase in LTL, whereas patients
who were not receiving chemotherapy at baseline and did not participate in the
intervention evidenced a decrease in LTL (all other patients evidenced no noticeable
change), supporting the notion that the intervention was associated with worsening
biological health among those who had recently undergone chemotherapy treatment.
What remains unclear from the current investigation, however, is why increasing,
opposed to shortening LTL, emerged as a marker of shorter survival, and was associated
with an increase in depressive symptoms only among those in the intervention group.
These findings are particularly perplexing given the substantial evidence to suggest that,
in general, telomeres shorten faster under stressful conditions and shorter telomeres are
indicative of poorer health. It is plausible, just as there appear to have been diseasespecific psychosocial considerations that were overlooked in the current intervention, that
there may be underlying disease-specific biological differences occurring in the current
NSCLC sample as well, especially given the complexity of cancer biology. As such, there
are still a number of unknowns about telomere biology in tumor environments and what
impact that has on the patient’s systemic biology.
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Greater attention has been directed toward telomerase in cancer contexts, more
recently, as it is the enzyme responsible for adding new DNA to the end of chromosomes
effectively lengthening telomeres (Blackburn, 2011), and may be a missing piece to
elucidating the current findings. Somewhat counter-intuitively, extremely short TLs that
are near senescence are actually protective against cell division and uncontrollable cell
growth, and therefore tumor progression, whereas continuous cell growth and advancing
tumors is associated with reactivation of telomerase (Shay & Wright, 2011). Indeed,
overexpression of telomerase has been observed in 90% of cancer cells (Kim et al.,
1994), and current hypotheses posit that as telomeres from cancer cells shorten rapidly,
telomerase facilitates indefinite cell division in an attempt to re-stabilize telomeres, which
ultimately leads to a state of “immortalization,” or unrest of cellular proliferation
(Augustine et al., 2017). In other words, as the host’s body produces greater telomerase to
rectify the excessively short TLs that may have conferred risk for the disease in the first
place (Hou et al., 2012), it actually unlocks tumorigenesis. Importantly, telomere length
in the current investigation was assessed peripherally via blood samples and telomerase
was not assessed, so limited conclusions can be drawn. Nonetheless, it is plausible that
the observed increase in LTL could be explained by an increase in telomerase, which
may actually confer risk for shorter survival as it likely indicates greater cell proliferation
both in and out of tumor environments, and therefore tumor growth.
It should be acknowledged, however, that the alternative – depletion of
telomerase in tumor microenvironments – appears to be equally problematic.
Experiments have revealed the elimination of telomerase leads to eventual loss of
telomere function, which also facilitates tumor progression (De Lange & Jacks, 1999).
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Thus, it is likely more accurate to conceptualize the disruption of the delicate balance
between cell division (telomere shortening) and telomerase (telomere lengthening) in the
tumor microenvironment as harmful as it appears to activate tumorigenesis. However, the
specific timing and mechanisms of this process remain unclear (Hackett & Greider,
2002), and no literature on the longitudinal changes to peripheral LTL in cancer samples
currently exists. Both gaps warrant greater attention to elucidate current findings, but
also, to strengthen LTL’s utility as a feasible, easily obtainable clinical biomarker in
cancer contexts.
Consistent with the proposed theory, if longer telomeres are actually indicative of
faster tumor growth and stress has been shown to tax telomere biology, then despite
being counterintuitive to findings in non-medically ill populations, it is logical that
worsening depression would be linked to longer telomeres in cancer populations, as
demonstrated in the current sample. It is plausible that, consistent with the literature in
non-medically ill populations, depressive symptoms shortened telomeres in the current
sample, but instead of being biologically adaptive, greater distress potentially amplified
the body’s production of telomerase indirectly, which ultimately supported
tumorigenesis. To clarify, none of the proposed explanations discussed in the current
section were tested in the current investigation, and should therefore, be considered on a
theoretical level. Considerably more research examining the nuanced relationships
between depression, LTL, telomerase, and medical factors known to influence tumor
biology, including disease stage and treatments, from a longitudinal perspective is
required to elucidate findings that emerged from the current investigation.
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Most importantly, however, elucidating the elements of the intervention that
contributed to poorer psychological and biological health should be prioritized. Although
it is challenging to interpret the LTL findings in context of the broader literature, as there
has only been one study that examined the effects of an MBI on TL among cancer
patients, the pilot intervention led to statistically significant increases in LTL, which was
unexpectedly associated with shorter survival. The only other study that examined the
effects of an MBI on TL to date revealed that TL was maintained following an MBCR
intervention compared to the control groups, whose TL decreased (Carlson et al., 2013).
Importantly, however, as previously mentioned, this sample was among breast cancer
survivors, who from a biological and psychosocial perspective, likely differ from NSCLC
patients many of which were far from survivorship status. Although a number of potential
explanations have been discussed under hypothesis 2a, findings from primary and posthoc analysis of hypothesis 2c, combine to suggest that active component(s) of the iPodbased MBI were detrimental to the small sample of NSCLC patients included in the
current investigation, demanding greater consideration from researchers and clinicians a
like.
Hypothesis 2d. Hypothesis 2d proposed that participation in and use of the
intervention would be associated with longer survival. Hypothesis 2d was partially
supported.
As hypothesized, the intervention emerged as a significant predictor of survival
calculated both from study entry and date of diagnosis; however, inconsistent with the
hypothesis, participation in the intervention was associated with shorter survival (Figures
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9 and 10). Thus, the hypothesized association emerged as significant, but not in the
hypothesized direction, yielding partial support for hypothesis 2d.
Similar to hypothesis 2a and 2c, among those who participated in the intervention,
greater use of the intervention did not predict shorter survival, only participation in the
intervention emerged as significant, suggesting that there was not a dose-response
relationship and findings could be attributable to a selection effect. Additionally, post-hoc
analyses demonstrated that use of practice tracks did not predict survival, and shorter
survival could not be explained by use of the track “Awareness of the breath,” further
suggesting that an aspect of the intervention, rather than the specific content of the
intervention, contributed to poorer outcomes. As discussed at length under hypothesis 2a
and 2c, there are a number of potential explanations hypothesizing why the pilot iPod
intervention was unexpectedly related too poorer outcomes, although greater listening
behavior, use of practice tracks, and use of the track with explicit focus on the breath,
based on the available data, did not emerge as a likely explanation. However, conclusions
surrounding listening behavior are restricted by the fact that participants largely did not
listen to didactic tracks, which restricted power to make comparisons. Thus, as discussed
under hypothesis 2a, it is possible lack of instruction regarding the order of tracks
(didactic followed by or intermixed with practice) inadvertently facilitated an increase in
awareness of distressing internal experiences, that without guidance, could have been
interpreted by intervention participants as both distressing and concerning, leading them
to terminate the intervention prior to fully gaining stress-reduction skills. Thus, it is more
likely that limited instruction regarding track order, compiled by a virtual instructor void
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of interpersonal dialogue contributed to poorer outcomes than the content of the
intervention.
As previously mentioned, although results from the current investigation should
be interpreted cautiously given the aforementioned limitations to the study, namely that
the design of the intervention was not randomized, results from the current hypothesis are
clinically concerning and cannot be dismissed, especially in conjunction with the results
that emerged following hypothesis 2a and 2c. While the current study should not be
replicated at minimum without random assignment for ethical reasons, these findings will
hopefully motivate efforts toward dismantling the active components of MBSR and MBIs
to subsequently be tested among cancer patients, and sub-samples of the cancer patient
population (i.e., lung cancer). Although the analysis from the current investigation was
exploratory in nature, given the gravity of the results, the findings from the current
dissertation should still be taken seriously in clinical contexts. The majority of published
research on the effects of MBSR and MBIs among cancer patients has demonstrated
benefit, or at least has not reported harm; thus, it is plausible to conclude that there was
an underlying component inherent to the current intervention that was detrimental. It is
still possible that the component of attention to the breath, which is common to
meditation practice, led to an increase in depressive symptoms and related outcomes
among this sample despite results that emerged following post-hoc analysis to suggest
that greater use of the “Awareness of the breath,” track was not associated with greater
depressive symptoms or shorter survival. However, the unspecified track order and
limited access to a trained instructor are equally viable competing hypotheses. Indeed, it
may have been a combination of the three. With greater power and a stronger
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methodological design, it would have been helpful to explore the moderating role of a
trained instructor on the potential association between increased attention to the breath
and inner experiences and an increase in depressive symptoms and shorter survival.
Summary. The evidence that emerged from analysis of Aim 2 hypotheses
cumulatively and cohesively suggest that the intervention was associated with worsening
psychological and physical health and shorter survival among a small sample of NSCLC
patients. Contrary to the hypothesized and intended benefits of the pilot iPod-based MBI,
the intervention yielded sobering negative associations. Because the intervention was not
randomized, it is possible there were undetected differences between the two groups
predisposing the intervention group to poorer outcomes. However, baseline differences
were controlled for in each analysis and the initial exploratory analysis comparing the
two groups demonstrated that chemotherapy treatment status at baseline was the only
demographic/medical factor differentiating the two groups. Importantly, those who were
receiving chemotherapy at study entry were actually less likely to participate in the
intervention, suggesting results are likely best explained by an unidentified factor related
to the intervention opposed to a biased sample.
Although unintentional, these analyses inadvertently contributed to a gap in the
mindfulness-based literature: absence of research on the harmful or negative of effects of
MBIs (Irving, Dobkin, & Park, 2009). These results demonstrate that under specific
conditions, MBIs may in fact confer risk and even be harmful. In accordance with Baer
and colleagues’ (2019) extensive discussion surrounding the potential sources for harm in
MBIs, including program/intervention, participant, and instructor/clinician factors, the
current dissertation identifies a number of factors from each of these categories that may
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have conferred risk for harm among the current sample. Unfortunately, although these
factors cannot be compared, and therefore, confirmed as explanations in the current
investigation, each one of these factors was discussed as a hypothetical explanation for
the current findings (i.e., program/intervention: iPod-based; participant: lung cancer
patients; instructor/clinician: optional and underutilized at the drop-in group). It is clear
that Baer and colleagues’ (2019) discussion surrounding the potential for MBIs to induce
harm should be taken seriously by researchers and clinicians a like.
Conclusions
Taken all together, although results from the current investigation should be
interpreted cautiously, the current dissertation provides a number of informative data
points regarding depressive symptoms, telomere length, survival, and the use of an iPodbased MBI among NSCLC patients (see Figure 2).
1. Only clinical, not sub-clinical, levels of depression at baseline predicted shorter
survival from both date of study entry and date of diagnosis (hypothesis 1a).
2. All things held constant, ethnic minorities evidenced greater shortening of LTL
(hypothesis 1c).
3. The intervention was associated with an increase in depressive symptoms, an
increase in LTL, and shorter survival from both date of study entry and date of
diagnosis (hypothesis 2a, 2c, 2d).
4. An increase in LTL was associated with shorter survival from both date of study
entry and date of diagnosis (post-hoc hypothesis 2c/hypothesis 1e).
5. Although an increase in depressive symptoms was initially associated with a
decrease in LTL (hypothesis 1c), upon closer examination, it seems as depressive
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symptoms increased, LTL only shortened among patients who did not participate
in the intervention, whereas LTL lengthened among those who participated in the
intervention (post-hoc hypothesis 2c/1c).
Although mediations and moderation analyses extend the scope of the current
dissertation, and the design of the study did not meet criteria for these analyses, these
results point to longer LTL as a potential biological explanation for the depressionsurvival relationship among lung cancer patients. Little is known about the longitudinal
changes in LTL across the cancer trajectory and how it is dynamically influenced by
telomerase, tumorigenesis, and psychological factors, such as worsening depression, but
results from this dissertation further support the importance and complexity of telomere
biology in cancer populations. Surprisingly, the less supported biomarker, TL, as
compared to cortisol, emerged as the potential link between worsening depressive
symptoms and shorter survival.
Results from the current dissertation also highlight the importance of taking a
humanistic approach to psycho-oncology by comprehensively considering the entire
biopsychosocial perspective of the population of interest. In clinical research it is often
both appropriate and efficient to generalize across sub-populations; however, it seems
that generalizations cannot always be made across cancer sub-types (i.e., breast to lung),
as there are unique factors differentiating their experience. Furthermore, it seems
generalizations across patients at different points in the cancer trajectory may not have
been appropriate as the majority of support for the intervention stemmed from research
among breast cancer survivors. Although the specific factors of the population and the
components of the intervention that contributed to poorer health on a psychological,
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biological, and clinical level remain unclear, results from the current investigation that
starkly contradict other findings in the literature demonstrate that active ingredients of the
current intervention were under considered. While these results are unsettling and
completely contradictory to a-priori hypotheses, they affirm the importance of
conducting pilots and may caution against feasibility to the point of sacrificing efficacy
of the intervention. Once again, although the underlying cause of risk cannot be
confirmed, it is reasonable to speculate that patients facing mortality might require
interpersonal support from a trained mental health professional, either in-person or
virtually, throughout the MBI, as it can prompt greater attention to difficult inner
experiences, both psychologically and physically.
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LIMITATIONS
Although a number of limitations to the current dissertation have already been
acknowledged, given the gravity of the findings, it is necessary to emphasize the
limitations to the current investigation. First, the directionality between depression and
biomarkers cannot be assumed since they were collected at roughly the same time point
(e.g., baseline and follow-up). For this reason, the temporal precedence criteria discussed
by Kraemer and colleagues (2008) for mediation and moderation statistical analysis was
not met, limiting the conclusions that could be made in the current investigation.
Although an increase in depressive symptoms was associated with change in LTL, and
both were predictive of shorter survival, LTL could not be tested as a mechanism in the
depression-survival pathway due to methodological limitations.
As previously mentioned, other methodological limitations also exist. Although
the overall sample size supported primary hypotheses, small sub-sample sizes (e.g.,
minority status, number of participants in the intervention, intervention listening
behavior, etc.) limited power and the ability to statistically test differences in observed
patterns and elucidate finings. Additionally, the pilot nature of the intervention (optional
and not randomized) further limited the conclusive nature of its effects. Although there
did not appear to be significant differences between those who opted to participate in the
intervention versus those who did not, other than chemotherapy treatment status at
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baseline, the intervention was not randomized, which further convolutes the striking and
unexpected intervention findings.
Lastly, there was considerable variation in the medical characteristics of the
sample given that one of the inclusion criterions was a NSCLC diagnosis within five
years of study entry. Interpretation of findings related to biomarkers (i.e., LTL) was
limited by the medical heterogeneity of the sample. There was considerable variability in
where each patient was in the cancer trajectory given that some were actively receiving
treatment (chemotherapy: n = 24; radiation: n = 3) at study entry, whereas others were
not, but had also not reached survivorship status.
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FUTURE DIRECTIONS
Given the exploratory rather than confirmatory nature of the current dissertation, a
number of questions remain unanswered and warrant future investigation. Regarding Aim
1 and the mechanisms of the depression-survival pathway, future investigations should
attempt to elucidate the role of factors and subtypes of depression as it relates to shorter
survival. As discussed under hypothesis 1a, greater investigation into the severity,
symptom clusters, history, and subtypes of depression could identity the patients at
greatest risk and inform nuanced interventions to improve clinical outcomes. Moreover,
in addition to testing LTL as a mediator of the depression-survival pathway, greater
investigation into the longitudinal change in peripheral TL as relates to telomerase,
tumorigenesis and distress/depression in current samples would increase the utility of
LTL as potentially feasible clinical biomarker in cancer contexts.
Regarding Aim 2 and the clinically concerning results that emerged following the
pilot iPod-based MBI, while future investigations should not aim to replicate the current
investigation, dismantling studies should attempt to identify the active components of
MBSR and MBIs to subsequently be tested among cancer patients and specific cancer
types (e.g., lung) at different points in the cancer trajectory (e.g., prior to survivorship).
Although other mobile studies without a group component have demonstrated efficacy in
reducing depressive symptoms among cancer patients (Lengacher et al., 2018), the
potential benefits of the group component should also be examined given the mounting
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evidence demonstrating that social support yields many benefits among cancer patient
populations (Uchino, 2004). The order and balance between didactics and practice
content in e-health interventions should also be clarified and adapted accordingly.
Additionally, future investigations should elucidate the role of a trained, easily accessible
instructor in e-health interventions to balance feasibility and efficacy.
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FINAL CONCLUSIONS
In conclusion, a cancer diagnosis can be devastating, as it is followed by an
arduous battle for survivorship that is, unfortunately, not always won. Typically, the
primary goal is to extend life given that much of the distress that accompanies cancer
stems from the very real, pressing threat of mortality. However, in consideration of this
harsh reality, that survivorship may not be achieved, quality of life becomes highly
valued. Said best by June Goodfield, and quoted by Siddhartha Mukherjee, in The
Emperor of All Maladies: A Biography of Cancer, “Cancer begins and ends with people.
In the midst of scientific abstraction, it is sometimes possible to forget this one basic fact”
(p. 1). The shortcomings of the well intentioned current intervention may be best
explained by this quote, as many of the proposed components that may have conferred
risk could have potentially been avoided following greater consideration of the larger
biopsychosocial perspective opposed to focus on scientific abstraction. Thus, identifying
interventions that treat people, by enhancing both quality and quality of life remain an
overarching priority in oncology settings.
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Table 1.
A list of the Mindfulness-Based iPod Intervention Tracks.
Didactic Tracks (minutes: seconds)
1. Introduction (11:26)
2. Foundation, Importance of
Attitudes (3:54)
3. Non-judging (4:04)
4. Patience (3:46)
5. Beginner’s Mind (3:41)
6. Trust (4:06)
7. Non-Striving (6:19)
8. Acceptance (4:46)
9. Letting Go (6:53)
10. The Present Moment (11:56)
11. Wandering Mind (1) (7:53)
12. Wandering Mind (2) (9:17)
13. Stress and Mindfulness (1) (7:45)
14. Stress and Mindfulness (2) (7:08)
15. Working with Difficult Emotions
(7:22)
16. Taking Care of Yourself (5:43)
17. Social Support (9:05)
18. Self Compassion (7:00)
19. Accepting Emotions (8:52)
20. Living with Cancer (1) (5:47)
21. Living with Cancer (2) (5:52)
22. Living with Cancer (3) (5:18)
23. Cancer Teamwork (6:17)
24. Caring and Sharing (8:37)
25. I am not this Cancer (7:56)
26. Waiting (11:35)
27. Holding on and Letting Go (7:40)
28. Acknowledgment (2:07)
29. Taking Your Place (4:26)
30. ‘Letting Go’ (3:29)
31. ‘Wild Geese’ (2:18)
32. ‘The Summer Day’ (2:25)

Practice Tracks (minutes: seconds)
1. Sitting Meditation Instructions (8:11)
2. Awareness of the Breath (11:05)
3. 5 Minute Sitting Meditation (5:18)
4. 10 Minute Sitting Meditation (10:16)
5. 15 Minute Sitting Meditation (15:16)
6. 20 Minute Sitting Meditation (20:19)
7. Extended Sitting Meditation (41:03)
8. Loving Kindness Meditation (5:40)
9. Informal Mindfulness Practice (3:17)
10. Mountain Meditation (20:04)
11. Body Scan Meditation (40:22)
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Table 2.
Sample characteristics.
Variable
Sex
Male
Female
*
Age
Race/Ethnicity
Non-Hispanic White
Black/African American
Hispanic or Latino
Asian/Asian American
Other
*
Minority Status
Yes
No
Annual Household Income
>$15,000 - 39,999
$40,000 - 79,999
$80,000 – 149,999
$150,000 - 249,999
*
Age at Diagnosis
Disease Stage at Diagnosis
I
II
III
IV
Early (I, II)
Late (III, IV)
Treatment Factors
Chemotherapy at study entry
Yes
No
*
Radiation at study entry
Yes
No
*
Chemotherapy ever
Yes
No

Frequency (n)

Percent (%)

21
41
5

31.3
61.2
7.5

Mean

61.5
39
10
1
1
1
15

58.2
14.9
1.5
1.5
1.5
22.4

13
39

19.4
58.2

36
15
7
1
8

53.7
22.4
10.5
1.5
11.9
59.6

15
8
28
16
23
44

22.4
11.9
41.8
23.9
34.3
65.7

21
38
8

31.3
56.7
11.9

3
57
7

4.5
85.1
10.4

48
12

71.6
17.9
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*

7

10.4

Yes
No
*
Time since diagnosis (months)
Predictors and Outcomes at Baseline
Depression
*
Above clinical cut-off a
Overall mean cortisol b
*
Bedtime mean cortisol b
*
Diurnal cortisol slope b
*
TL at baseline
*
Notes. *Missing data.

38
22
7

56.7
32.8
10.4

Radiation ever

a

The clinical cut off on the CES-D is 16.

b

Log transformed variables.

23.5
59
8
29
58
9
58
9
57
10
64
3
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88.1
11.9
43.3
86.6
13.4
86.6
13.4
85.1
14.9
95.5
4.5

15.5
23.9
-2.17
-2.83
-0.05
0.82

Table 3.
Correlations between Theoretically-Derived Covariates and Independent and Dependent Variables
(‘a’ and ‘d’ Hypotheses).
Correlations
10

11

12

13

14

1. Disease stage

-.066

.017

.094

-.252

-.262

2. Age

-.092

-.247

-.176

-.056

-.088

3. Age at diagnosis

-.074

-.205

-.146

-.056

-.194

4. Sex

-.060

.154

.053

.305*

.209

5. Chemotherapy treatment at baseline

.325*

-.057

-.066

-.183

-.200

6. Ever received chemotherapy

-.063

-.027

.018

.149

.109

7. Radiation treatment at baseline

.077

.265

.201

.002

.000

8. Every received radiation

-.044

-.175

.011

-.132

.091

9. Smoking history

.109

.063

.045

-.265

-.069

10. Depressive symptoms at baseline

1

-

-

-

-

11. Change in depressive symptoms

-

1

-

-

-

12. Intent-to-treat

-

-

1

-

13. Survival from study entry

-

-

-

1

-

14. Survival from date of diagnosis

-

-

-

-

1

Note. *r > 0.3 and < 0.5
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Table 4.
Correlations Between Theoretically-Derived Covariates and Independent and Dependent Variables
(‘b’ Hypotheses).
Correlation
10

11

12

13

14

15

16

17

18

19

20

21

1. Disease
stage

-.07

.02

.09

.19

-.14

-.05

.21

-.11

-.10

.04

.12

.06

2. Age

-.09

-.25

-.18

.26

-.18

-.08

.33*

-.06

.01

.13

-.05

-.07

3. Age at
diagnosis

-.07

-.21

-.15

.25

-.15

-.07

.31*

-.06

.02

.13

-.04

-.06

4. Sex

-.06

.15

.05

-.08

-.12

-.04

-.11

.10

.08

-.06

-.07

-.06

.33*

-.06

-.07

.16

.02

-.01

.05

.01

-.02

.01

.27

.21

-.06

-.03

.02

-.09

.03

.05

-.09

-.23

-.10

-.06

-.24

-.20

.08

.27

.20

.03

.08

.08

.07

-.08

-.10

.11

-.27

-.13

-.04

-.18

.01

-.01

.01

.03

-.01

-.17

-.11

.03

-.13

-.09

.11

.06

.05

.02

-.03

-.01

.08

.07

.10

.21

-.05

.06

1

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-

-

-

-

-

-

-

-

5. Chemo at
baseline
6. Ever
received
chemo
7. Radiation
at baseline
8. Ever
received
radiation
9. Smoking
history
10.
Depressive
symptoms at
baseline
11. Change
in depressive
symptoms
12. Intent-totreat
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13. Baseline
overall mean
cortisol
14. Change
in overall
mean cortisol
15. Intent-totreat
16. Baseline
bedtime
mean cortisol
17. Change
in bedtime
mean cortisol
18. Intent-totreat
19. Baseline
diurnal
cortisol slope
20. Change
in diurnal
cortisol slope
21. Intent-totreat

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

1

-

Note. *r > 0.3 and < 0.5

154

Table 5.
Correlations Between Theoretically-Derived Covariates and Independent and Dependent
Variables (‘c’ Hypotheses).
Correlation
11

12

13

14

15

16

1. Disease stage

-.066

.017

.094

.117

-.037

.011

2. Age

-.092

-.247

-.176

-.295

-.070

-.024

3. Age at diagnosis

-.074

-.205

-.146

-.312*

-.120

-.053

4. Sex

-.060

.154

.053

.136

.068

.087

5. Chemo at baseline

.325*

-.057

-.066

-.018

.212

.249

6. Ever received chemo

-.063

-.027

.018

.246

.065

.100

7. Radiation at baseline

.077

.265

.201

-.049

-.134

-.146

8. Ever received radiation

-.044

-.175

.011

.062

.294

.193

9. Smoking history

.109

.063

.045

-.258

.126

.057

10. Ethnic minority status

.151

.251

.265

.003

-.332*

.251

1

-

-

-

-

-

-

1

-

-

-

-

-

-

1

-

-

-

14. Baseline LTL

-

-

-

1

-

-

15. Change in LTL

-

-

-

-

1

-

-

-

-

-

-

1

11. Depressive symptoms at
baseline
12. Change in depressive
symptoms
13. Intent-to-treat

16. Intent-to-treat
Note. *r > 0.3 and < 0.5
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Table 6.
Demographic and Medical Differences Between Intervention Groups (Exploratory Analysis).
Completed
Intervention

Did not
Complete
Intervention

χ2

U

M

SD

M

SD

t-test

Age

61.0

9.5

61.7

8.4

.729

Age at Diagnosis

59.2

9.6

59.8

8.6

.775

Sex

-

-

-

-

-

Minority Status

-

-

-

-

-

Education †

-

-

-

-

-

.301

Income †

-

-

-

-

-

.239

Disease Stage

-

-

-

-

-

Treatment

-

-

-

-

-

At baseline

-

-

-

-

-

.050*

Ever

-

-

-

-

-

.190

At baseline

-

-

-

-

-

.764

-

-

-

-

-

.085

626.7

389.9

749.5

616.0

.375

46.7

36.2

37.5

24.4

.269

Demographics

.798
.142

Medical

Chemotherapy

Radiation
Ever
Months between diagnosis
and study entry
Pack Years

Notes. *p < .05
† Continuous variable, tested with Mann-Whitney U test
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Table 7.
Associations Between Depressive Symptoms and Survival (Hypothesis 1a).
Depressive Symptoms at Baseline on Survival from Study Entry
Predictor

B

df

Hazard
Ratio

p

95% CI

Sex

0.669

1

.090

1.953

0.901

4.231

Depression

0.023

1

.206

1.023

0.987

1.06

Sex

0.654

1

.096

1.924

0.89

4.16

Intervention

-0.926

1

.017*

0.396

0.185

0.85

Depression

0.025

1

.175

1.025

0.989

1.062

Depressive Symptoms at Baseline on Survival from Diagnosis
Predictor

B

df

Hazard
Ratio

p

95% CI

Depression

0.027

1

.139

1.027

0.991

1.064

Intervention

-0.905

1

.021*

0.405

0.188

0.87

Depression

0.024

1

.180

1.024

0.989

1.061

Change in Depressive Symptoms on Survival from Study Entry
Predictor

B

df

Hazard
Ratio

p

95% CI

Sex

0.763

1

.154

2.145

0.752

6.121

Depression

0.453

1

.869

1.573

0.007

338.148

Sex

0.736

1

.185

2.088

0.736

1

Intervention

-1.12

1

.087

0.326

-1.12

1

Depression

-0.728

1

.810

0.483

-0.728

1

Change in Depressive Symptoms on Survival from Diagnosis
Predictor

B

df

Hazard
Ratio

p

95% CI

Depression

0.625

1

.798

1.869

0.015

226.456

Intervention

-0.781

1

.241

0.458

0.124

1.688
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Depression

-0.318

1

.904

0.727

0.004

128.856

Change in Depressive Symptoms (intent-to-treat) on Survival from Study Entry
Predictor

B

df

Hazard
Ratio

p

95% CI

Sex

0.686

1

.086

1.985

0.908

4.338

Depression

1.085

1

.663

2.961

0.022

391.42

Sex

0.684

1

0.09

1.982

0.899

4.371

Intervention

-0.915

1

0.021

0.4

0.184

0.871

Depression

-0.233

1

0.926

0.792

0.006

111.355

Change in Depressive Symptoms (intent-to-treat) on Survival from Diagnosis
B

df

p

Hazard
Ratio

95% CI

Depression

1.5

1

.526

4.484

0.044

Intervention

-0.939

1

.020*

0.391

0.178

Depression

-0.026

1

.991

0.975

0.01

Predictor

Note. *p < .05
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Table 8.
Depressive Symptoms Regressed on Markers of Diurnal Cortisol (Hypothesis 1b).
Depressive Symptoms on Overall Mean Cortisol Assessed at Baseline
Variable

β

t

p

Model 1
Depression

0.127

0.93

R

R2

ΔR2

p(ΔR2)

F

p

0.127

0.016

0.016

.356

.866

.356

0.356

Depressive Symptoms on Bedtime Mean Cortisol Assessed at Baseline
Variable

β

t

p

Model 1
Depression

0.058

0.422

R

R2

ΔR2

p(ΔR2)

F

p

0.058

0.003

0.003

.675

.178

.675

0.354

0.125

0.122

.010

3.720

.031*

0.328

0.108

0.104

.017*

3.133

.052

.675

Model 2
Depression

0.100

0.764

.448

Age

0.352

2.691

.010*

Model 2
Depression

0.09

0.682

0.499

Age at
diagnosis

0.324

2.464

0.017

Depressive Symptoms on Diurnal Cortisol Slope Assessed at Baseline
Variable

β

t

p

Model 1
Depression

0.069

0.506

R

R2

ΔR2

p(ΔR2)

F

p

0.069

0.005

0.005

.615

.256

.615

.615
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Change in Depressive Symptoms on Change in Overall Mean Cortisol
Variable

β

t

p

Model 1
Depression

0.176

0.84

R

R2

ΔR2

p(ΔR2)

F

p

0.176

0.031

0.031

0.41

.706

.410

0.328

0.108

0.077

0.193

1.270

.302

0.410

Model 2
Depression

0.283

1.281

.214

Intervention

-0.297

-1.344

.193

Change in Depressive Symptoms on Change in Bedtime Mean Cortisol
Variable

β

t

p

Model 1
Depression

0.231

1.112

R

R2

ΔR2

p(ΔR2)

F

p

0.231

0.053

0.053

0.278

1.237

.278

0.362

0.131

0.078

0.185

.1580

.229

0.278

Model 2
Depression

0.338

1.55

0.136

Intervention

-0.298

-1.369

0.185

Change in Depressive Symptoms on Change in Diurnal Cortisol Slope
Variable

β

t

p

Model 1
Depression

0.209

0.978

R

R2

ΔR2

p(ΔR2)

F

p

0.209

0.044

0.044

.339

.957

.339

0.222

0.049

0.006

.730

.520

.602

.339

Model 2
Depression

0.181

0.783

.443

Intervention

0.081

0.350

.730
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Change in Depressive Symptoms on Change in Overall Mean Cortisol (intent-to-treat)
Variable

β

t

p

Model 1
Depression

0.138

1.012

R

R2

ΔR2

p(ΔR2)

F

p

0.138

0.019

0.019

.316

1.024

.316

0.238

0.057

0.038

0.155

1.564

.219

.316

Model 2
Depression

0.194

1.384

.172

Intervention

-0.202

-1.443

.155

Change in Depressive Symptoms on Change in Bedtime Mean Cortisol (intent-to-treat)
Variable

β

t

p

Model 1
Depression

0.187

1.384

R

R2

ΔR2

p(ΔR2)

F

p

0.187

0.035

0.035

.172

1.916

.172

0.248

0.061

0.026

.231

1.700

.193

.172

Model 2
Depression

0.234

1.672

.100

Intervention

-0.169

-1.211

.231

Change in Depressive Symptoms on Change in Diurnal Cortisol Slope (intent-to-treat)
Variable

β

t

p

Model 1
Depression

0.198

1.457

R

R2

ΔR2

p(ΔR2)

F

p

0.198

0.039

0.039

.151

2.122

.151

0.205

0.042

0.003

.693

1.123

.333

.151

Model 2
Depression

0.182

1.278

.207

Intervention

0.057

0.397

.693

Note. *p < .05
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Table 9.
Depressive Symptoms Regressed on LTL (Hypothesis 1c).
Depressive Symptoms on LTL Assessed at Baseline
Variable

β

t

p

Model 1
Depression

-0.157

-1.182

R

R2

ΔR2

p(ΔR2)

F

p

0.157

0.025

0.025

.242

1.398

.242

0.356

0.127

0.102

.015

3.915

.026*

.242

Model 2
Depression

-0.191

-1.495

.141

Age at
diagnosis

-0.321

-2.509

.015*

Depressive Symptoms on Change in LTL
Variable

β

t

p

Model 1
Depression

-0.271

-1.41

R

R2

ΔR2

p(ΔR2)

F

p

0.058

0.003

0.003

.675

1.988

.171

0.354

0.125

0.122

.010*

4.914

.016*

0.626

0.391

0.101

.063

4.930

.009**

.171

Model 2
Depression

-0.418

-2.318

.029*

Minority
Status

0.488

2.708

.012*

Model 3
Depression

-0.508

-2.875

.009**

Minority
Status

0.453

2.639

.015*

Intervention

0.335

1.952

.063
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Change in Depressive Symptoms on Change in LTL (intent-to-treat)
Variable

β

t

p

Model 1
Depression

-0.102

-0.763

R

R2

ΔR2

p(ΔR2)

F

p

0.102

0.01

0.01

.449

.582

.449

0.228

0.052

0.042

.130

1.481

.237

.449

Model 2
Depression

-0.159

-1.155

.253

Intervention

0.211

1.538

.130

Note. *p < .05, **p < .01
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Table 10.
Association Between the Intervention and Change in Depressive Symptoms (Hypothesis 2a).
Change in Depressive Symptoms
SS

df

MS

F

p

Partial η2

Baseline differences
(intercept)

0.002

1

0.002

0.264

.612

0.010

Chemotherapy

0.001

1

0.001

0.145

.706

0.006

Intervention

0.018

1

0.018

2.314

.140

0.082

Source

Change in Depressive Symptoms (intent-to-treat)
SS

df

MS

F

p

Partial η2

Baseline differences
(intercept)

0.001

1

0.001

0.269

.606

0.005

Chemotherapy

0.002

1

0.002

0.367

.547

0.007

Intervention

0.023

1

0.023

5.36

.024*

0.09

Baseline differences
(intercept)

0.002

1

0.002

0.641

.427

0.002

Chemotherapy

0.003

1

0.003

1.139

.291

0.003

Intervention

0.013

1

0.013

4.275

.044*

0.013

Source

Note. *p < .05, **p < .01
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Table 11.
Use of the Intervention Regressed on Change in Depressive Symptoms (Hypothesis 2a).
Total Listening Time on Change in Depressive Symptoms
Variable

β

t

p

Model 1
Intervention

-0.196

-0.848

R

R2

ΔR2

p(ΔR2)

F

p

0.196

0.038

0.038

.407

.719

.407

.407

Total Number of Tracks on Change in Depressive Symptoms
Variable

β

t

p

Model 1
Intervention

-0.206

-0.894

R

R2

ΔR2

p(ΔR2)

F

p

0.206

0.043

0.043

.383

.800

.383

.383

Total Listening Time on Change in Depressive Symptoms (intent-to-treat)
Variable

β

t

p

Model 1
Intervention

0.313

0.098

R

R2

ΔR2

p(ΔR2)

F

p

0.313

0.098

0.098

.128

2.494

.128

.098

Total Number of Tracks on Change in Depressive Symptoms (intent-to-treat)
Variable

β

t

p

Model 1
Intervention

0.318

0.101

R

R2

ΔR2

p(ΔR2)

F

p

0.318

0.101

0.101

0.121

2.587

.121

0.101

Note. *p < .05

165

Table 12.
Association Between the Intervention and Change in Markers of Diurnal Cortisol
(Hypothesis 2b).
Change in Overall Mean Cortisol
SS

df

MS

F

p

Partial
η2

Baseline differences
(intercept)

4.70E-05

1

4.70E-05

1.505

.231

0.057

Chemotherapy

1.14E-05

1

1.14E-05

0.364

.552

0.014

Intervention

3.46E-05

1

3.46E-05

1.108

.303

0.042

Source

Change in Bedtime Mean Cortisol
SS

df

MS

F

p

Partial
η2

Baseline differences
(intercept)

1.86E-05

1

1.86E-05

0.32

.576

0.013

Chemotherapy

1.23E-06

1

1.23E-06

0.021

.886

0.001

Intervention

1.37E-05

1

1.37E-05

0.236

.631

0.009

Source

Change in Diurnal Cortisol Slope
SS

df

MS

F

p

Partial
η2

Baseline differences
(intercept)

4.49E-06

1

4.49E-06

9.844

.004**

0.291

Chemotherapy

1.32E-06

1

1.32E-06

2.903

.101

0.108

Intervention

2.40E-08

1

2.40E-08

0.053

.821

0.002

Source

Change in Overall Mean Cortisol (intent-to-treat)
SS

df

MS

F

p

Partial
η2

Baseline differences
(intercept)

2.33E-05

1

2.33E-05

1.398

.243

0.027

Chemotherapy

1.22E-05

1

1.22E-05

0.732

.396

0.014

Intervention

3.24E-05

1

3.24E-05

1.946

.169

0.037

Source
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Change in Bedtime Mean Cortisol (intent-to-treat)
SS

df

MS

F

p

Partial
η2

Baseline differences
(intercept)

2.42E-05

1

2.42E-05

0.786

.379

0.015

Chemotherapy

4.14E-07

1

4.14E-07

0.013

.908

0

Intervention

2.60E-05

1

2.60E-05

0.844

.363

0.016

Source

Change in Diurnal Cortisol Slope (intent-to-treat)
SS

df

MS

F

p

Partial
η2

Baseline differences
(intercept)

1.13E-06

1

1.13E-06

3.58

.064

0.067

Chemotherapy

6.81E-07

1

6.81E-07

2.16

.148

0.041

Intervention

1.21E-07

1

1.21E-07

0.384

.539

0.008

Source

Note. *p < .05, **p < .01
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Table 13.
Use of the Intervention Regressed on Change in Markers of Diurnal Cortisol (Hypothesis 2b).
Total Listening Time on Change in Overall Mean Cortisol
Variable

β

T

p

Model 1
Intervention

0.01

0.038

R

R2

ΔR2

p(ΔR2)

F

p

0.01

0

0

.970

.001

.970

.970

Total Number of Tracks on Change in Overall Mean Cortisol
Variable

β

t

p

Model 1
Intervention

-0.018

-0.07

R

R2

ΔR2

p(ΔR2)

F

p

0.018

0

0

.945

.005

.945

.945

Total Listening Time on Change in Bedtime Mean Cortisol
Variable

β

t

p

Model 1
Intervention

0.026

0.101

R

R2

ΔR2

p(ΔR2)

F

p

0.026

0.001

0.001

.921

.010

.921

.921

Total Number of Tracks on Change in Bedtime Mean Cortisol
Variable

β

t

p

Model 1
Intervention

0.02

0.076

R

R2

ΔR2

p(ΔR2)

F

p

0.020

0

0

.940

.006

.940

.940

Total Listening Time on Change in Diurnal Cortisol Slope
Variable
Model 1

β

t

p

R

R2

ΔR2

p(ΔR2)

F

p

0.093

0.009

0.009

.731

.123

.731
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Intervention

0.093

0.351

.731

Total Number of Tracks on Change in Diurnal Cortisol Slope
Variable

β

t

Model 1
Intervention

0.104

0.39

R

R2

ΔR2

p(ΔR2)

F

p

0.104

0.011

0.011

0.702

.152

.702

p

.702

Total Listening Time on Change in Overall Mean Cortisol (intent-to-treat)
Variable

β

T

Model 1
Intervention

-0.02

-0.09

R

R2

ΔR2

p(ΔR2)

F

p

0.02

0

0

.929

.008

.929

p

.929

Total Number of Tracks on Change in Overall Mean Cortisol (intent-to-treat)
Variable

β

t

Model 1
Intervention

-0.05

-0.231

R

R2

ΔR2

p(ΔR2)

F

p

0.05

0.003

0.003

.819

.053

.819

p

.819

Total Listening Time on Change in Bedtime Mean Cortisol (intent-to-treat)
Variable

β

t

Model 1
Intervention

-0.015

-0.069

R

R2

ΔR2

p(ΔR2)

F

p

0.015

0

0

.946

.005

.946

p

.946

Total Number of Tracks on Change in Bedtime Mean Cortisol (intent-to-treat)
Variable

β

t

p

Model 1
Intervention

-0.031

-0.14

R

R2

ΔR2

0.031

0.001

0.001

.890
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p(ΔR2)
.890

F

p

.002

.890

Total Listening Time on Change in Diurnal Cortisol Slope (intent-to-treat)
Variable

β

t

p

Model 1
Intervention

0.071

0.327

R

R2

ΔR2

p(ΔR2)

F

p

0.071

0.005

0.005

.747

.107

.747

.747

Total Number of Tracks on Change in Diurnal Cortisol Slope (intent-to-treat)
Variable

β

t

p

Model 1
Intervention

0.081

0.374

R

R2

ΔR2

p(ΔR2)

F

p

0.081

0.007

0.007

.007

.140

.712

.712
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Table 14.
Association Between the Intervention and Change in LTL (Hypothesis 2c).
Change in LTL
SS

df

MS

F

p

Partial
η2

Baseline differences
(intercept)

9.01E-10

1

9.01E-10

0.003

.960

0

Chemotherapy

1.75E-06

1

1.75E-06

4.915

.033*

0.126

Intervention

1.95E-06

1

1.95E-06

5.454

.026*

0.138

Source

Change in LTL (intent-to-treat)
SS

df

MS

F

p

Partial
η2

Baseline differences
(intercept)

2.94E-08

1

2.94E-08

0.106

.746

0.002

Chemotherapy

1.57E-06

1

1.57E-06

5.652

.021*

0.096

Intervention

7.75E-07

1

7.75E-07

2.791

.101

0.05

Source

Note. *p < .05
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Table 15.
Use of the Intervention Regressed on Change in LTL (Hypothesis 2c).
Total Listening Time on Change in LTL
Variable

β

T

p

Model 1
Intervention

-0.167

-0.776

R

R2

ΔR2

p(ΔR2)

F

p

0.167

0.028

0.028

.446

.603

.446

.446

Total Number of Tracks on Change in LTL
Variable

β

t

p

Model 1
Intervention

-0.134

-0.619

R

R2

ΔR2

p(ΔR2)

F

p

0.134

0.018

0.018

.543

.383

.543

.543

Total Listening Time on Change in LTL (intent-to-treat)
Variable

β

t

p

Model 1
Intervention

-0.156

-0.742

R

R2

ΔR2

p(ΔR2)

F

p

0.156

0.024

0.024

.466

.551

.466

.466

Total Number of Tracks on Change in LTL (intent-to-treat)
Variable

β

t

p

Model 1
Intervention

-0.13

-0.613

R

R2

ΔR2

p(ΔR2)

F

p

0.13

0.017

0.017

.546

.376

.546

.546
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Table 16.
Association Between Use of the Intervention and Survival from Date of Study Entry and Date of
Diagnosis (Hypothesis 2d).
Total Listening Time on Survival from Study Entry
Predictor

B

df

p

Hazard
Ratio

Intervention

0

1

.107

1

1

1

0.525

1

.179

1.69

0.787

3.632

Sex

95% CI

Total Number of Tracks on Survival from Study Entry
B

df

p

Hazard
Ratio

Intervention

0.001

1

.210

1.001

0.999

1.003

Sex

0.57

1

.177

1.768

0.773

4.043

Predictor

95% CI

Total Listening Time on Survival from Diagnosis
Predictor

B

df

p

Hazard
Ratio

Intervention

0

1

.094

1

95% CI
1

1

Total Number of Tracks on Survival from Diagnosis
Predictor
Intervention

B

df

p

Hazard
Ratio

0.001

1

.179

1.001
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95% CI
0.999

1.003

Table 17.
Sub- and Clinical Levels of Depressive Symptoms Regressed on Markers of Diurnal Cortisol (Posthoc, Hypothesis 1b).
Depressive Symptoms on Overall Mean Cortisol Assessed at Baseline
β

t

p

R

R2

ΔR2

p(ΔR2)

F

p

Subclinical

0.01

0.049

.961

0.01

0

0

.961

.002

.961

Clinical

-0.258

-1.362

.185

0.258

0.067

0.067

.185

1.854

.185

Model 1

Depressive Symptoms on Bedtime Mean Cortisol Assessed at Baseline
β

t

p

R

R2

ΔR2

p(ΔR2)

F

p

Subclinical

0.239

1.229

.23

0.239

0.057

1.512

.230

1.512

.230

Clinical

-0.342

-1.858

.074

0.342

0.117

3.453

.074

3.453

.074

Subclinical

0.119

0.655

.519

0.512

0.262

6.676

.016

4.265

.026*

Age

0.469

2.584

.016*

Clinical

-0.309

-1.627

.116

0.375

0.141

0.69

.414

2.051

.150

Age

0.158

0.831

.414

Subclinical

0.239

1.229

.230

0.239

0.057

0.057

.230

1.512

.230

Clinical

-0.342

-1.858

.074

0.342

0.117

0.117

.074

3.453

.074

Model 1

Model 2

Model 1
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Model 2
Subclinical
Age at
diagnosis

0.138

0.75

.461

0.435

2.368

.026*

Clinical

-0.316

-1.663

.109

Age at
diagnosis

0.129

0.68

.503

0.485

0.236

0.179

.026*

3.698

.040*

0.365

0.133

0.016

.503

1.922

.167

Depressive Symptoms on Diurnal Cortisol Slope Assessed at Baseline
β

t

p

R

R2

ΔR2

p(ΔR2)

F

p

Subclinical

0.411

2.252

.033*

0.411

0.169

0.169

.033

5.073

.033*

Clinical

-0.366

-2.002

.056

0.366

0.134

0.134

.056

4.009

.056

Model 1

Note. *p < .05
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Table 18.
Sub- and Clinical Levels of Depressive Symptoms Regressed on LTL (Post-hoc, Hypothesis 1c).
Depressive Symptoms on LTL Assessed at Baseline
β

t

p

R

R2

ΔR2

p(ΔR2)

F

p

Subclinical

-0.268

-1.443

.161

0.268

0.072

0.072

.161

2.081

.161

Clinical

0.132

0.68

.503

0.132

0.017

0.017

.503

.462

.503

Subclinical

-0.193

-1.051

.303

0.413

0.17

0.099

.091

2.666

.088

Age

-0.323

-1.758

.091

Clinical

0.075

0.382

.706

0.283

0.08

0.062

.205

1.085

.353

Age

-0.256

-1.302

.205

Model 1

Model 2
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Table 19.
Change in Depressive Symptoms Regressed on Change in LTL Including an Interaction Between
Change in Depressive Symptoms and Minority Status (Post-hoc, Hypothesis 1c).
Depressive Symptoms on LTL Assessed at Baseline
β

t

Model 1
Depression

-0.271

-1.41

R

R2

ΔR2

p(ΔR2)

F

p

0.271

0.074

0.074

.171

1.988

.171

0.539

0.291

0.217

.012

4.914

.016*

0.626

0.391

0.101

.063

.4930

.009*

0.639

0.408

0.017

.436

2.795

.017*

p

.171

Model 2
Depression

-0.418

-2.318

.029

Minority Status

0.488

2.708

.012

Model 3
Depression

-0.508

-2.875

.009

Minority Status

0.453

2.639

.015

Intervention

0.335

1.952

.063

Model 4
Depression

-0.856

-1.81

.084

Minority Status

0.485

2.73

.012*

Intervention

0.362

2.053

.052

Change in
Depression x
Minority status

0.357

0.794

.436

Note. *p < .05
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Table 20.
Association Between the Intervention and Change in Depressive Symptoms Including an
Interaction Between the Intervention and Chemotherapy (Post-hoc, Hypothesis 2a).
Change in Depressive Symptoms (intent-to-treat)
SS

df

MS

F

p

Partial
η2

Baseline differences
(intercept)

0.001

1

0.001

0.219

.642

0.004

Chemotherapy

0.001

1

0.001

0.149

.701

0.003

Intervention

0.028

2

0.014

3.142

.051

0.106

Intervention x
Chemotherapy

0.001

1

0.001

0.213

.646

0.004

Source
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Table 21.
Association Between Low Versus High (Median Split) Use of the Intervention and Depressive
Symptoms (Post-hoc, Hypothesis 2a).
Total Track Time

Total Number of Tracks

Low

Low

M
Depression (intentto-treat)

0.052

SD

High
M

0.100 0.011

SD

t-test

0.068

.233
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M

High
SD

0.052 0.100

M

SD

0.011 0.068

t-test
.291

Table 22.
Use of the Intervention (Practice Tracks and “Awareness of the Breath” Track) Regressed on Change
in Depressive Symptoms (Post-hoc, Hypothesis 2a).
Total Practice Track Listening Time on Change in Depressive Symptoms (intent-to-treat)
Variable
Intervention

β

t

p

R

R2

ΔR2

p(ΔR2)

F

p

-0.535

-2.002

.073

0.535

0.286

0.286

.073

4.007

.073

Total Number of Practice Tracks on Change in Depressive Symptoms (intent-to-treat)
Variable
Intervention

β

t

p

R

R2

ΔR2

p(ΔR2)

F

p

-0.551

-2.089

.063

0.551

0.304

0.304

.063

4.364

.063

Total Listening Time of the “Awareness of the Breath” Track on Change in Depressive Symptoms
(intent-to-treat)
Variable
Intervention

β

t

p

R

R2

ΔR2

p(ΔR2)

F

p

-0.327

-1.583

.128

0.327

0.107

0.107

.128

2.507

.128

Total Number of Times the “Awareness of the Breath” Track Listened to on Change in Depressive
Symptoms (intent-to-treat)
Variable
Intervention

β

t

p

R

R2

ΔR2

p(ΔR2)

F

p

-0.327

-1.583

.128

0.327

0.107

0.107

.128

2.507

.128
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Table 23.
Association Between the Intervention and Change in LTL Including an Interaction Between
the Intervention and Chemotherapy (Post-hoc, Hypothesis 2c).
Change in LTL
SS

df

MS

F

p

Partial
η2

Baseline differences
(intercept)

1.68E-07

1

1.68E-07

0.537

.469

0.016

Chemotherapy

1.91E-06

1

1.91E-06

6.104

.019*

0.156

Intervention

1.55E-07

2

7.73E-08

0.248

.782

0.015

1.82E-06

1

1.82E-06

5.831

.021*

0.150

Source

Intervention x
Chemotherapy
Note. *p < .05
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Table 24.
Change in LTL Regressed on Survival (Post-hoc, Hypothesis 2c/Hypothesis 1e).
Survival Analysis from Study Entry: Change in LTL
Predictor

B

df

p

1

.002**

1

.001**

2

002**

731.339

1

-1.178

1

Model
LTL

959.435

Model
LTL
Intervention

Hazard
Ratio

95% CI

-

1.92E+166

-

.017*

.

9.27E+56

.

.075

0.308

0.084

1.128

Survival Analysis from Diagnosis: Change in LTL
Predictor

B

df

p

1

.026*

1

.018*

2

.017*

496.454

1

-1.085

1

Model
LTL

695.08

Model
LTL
Intervention

Note. *p < .05, **p < .01.
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Hazard
Ratio

95% CI

7.40E+301

1.00E+52

-

.103

4.05E+215

0

.

.100

0.338

0.093

1.231

Table 25.
Change in Depressive Symptoms Regressed on Change in LTL Including an Interaction Between
Change in Depressive Symptoms and the Intervention (Post-hoc, Hypothesis 2c).
Variable

β

T

Model 1
Depression

-0.271

-1.41

R2

ΔR2

p(ΔR2)

F

p

0.271

0.074

0.074

0.171

1.988

.171

0.455

0.207

0.133

0.056

3.133

.062*

0.626

0.391

0.184

0.015

4.93

.009**

0.63

0.397

0.006

0.65

3.623

.021*

.171

Model 2
Depression

-0.387

-2.029

.054

Intervention

0.383

2.009

.056

Model 3
Depression

-0.508

-2.875

.009**

Intervention
Minority
Status
Model 4

0.335

1.952

.063

0.453

2.639

.015*

Depression

-0.474

Intervention
0.325
Minority
0.43
Status
Depression x
0.084
Intervention
Note. *p < .05, **p < .01

R

p

-2.438

.023*

1.847

.078

2.374

.027*

0.46

.650
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Table 26.
Use of the Intervention (Practice Tracks and “Awareness of the Breath” Track)
Regressed on Survival (Post-hoc, Hypothesis 2d).
Total Practice Track Listening Time on Survival from Study Entry
Predictor

B

Model
Intervention

0

df

p

1

.759

1

0.757

Hazard
Ratio

1

95% CI

0.999

1.001

Total Number of Practice Tracks Listened to on Survival from Study Entry
Predictor

B

Model
Intervention

0.001

df

p

1

.762

1

0.76

Hazard
Ratio

1.001

95% CI

0.993

1.009

Total Practice Track Listening Time on Survival from Diagnosis
Predictor

B

Model
Intervention

0

df

p

1

.965

1

0.965

Hazard
Ratio

1

95% CI

0.999

1.001

Total Number of Practice Tracks Listened to on Survival from Diagnosis
Predictor

B

Model
Intervention
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Figure 1. The yellow line depicts a “normal” diurnal cortisol profile. The red line is a visual
representation of cortisol slope calculated from waking and bedtime samples. Steeper slopes
have been linked to favorable health outcomes, whereas flatter slopes are considered aberrant
and have been linked to shorter survival in cancer.
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.Figure 2. The proposed study model, aims, and hypotheses. The shaded arrows represent the
primary associations that will be examined, whereas the unshaded arrows represent the
relationships that will be explored contingent on the associations that emerge following the
analysis of the shaded arrows
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Figure 3. A timeline of the study outlining when variables of interest were assessed.
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Figure 4. Change in depressive symptoms regressed on change in LTL by ethnicity
minority status (hypothesis 1c).
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Figure 5. Critical values used to determine variance ratio cut-offs for assessment of the
homogeneity of variances assumption for ANCOVA analysis (Field, 2013).

190

Figure 6. Change in depressive symptoms by intervention participation status (hypothesis
2a).
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Figure 7. Change in LTL by intervention participation status (hypothesis 2c).
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Figure 8. Change in LTL by chemotherapy treatment status at baseline (hypothesis 2c).
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Figure 9. Kaplan-Meier curves depicting all-cause mortality for each of the intervention
groups from date of study entry (hypothesis 2d).
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Figure 10. Kaplan-Meier curves depicting all-cause mortality for each of the intervention
groups from date of diagnosis (hypothesis 2d).
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Figure 11. Kaplan-Meier curves depicting all-cause mortality for sub- and clinical levels
of depressive symptoms from date of study entry (post-hoc, hypothesis 2a).
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Figure 12. Diurnal cortisol slope at baseline by intervention participation status (posthoc, hypothesis 2b).
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Figure 13. Change in LTL by intervention participation status and chemotherapy
treatment status at baseline (post-hoc, hypothesis 2c).
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Figure 14. Kaplan-Meier curves depicting all-cause mortality for low versus high
(median split) change in LTL from date of study entry (post-hoc, hypothesis 2c).
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Figure 15. Kaplan-Meier curves depicting all-cause mortality for low versus high
(median split) change in LTL from date of diagnosis (post-hoc, hypothesis 2c).
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Figure 16. Change in depressive symptoms regressed on change in LTL by intervention
participation status (post-hoc, hypothesis 2c).
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Figure 17. Change in depressive symptoms regressed on change in LTL (hypothesis 1c).
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8. van der Gryp, K., Siwik, C., Zimmaro, L., Phillips, K., Rebholz, W., Cash, E.,
Hicks, A., & Sephton, S.E. (2018, March). Lung Cancer-related Distress is
Associated with Elevated Mean Diurnal Cortisol Levels. American
Psychosomatic Society 76th Annual Scientific Meeting, Louisville, KY.
9. Phillips, K., Siwik, C., Hicks, A., Salmon, P., Cash, E., Litvan, I., Filoteo, J.V.,
van der Gryp, K., & Sephton S.E. (2017, October). Exploration of dyadic
associations of anxiety and diurnal cortisol among Parkinson’s disease
patient/caregiver dyads. American Psychosomatic Society Mid-Year Meeting –
“Emotions in Social Relationships: Implications for Health and Disease,”
Berkeley, CA.
10. Siwik, C., Phillips, K., Salmon, P., Litvan, I., Filoteo, V., Rebholz, W., Cash, E.,
Hicks, A., van der Gryp, K., & Sephton, S.E. (2017, October). An MBSR
intervention for Parkinson’s disease patients and caregiving partners: Effects on
distress, social support, cortisol and inflammation. American Psychosomatic
Society Mid-Year Meeting – “Emotions in Social Relationships: Implications for
Health and Disease,” Berkeley, CA.
11. Cash, E., Rebholz, W., Albert, C., Fields, O., Zimmaro, L., Siwik, C., Phillips, K.,
Kloecker, G., & Sephton, S.E. (2017, June). Associations between the prognostic
indicators rest/activity rhythm and diurnal cortisol profiles in patients with lung
cancer. PsychoNeuroImmunology Research Society 24th Annual Scientific
Meeting, Galveston, TX.
12. *Phillips, K., Salmon, P., Siwik, C., Rebholz, W., Cash, E., Litvan, I., Filoteo,
J.V., Kayser, K., & Sephton, S.E. (2017, June). A dyadic MBSR intervention for
Parkinson’s disease patients/caregivers: Effects on distress, cortisol, and
inflammation. Oral Session on Inflammation and Relationships Through the
Lifespan, PsychoNeuroImmunology Research Society 24th Annual Scientific
Meeting, Galveston, TX.
13. Rebholz, W.N., Cash, E., Siwik, C., Phillips, K., Albert, C., Zimmaro, L.,
Dhabhar, F.S., Barve, S., & Sephton, S.E. (2017, June). Pro-inflammatory,
chemotactic, and anti-inflammatory cytokine responses associate with HPA, but
not SNS, function in lung cancer patients. PsychoNeuroImmunology Research
Society 24th Annual Scientific Meeting, Galveston, TX.
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14. Siwik, C., Rebholz, W., Phillips, K., Cash, E., Dhabhar, F.S., Barve, S., Zimmaro,
L., & Sephton, S.E. (2017, June). Sense of coherence in lung cancer patients:
Association with coping, immune function, and fatigue. PsychoNeuroImmunology
Research Society 24th Annual Scientific Meeting, Galveston, TX.
15. Zimmaro, L.A., Segerstrom, S., Cash, E., Siwik, C., Phillips, K., Rebholz, W., &
Sephton, S.E. (2017, March). Moderating Role of Mindfulness on Daily Affect and
Cortisol in Lung Cancer Patients. American Psychosomatic Society 75th Annual
Scientific Meeting, Sevilla, Spain.
16. Hicks, A., Salmon, P., Phillips, K., Zimmaro, L., Siwik, C., Bayley-Veloso, R.,
Albert, C., Fields, O., Cash, E., & Sephton, S.E. (2016, March). The role of
mindfulness in stress and depressive symptoms of undergraduate students.
American Psychosomatic Society 74th Annual Scientific Meeting, Denver, CO.
17. Phillips, K., Bayley-Veloso, R., Zimmaro, L.A., Siwik, C., Hicks, A.M., Cash, E.,
Salmon, P., & Sephton, S.E. (2016, March). Does living situation affect stress and
health outcomes among cancer patients? American Psychosomatic Society 74th
Annual Scientific Meeting, Denver, CO.
18. Siwik, C., Phillips, K., Zimmaro, L.A., Bayley-Veloso, R., Hicks, A., Cash, E.,
Salmon, P., & Sephton, S.E. (2016, March). Psychological and physiological
effects of problem-focused and emotional approach to coping styles in
gynecological cancer patients. American Psychosomatic Society 74th Annual
Scientific Meeting, Denver, CO.
19. Siwik, C., Hoks, R.M., Walsh, E., & Abercrombie, H.C. (2014, May). Memory
Formation: Moments Matter. University of Wisconsin, Madison Undergraduate
Honors Symposium, Madison, WI.
20. *Siwik, C. (2012, May). Emotional Memory: Effects of Valence, Modality, and
Distraction. University of Wisconsin, Madison Experimental Psychology
Symposium, Madison, WI.
LAB AND DATA ANALYTIC SKILLS
fMRI
Experience in independently conducting study protocol and collecting data using a GE 3T
fMRI scanner.
Endocrinology
Experience in collecting, preparing, processing, and preserving human saliva samples.
Proficient in cortisol data cleaning and reduction.
Immunology and Cellular Aging
Experience in processing and preserving serum and plasma human blood samples.
Experience preparing and preserving whole blood samples for stimulated analysis.
Circadian Rhythms
Experience in initializing and downloading MicroMini Motionlogger Actiwatches.
Data Analysis
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Experience conducting univariate and multivariate analyses, structural equation
modeling, and survival analyses. Experience using the following statistical software:
SPSS, AMOS. Experience in REDCap and Qualtrics data capture systems.
HONORS, AWARDS & SCHOLARSHIPS
March 2018

Selected to Present Orally at a Session on Sleep
American Psychosomatic Society 76th Annual Scientific
Meeting, Louisville, KY

Fall 2017

Graduate Network in Arts and Sciences Research Fund
Award
University of Louisville, Louisville, KY

Summer 2017

Graduate Student Council Travel Award
University of Louisville, Louisville, KY

Spring 2016
Award

Research Presentation Selected for Citation Poster
American Psychosomatic Society, Denver, CO

Spring 2016

Graduate Student Council Travel Award
University of Louisville, Louisville, KY

Spring 2016

Graduate Network in Arts and Sciences Research Fund
Award
University of Louisville, Louisville, KY

Spring 2013

Dean’s List
College of Arts and Sciences
University of Wisconsin, Madison, Madison, WI

Fall 2012

UW Alumni Association Study Abroad Scholarship
University of Wisconsin, Madison, Madison, WI

MULTICULTURAL AND DIVERSITY TRAINING
Fall 2015, 2018

Safe Zone Training
LGBT Center
University of Louisville, Louisville, KY

This two-part workshop was designed to provide university community members the
tools and resources needed to understand LGBTQ+ students and colleagues, and how to
appropriately create a welcoming, affirming environment for all. Provided valuable
information on how to advocate for individuals who identify as LGBTQ+ and
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psychoeducation on common misconceptions, defining terms, and outlining risk factors
for mental health disparities.
May 2017

Operation Immersion
Wendell H. Ford, Regional Training Center, Greenville,

KY
Attended a four-day/night intensive training for healthcare providers to become immersed
in military culture and explore issues unique to service members, veterans, and their
families. Hosted by the Kentucky Army National Guard, this immersion required
overnight stay in barrack-like quarters to simulate day-to-day military culture. Education
activities geared toward behavioral health for active military and veterans accounted for a
significant portion of the day.
Jan. 2017

White Allies Training
Multicultural Center
University of Louisville, Louisville, KY

Individuals from primarily white backgrounds gathered together to recognize the need for
and brainstorm actions to be taken to protect and minimize discrimination against
minorities, both on campus and in the greater Louisville community.
Dec. 2016

Tier One Training: The Impact of Deployment on
Service Members and Their Families
Center for Deployment Psychology
Star Behavioral Health Providers
Indiana Family and Social Services Administration, New
Albany, IN

A one-day training geared toward training of civilian behavioral health providers in
military specific culture, the deployment cycle, and treatments that focus on the needs of
the military population.
Jan. 2016

Diversity Workshop
College of Arts and Sciences
University of Louisville, Louisville, KY

This workshop provided opportunity for graduate students and faculty members to gather,
discuss, and think critically about diversity in the classroom. Topics included power
dynamics, handling conflict, and negotiating social identities.
EDUCATIONAL ACTIVITIES
CLINICAL TEACHING EXPERIENCE
Current

Co-Instructor
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Intellectual and Cognitive Assessment
University of Louisville, Louisville, KY
Taught clinical psychology graduate students how to conduct intellectual assessments.
Supervised graduate students’ first administration of WAIS-IV and WISC-V. Provided
extensive and corrective feedback on administration, scoring, and report writing.
Summer 2017, 2018

Co-Instructor
Interview Skills
University of Louisville, Louisville, KY

Taught clinical psychology graduate students introductory material to interviewing and
clinical and multicultural competence. Provided direct supervision of graduate students’
first therapy intake interview.
Spring 2018

Co-Instructor
Intellectual and Cognitive Assessment
University of Louisville, Louisville, KY

Taught clinical psychology graduate students how to conduct intellectual assessments.
Supervised graduate students’ first administration of WAIS-IV and WISC-V. Provided
extensive and corrective feedback on administration, scoring, and report writing.
RESEARCH TEACHING EXPERIENCE
Sept. 2018 - Current

Graduate Student Mentor
Undergraduate Honors Thesis
“Hashtag F.O.M.O.: Understanding the Relationships
Between Mental Health, Social Media Use, and the Fear of
Mission Out Phenomenon”
Psychological and Brain Sciences
University of Louisville, Louisville, KY
Student: Abigail Fischbach

I am currently mentoring an undergraduate student through the yearlong process of
designing, analyzing, drafting, and defending an honors thesis.
Summer 2018

Graduate Student Mentor
NCI R25 Cancer Education Program
“Factors Related to Cancer Patients’ Willingness to
Participate in an iPod-based MBSR Intervention”
School of Medicine
University of Louisville, Louisville, KY
Student: Tessa Blevins
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Mentored an undergraduate student through a National Cancer Institute (NCI)-funded 10week summer program. Demonstrated the scientific process and assisted with the steps
required to design and present a poster at a local conference.
Sept. 2017 – May 2018

Graduate Student Mentor
Undergraduate Honors Thesis
“Mindfulness, Psychological Distress, and Cognitive
Functioning Among University Students”
Psychological and Brain Sciences
University of Louisville, Louisville, KY
Student: Samantha Melton

Mentored an undergraduate student through the yearlong process of designing, analyzing,
drafting, and defending an honors thesis.
ACADEMIC TEACHING EXPERIENCE
Summer 2018

Lecturer
Topic: Stress, Health, and Resilience: Optimizing Quality
and Quantity of Life
Course: Undergraduate Human Development
University of Louisville, Louisville, KY

Spring 2017

Lecturer
Topic: Pain, the Brain, and Culture
Course: Graduate Cultural Neuroscience
University of Louisville, Louisville, KY

Spring 2017

Graduate Teaching Assistant
Course: Physiological Psychology
University of Louisville, Louisville, KY

Oct. 2016

Lecturer
Topic: Sensorimotor Function
Course: Physiological Psychology
University of Louisville, Louisville, KY

September 2016

Lecturer
Topic: Neural Anatomy
Course: Physiological Psychology
University of Louisville, Louisville, KY

Fall 2016

Graduate Teaching Assistant
Courses: Physiological Psychology; Personality
University of Louisville, Louisville, KY
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Summer 2016

Graduate Teaching Assistant
Courses: Physiological Psychology; Intro to Neuroscience;
Abnormal Psychology
University of Louisville, Louisville, KY

2015 - 2016

Graduate Teaching Assistant Academy
School of Interdisciplinary and Graduate Studies
University of Louisville, Louisville, KY

Participated in a yearlong teaching academy designed to assist graduate teaching
assistants develop knowledge, skills, and excellence in the classroom. Partook in
interactive workshops with faculty mentors selected for their expertise in teaching.
Learned scholarly and conceptual frameworks for understanding “today’s” students,
practical teaching strategies, and scholarship of teaching and learning.
Spring 2016

Graduate Teaching Assistant
Courses: Personality Psychology; Abnormal Psychology
University of Louisville, Louisville, KY

Fall 2015

Graduate Teaching Assistant
Courses: Abnormal Psychology
University of Louisville, Louisville, KY

PROFESSIONAL ACTIVITIES, LEADERSHIP & SERVICE
2018 – Current

Graduate Student Cohort Liaison
Psychological and Brain Sciences
University of Louisville, Louisville, KY

Serve as a representative of the 4th year Clinical Psychology Doctoral Student cohort.
Communicate with peers regarding program-wide issues and ensure concerns are
effectively communicated to faculty.
Jan. 2019

Abstract Reviewer
National Conference of Undergraduate Research (NCUR)
Kennesaw State University, Kennesaw, GA

May – Aug. 2018

Graduate Student Advocate
Diversity Recruitment and Retention Committee
Psychological and Brain Sciences
University of Louisville, Louisville, KY

Serve as a graduate student advocate for greater inclusion of underrepresented minorities
in the doctoral psychology programs at the University of Louisville and in higher
education more broadly. Collaborate with faculty and graduate peers to discuss goals,
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outline strategies, and formalize plans to increase and improve recruitment and retention
of diverse students and faculty within our department.
Aug. 2016 – Aug. 2018

Graduate Student Ambassador
School of Interdisciplinary and Graduate Studies
University of Louisville, Louisville, KY

Assisted the graduate school with recruitment and retention efforts. Provided other
graduate students with networking and professional development opportunities and skills.
Assisted with the organization and implementation of graduate student orientations and
graduation ceremonies.
Aug. 2017 – May 2018

Colloquium Development and Community Liaison
Clinical Psychology Professional Development Series
Department of Psychological and Brain Sciences
Noble H. Kelley Psychological Services Center
University of Louisville, Louisville, KY

Communicated with behavioral health professionals in the Louisville community to
coordinate the colloquium series for the 2017-2018 academic year. Attendance that is
required by all clinical psychology doctoral students, the colloquium series is designed to
expand on student and faculty knowledge of community resources and facilitate
professional development. Collected and organized APA-accredited materials including
presentation aims, CVs, and assessment measures in order to provide faculty with
continued education credits.
Oct. 2017

Ad-Hoc Reviewer
Journal of Health Psychology

April 2017

Poster Judge
Kentucky Psychological Association
Spring Academic Conference
Spalding University, Louisville, KY

Nov. 2016

Abstract Reviewer
American Psychosomatic Society 75th Annual Scientific
Meeting
Sevilla, Spain

Fall 2016

Co-facilitator
20 Minutes of Mindfulness
Health Promotions Office
Campus Health Services
University of Louisville, Louisville, KY
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Co-facilitated a university-wide initiative aimed at decreasing stress and improving
coping and health among undergraduate students through brief mindfulness-based
intervention.
April 2016

Poster Judge
Kentucky Psychological Association
Spring Academic Conference
Georgetown College, Georgetown, KY

Sept. 2015

Psychological Services Center Representative
Community Outreach at Health and Wellness Fair
Baptist Church, Louisville, KY

Spring 2012

Volunteer Tutor
Schools of Hope, Madison, WI

Volunteered for the community initiative aimed at reducing the academic achievement
gap between students of color and their white peers. Paired one-on-one with students to
ensure adequate preparation for successful completion of academic requirements. Created
weekly lesson plans and interactive games to improve literacy and math skills of
bilingual students ranging from 5 – 11 in age. Portrayed academic role model
characteristics.
COMMUNITY & OTHER PRESENTATIONS
1. Siwik, C. J. & Mier-Chairez, J. (2018, June). Stress and Coping. Summer Health
Professions Education Program (SHPEP). University of Louisville, Louisville,
KY.
2. Siwik, C. J. (2018, April). Stress, Health, and Resilience: Optimizing Quality and
Quantity of Life. Oral Session, Clinical Psychology Department Faculty Meeting.
University of Louisville, Louisville, KY.
3. Siwik, C. J., Segerstrom, S., Phillips, K., Cash, E., Rebholz, W., Zimmaro, L.,
Hicks, A., van der Gryp, K., & Sephton, S.E. (2018, April). Associations of
Actigraphically Measured Daytime Sedentariness, Nighttime Restfulness, and
Rest-Activity Rhythms with Daily Waking and Bedtime Salivary Cortisol Levels.
Oral Session, Graduate Student Brown Bag Series. University of Louisville,
Louisville, KY.
4. Siwik, C. & Phillips, K. (2018, April). Implementing Self-compassion Skills
Among Veteran Women. Athena’s Sisters – Support group for women veterans,
Louisville, KY.
5. Siwik, C. & Phillips, K. (2017, September). Coping with Symptoms of Anxiety
and
Depression in the Context of Chronic Illness. Better Breathers Club – Support
group for individuals with chronic lung disease, University of Louisville School
of Medicine, Louisville, KY.
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PROFESSIONAL DEVELOPMENT
Feb. 2017

Writing a Literature Review Workshop
School of Interdisciplinary & Graduate Studies
University of Louisville, Louisville, KY

Spring 2016

Entrepreneurship Academy
School of Interdisciplinary and Graduate Studies
University of Louisville, Louisville, KY

Participated in a semester-long academy aimed to teach entrepreneurial thinking and
skills. Session topics included entrepreneurial thinking, the business model canvas,
learning to launch, and social entrepreneurship.
May 2016

Mindfulness Counseling Meeting
Earth and Spirits Center, Louisville, KY

Attended a mindfulness-based practice and discussion among other mental health
professionals regarding personal and professional meditation practice.
March 2016

Resilient Families Training Program
Hotel Louisville, Louisville, KY
Facilitator: Dr. Barbara Burns, Ph.D.

Attended a workshop on the Resilient Families Project to learn how science on resilience
has informed new approaches to supporting the well being of children from families
facing trauma, stress, and adversity.
Fall 2015

Mindfulness-based Stress Reduction (MBSR) Program
Earth and Spirits Center, Louisville, KY

Attended a comprehensive 8-week MBSR program to actively learn by doing. The
program facilitated integration of meditation practice, observation of group-based
meditation to inform clinical application.
Nov. 2015

Understanding the Gut Brain: Stress,
Digestion and Mood Workshop
Institute for Brain Potential, Lexington, KY
Facilitator: Dr. Merrily Kuhn, RN, Ph.D., ND

Appetite,

Attended a daylong seminar on the enteric nervous system and its pivotal role in
regulating inflammation, stress, metabolism, appetite and mood. The workshop
elucidated the mind-body connection by discussing the effects of stress on digestive and
gastrointestinal disorders.
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PROFESSIONAL AFFILIATIONS AND HONOR SOCIETIES
2016 – 2018

American Psychosomatic Society

2014 – 2018

Psi Chi, The International Honor Society in Psychology

2017 – 2018

Kentucky Psychological Association

2017 – 2018

American Psychological Association
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